Conditions: HBV Chronic HBV Infection
Keywords: Hepatitis Tenofovir Viread
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 181
Healthy volunteers: no

Brief summary:
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection in China.

Detailed description:
This study GS-US-320-0110 is an international study planned to enroll participants in global countries, including China. However, due to the review timeline difference in China, full enrollment was reached in the main study (NCT01940471) before China was able to participate. Therefore, this registration only includes the China cohorts as they were not part of the main study analysis. Data for China cohorts were analyzed separately after the main study analysis was completed.

Arms:
arm 1: Tenofovir alafenamide (Vemlidy®; TAF) 25 mg tablet + tenofovir disoproxil fumarate (Viread®; TDF) placebo tablet once daily for up to 144 weeks (per amendment 3.1). arm 2: TDF 300 mg tablet + TAF placebo tablet once daily for up to 144 weeks (per amendment 3.1). arm 3: All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.

Interventions: intervention 1: TAF intervention 2: TDF intervention 3: TAF Placebo intervention 4: TDF Placebo
Intervention descriptions: intervention 1: TAF 25 mg tablet administered orally once daily intervention 2: TDF 300 mg tablet administered orally once daily intervention 3: TAF placebo tablet administered orally once daily intervention 4: TDF placebo tablet administered orally once daily

Protocol document:
Prot_000.pdf: 
Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
ClinicalTrials.gov 
Identifier: 
Indication: 
Protocol ID: 
Gilead Sciences 
Study Director: 
Gilead Sciences 
Medical Monitor: 
Protocol Version/Date: 
(!') GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3, Randomized, Double-Blind Study to Evaluate the 
Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD 
versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the 
Treatment of HBeAg Positive, Chronic Hepatitis B 
Gilead Sciences, Inc. 
333 Lakeside Dr. 
Foster City, CA 94404 
115,561 
2013-000636-10 
NCT01940471 
HBeAg-positive Chronic Hepatitis B 
GS-US-320-0110 
Name: 
PPD 
Telephone: 
PPD 
Fax: 
PPD 
Mobile: 
PPD 
Email: 
t-'t-'U 
Name: 
PPD 
Telephone: 
PPD 
Fax: 
PPD 
Email: 
t-'t-'U 
Amendment 3.4: 
25 September 2019 
CONFIDENTIALITY STATEMENT 
I 
I 
The infonnation contained in this document, particularly unpublished data, is the property or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable 
Institutional Review Board or Independent Ethics Committee. The infonnation is only to be used 
by you in c01mection with authorized clinical studies of the investigational drug described in the 
protocol. You will not disclose any of the infonnation to others without written authorization 
from Gilead Sciences, Inc., except to the extent necessary to obtain infonned consent from those 
persons to whom the drug may be administered. 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
TABLE OF CONTENTS 
TABLE OF CONTENTS .............................................................................................................................................. 2 
LIST OF IN-TEXTTABLES ........................................................................................................................................ 5 
LIST OF IN-TEXT FIGURES ...................................................................................................................................... 5 
PROTOCOL SYNOPSIS .............................................................................................................................................. 6 
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS .................................................................... 20 
I. 
INTRODUCTION .............................................................................................................................................. 24 
1.1. 
Background ............................................................................................................................................ 24 
1.2. 
Tenofovir Alafenamide (TAF, GS-7340) ............................................................................................... 26 
1.2.1. 
General Information ............................................................................................................. 26 
1.2.2. 
Preclinical Pharmacology and Toxicology ........................................................................... 27 
1.2.3. 
Clinical Trials ofTenofovir Alafenamide (TAF, GS-7340) ................................................. 30 
1.2.4. 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 
(EiC/FIT AF) ......................................................................................................................... 42 
1.3. 
Rationale for This Study ........................................................................................................................ 50 
1.3. I. 
Tenofovir Alafenamide (T AF) for Treatment of Chronic Hepatitis B ................................. 50 
1.3.2. 
Rationale for the Current Study ............................................................................................ 51 
1.3.3. 
Rationale for Dose Selection ................................................................................................ 53 
1.4. 
Compliance ............................................................................................................................................ 54 
2. 
OBJECTIVES ..................................................................................................................................................... 55 
3. 
STUDY DESIGN ................................................................................................................................................ 57 
3.1. 
3.2. 
3.3. 
3.4. 
3.5. 
3.6. 
3.7. 
3.8. 
Endpoints ............................................................................................................................................... 57 
3. I. I. 
Secondary Endpoints ............................................................................................................ 57 
3 .1.2. 
Other Endpoints of Interest .................................................................................................. 57 
Study Design .......................................................................................................................................... 58 
Study Treatments ................................................................................................................................... 59 
Duration of Treatment ............................................................................................................................ 60 
Discontinuation Criteria ......................................................................................................................... 60 
Biomarker Testing .................................................................................................................................. 6 1 
3.6.1. 
Biomarker Sam les to Address theStud Ob·ectives .......................................................... 6 1 
3.6.2. 
. ........................................... 6 1 
......................................................................................................... 6 1 
. ................................................................................................... 
4. 
SUBJECT POPULATION .................................................................................................................................. 63 
4.1. 
Number of Subjects and Subject Selection ............................................................................................ 63 
4.2. 
Inclusion Criteria .................................................................................................................................... 63 
4.3. 
Exclusion Criteria ................................................................................................................................... 64 
5. 
INVESTIGATIONAL MEDICINAL PRODUCTS ........................................................................................... 66 
5.1. 
Randomization, Blinding and Treatment Codes .................................................................................... 66 
5.1.1. 
Procedures for Breaking Treatment Codes ........................................................................... 66 
5.2. 
Description and Handling ofTenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate 
(TDF) and Matched Placebos ................................................................................................................. 67 
5.2.1. 
Formulation .......................................................................................................................... 67 
5.2.2. 
Packaging and Labeling ....................................................................................................... 68 
5.2.3. 
Storage and Handling ........................................................................................................... 68 
5.3. 
Dosage and Administration ofT AF and TDF ........................................................................................ 68 
CONFIDENTIAL 
Page 2 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 3
25 September 2019
5.4.
Prior and Concomitant Medications.......................................................................................................69
5.5.
Accountability for Tenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate (TDF) and 
Matched Placebos...................................................................................................................................71
5.5.1.
Investigational Medicinal Product Return or Disposal.........................................................71
6.
STUDY PROCEDURES ....................................................................................................................................72
6.1.
Subject Enrollment and Treatment Assignment.....................................................................................72
6.2.
Pretreatment Assessments......................................................................................................................72
6.2.1.
Screening Visit .....................................................................................................................72
6.2.2.
Baseline Assessments...........................................................................................................73
6.3.
Treatment Assessments..........................................................................................................................74
6.3.1.
Double-blind Visits (Including Amend 2.1 Open-label Visits 
Weeks 108 through 144) ......................................................................................................74
6.3.2.
Open-label Visits..................................................................................................................84
6.4.
Post-treatment Assessments ...................................................................................................................86
6.4.1.
HBsAg Loss and Seroconversion Subjects ..........................................................................86
6.4.2.
All other subjects who discontinue study drug.....................................................................86
6.4.3.
Follow up visit assessments (all subjects)............................................................................86
6.5.
Early Discontinuation (ED) from Study.................................................................................................87
6.6.
Criteria for Discontinuation of Study Treatment....................................................................................87
6.7.
....................................................................................88
6.8.
Urine, Serum and Plasma for Storage ....................................................................................................88
6.9.
Resistance Surveillance..........................................................................................................................89
6.10.
Hepatic Ultrasound for Hepatocellular Carcinoma Surveillance ...........................................................89
6.11.
End of Study...........................................................................................................................................89
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT...............................................................................90
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events.................................90
7.1.1.
Adverse Events.....................................................................................................................90
7.1.2.
Serious Adverse Events........................................................................................................90
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events .........................................................................91
7.2.
Assessment of Adverse Events and Serious Adverse Events.................................................................91
7.2.1.
Assessment of Causality for Study Drugs and Procedures...................................................91
7.2.2.
Assessment of Severity ........................................................................................................92
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead or CRO .........................................................................................................92
7.4.
Gilead Reporting Requirements.............................................................................................................95
7.5.
Toxicity Management ............................................................................................................................95
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event..................................................96
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event.............................................................96
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event.............................................................96
7.5.4.
Management of Bone Evaluation.........................................................................................97
7.5.5.
Management of Potential Nephrotoxicity.............................................................................97
7.5.6.
On-Treatment ALT Flare and Post-Treatment Exacerbation of Hepatitis 
Management.........................................................................................................................98
7.5.7.
Management of Potential Posterior Uveitis Cases..............................................................100
7.6.
Special Situations Reports....................................................................................................................100
7.6.1.
Definitions of Special Situations........................................................................................100
7.6.2.
Instructions for Reporting Special Situations.....................................................................101
8.
STATISTICAL CONSIDERATIONS..............................................................................................................103
8.1.
Analysis Objectives and Endpoints......................................................................................................103
8.1.1.
Analysis Objectives............................................................................................................103
CCI


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
8.1.2. 
Primary Endpoint ............................................................................................................... I 04 
8.1.3. 
Secondary Endpoints .......................................................................................................... 104 
8.1 .4. 
Other Endpoints of Interest ................................................................................................ I 05 
8.2. 
Analysis Conventions ........................................................................................................................... I 05 
8.2.1. 
Analysis Sets ...................................................................................................................... I 05 
8.3. 
Data Handling Conventions ................................................................................................................. 106 
8.4. 
Multiplicity Adjustments ...................................................................................................................... I 06 
8.5. 
Demographic Data and Baseline Characteristics ................................................................................. 107 
8.6. 
Efficacy Analysis ................................................................................................................................. I 08 
8.6.1. 
Primary Analysis ................................................................................................................ I 08 
8.6.2. 
Key Secondary Efficacy Analyses ..................................................................................... I 09 
8.6.3. 
Analyses of Other Endpoints of Interest ............................................................................. I 09 
8.7. 
Safety Analysis ..................................................................................................................................... 109 
8.7.1. 
Key Secondary Safety Analyses ......................................................................................... 109 
8.7.2. 
Extent of Exposure ............................................................................................................. 109 
8.7.3. 
Adverse Events ................................................................................................................... 110 
8.7.4. 
Laboratory Evaluations ...................................................................................................... 110 
8.8. 
Pharmacokinetic Analysis .................................................................................................................... 111 
8.9. 
Biomarker Analysis .............................................................................................................................. 111 
8.10. 
Sample Size .......................................................................................................................................... 111 
8.11. 
Data Monitoring Committee ................................................................................................................ 112 
9. 
RESPONSIBILITIES ........................................................................................................................................ 113 
9.1. 
Investigator Responsibilities ................................................................................................................ 113 
9.1.1. 
Good Clinical Practice ........................................................................................................ I 13 
9.1.2. 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ......................................................................................................... 113 
9.1.3. 
Informed Consent ............................................................................................................... 113 
9.1 .4. 
Confidentiality .................................................................................................................... 114 
9.1.5. 
Study Files and Retention of Records ................................................................................ 114 
9.1.6. 
Case Report Forms ............................................................................................................. 115 
9.1.7. 
Investigational Medicinal Product Accountability and Return ........................................... I 16 
9 .1.8. 
Inspections .......................................................................................................................... 116 
9 .1 .9. 
Protocol Comp I iance .......................................................................................................... I I 6 
9.2. 
Sponsor Responsibilities ...................................................................................................................... 117 
9 .2.1. 
Protocol Modifications ....................................................................................................... 117 
9 .2.2. 
Study Report and Publications ........................................................................................... 117 
9.3. 
Joint Investigator/Sponsor Responsibilities ......................................................................................... 117 
9.3.1. 
Access to Information for Monitoring ................................................................................ 117 
9 .3 .2. 
Access to Information for Auditing or Inspections ............................................................ I I 8 
9.3.3. 
Study Discontinuation ........................................................................................................ 11 8 
10. REFERENCES ................................................................................................................................................. 119 
11. APP ENDICES .................................................................................................................................................. 12 1 
Appendix I. 
Appendix 2. 
Appendix 3. 
Appendix 4. 
Appendix 5. 
Appendix 6. 
CONFIDENTIAL 
Investigator Signature Page .................................................................................................. 122 
Stud Procedures Table ........................................................................................................ 123 
Management o 
mica an La oratory Adverse Events .................................................... I 30 
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............. 13 1 
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Recommendations ......................................................................................... 152 
Page 4 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 5
25 September 2019
LIST OF IN-TEXT TABLES
Table 1-1.
Summary of TAF Phase 1 and Phase 1/2 Studies for HIV Infection......................................31
Table 1-2.
GS-US-320-0101: Baseline Demographics and Disease Characteristics ...............................34
Table 1-3.
GS-US-320-0101: Treatment-Emergent Adverse Events and Laboratory 
Abnormalities: Overall Summary, Safety Analysis Set..........................................................35
Table 1-4.
GS-US-320-0101: HBV DNA Results: Median Change from Baseline at Day 15 
and Day 29 by Treatment Group ............................................................................................38
Table 1-5.
GS-US-320-0101: Single Dose Pharmacokinetic Results for TAF on Day 1 ........................40
Table 1-6.
GS-US-320-0101: Single Dose Pharmacokinetic Results for TFV on Day 1 ........................41
Table 1-7.
GS-US-292-0102: Treatment-Emergent Adverse Events: Overall Summary, Safety 
Analysis Set............................................................................................................................45
Table 1-8.
GS-US-292-0102: Treatment-Emergent Grade 3 or 4 Laboratory Abnormalities, 
Safety Analysis Set.................................................................................................................46
Table 1-9.
GS-US-292-0102: Percent Change from Baseline in Lumbar Spine and Hip Bone 
Mineral Density at Week 24, DXA Analysis Set ...................................................................48
Table 1-10.
GS-US-292-0102: Percent Change in Bone Mineral Density by Gradation at Week 
24, DXA Analysis Set ............................................................................................................49
Table 1-11.
GS-US-292-0102: Percentage Change from Baseline in Bone Turnover Markers, 
Safety Analysis Set.................................................................................................................50
Table 5-1.
List of medications that are prohibited or to be used with caution due to the 
potential for drug-drug interaction with Study Medication ....................................................70
LIST OF IN-TEXT FIGURES
Figure 1-1.
Median Change (Q1, Q3) from Baseline in Creatinine Clearance (Cockcroft-Gault 
Method) in GS-US-320-0101.................................................................................................36
Figure 1-2.
GS-US-320-0101: Median Change (Q1, Q3) from Baseline HBV DNA (log10
IU/mL) by Treatment Group ..................................................................................................37
Figure 1-3.
GS-US-320-0101: Mean (SD) Plasma Concentrations vs. Time on Day 1: TAF (GS-
7340), Linear Scale.................................................................................................................39
Figure 1-4.
GS-US-320-0101: Mean (SD) Plasma Concentrations vs. Time on Day 1: 
Tenofovir, Linear Scale..........................................................................................................40
Figure 1-5.
GS-US-292-0102: Median (Q1, Q3) of Change from Baseline in Estimated GFR by 
Cockcroft-Gault by Visit, Safety Analysis Set.......................................................................47
Figure 3-1.
Study Schema.........................................................................................................................59


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 6
25 September 2019
PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus 
Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the 
Treatment of HBeAg-Positive, Chronic Hepatitis B
IND Number:
EudraCT Number:
ClinicalTrials.gov:
115,561
2013-000636-10
NCT01940471
Study Centers Planned:
Approximately 260 centers worldwide
Objectives:
The primary objectives of this study are as follows:

To compare the efficacy of tenofovir alafenamide (TAF) 25 mg 
QD versus tenofovir disoproxil fumarate (TDF) 300 mg QD for 
the treatment of HBeAg-positive, chronic hepatitis B at 
Week 48 in treatment-naïve and treatment-experienced subjects. 
The primary efficacy parameter is the proportion of subjects 
with plasma HBV DNA levels below 29 IU/mL 

To compare the safety and tolerability of TAF 25 mg QD versus 
TDF 300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Week 48 in treatment naïve and 
treatment-experienced subjects
The key secondary safety objectives of this study are as follows: 

To compare the safety of TAF 25 mg QD versus TDF 300 mg 
QD as determined by the percent change from baseline in hip 
and spine bone mineral density (BMD) at Week 48

To compare the safety of TAF 25 mg QD versus TDF 300 mg 
QD as determined by the change from baseline in serum 
creatinine at Week 48


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 7
25 September 2019
The key secondary efficacy objective of this study is as follows:

To compare the serological response (loss of HBeAg with 
seroconversion to anti-HBe) of TAF 25 mg QD versus TDF 
300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Week 48
Other secondary objectives of this study are as follows:

To compare the efficacy of TAF 25 mg QD versus TDF 300 mg
QD for the treatment of HBeAg-positive, chronic hepatitis B in
regard to the proportion of subjects with plasma HBV DNA
levels below 29 IU/mL at Weeks 96, and 144

To compare the efficacy of TAF 25 mg QD versus TDF 300 mg
QD for the treatment of HBeAg-positive, chronic hepatitis B in
regard to the proportion of subjects with plasma HBV DNA
levels below 29 IU/mL (target not detected) at 
Weeks 48, 96, and 144

To compare the biochemical (ALT normalization) response of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, chronic hepatitis B at Weeks 48, 96, and 144

To compare the serological response (loss of HBeAg with 
seroconversion to anti-HBe) of TAF 25 mg QD versus TDF 
300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Weeks 96, and 144

To compare the serological response (loss of HBsAg with 
seroconversion to anti-HBs) of TAF 25 mg QD versus TDF 
300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Weeks 48, 96, and 144

To compare the change in fibrosis as assessed by FibroTest® of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, chronic hepatitis B at Weeks 48, 96, and 144

To compare the incidence of drug resistant mutations of TAF 
25 mg QD versus TDF 300 mg QD at Weeks 48, 96, and 144

To compare the change from baseline, in ophthalmologic 
findings by fundoscopic examination of TAF 25 mg QD versus 
TDF 300 mg QD at Weeks 24, 48, 72, 96, and 144 in a subset 
of subjects 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 8
25 September 2019

To characterize the pharmacokinetics of TAF and tenofovir 
(TFV) and determine intracellular concentrations of tenofovir 
diphosphate (TFV-DP) within peripheral blood mononuclear 
cells (PBMCs) in subjects receiving TAF or TDF

To evaluate the comparative open label efficacy, safety, and 
incidence of drug resistance mutations of TAF 25 mg QD in 
subjects initially randomized to TAF 25 mg QD and in subjects 
sequentially treated with TDF 300 mg QD and then switched to 
open label TAF 25 mg QD
Study Design:
This is a randomized, double-blind, non-inferiority study to 
compare the antiviral activity of TAF 25 mg QD versus TDF 
300 mg QD. Approximately 864 subjects will be randomized in a 
2:1 ratio (A:B) to the treatment arms and will be stratified by 
plasma HBV DNA level (≥ 8 log10 IU/mL vs. < 8 log10 IU/mL) and 
oral antiviral treatment status (treatment-naïve vs. 
treatment-experienced).
Treatment Arm A: 576 subjects TAF 25 mg QD and matched 
placebo of TDF 300 mg QD
Treatment Arm B: 288 subjects TDF 300 mg QD and matched 
placebo of TAF 25 mg QD
For China, approximately 150 additional subjects 
(100 in Treatment Arm A and 50 in Treatment Arm B) will be 
enrolled for local registration purposes.
The duration of double-blind treatment is 144 weeks (96 weeks 
under Amendment 2.1). All subjects who complete the double-blind 
period of treatment are eligible for participation in the open label 
TAF 25 mg extension period for an additional 240 weeks 
(through Week 384/ED). Subjects already assigned to open label 
TAF 25 mg QD at Week 96 per Amendment 2.1 will continue on 
open label TAF 25 mg QD through Week 384/ED. For the entire 
duration of the study, subjects and investigators will remain blinded 
to the initial treatment regimen to which they were randomized. 
Subjects with a confirmed creatinine clearance (CLCr) < 50 ml/min 
and > 20 % decline in eGFR by CKD-EPI (cystatin C), at any time 
during the double blind period of the study will be required to 
undergo dose modification to every other day dosing of study drug. 
Subjects with confirmed creatinine clearance < 30 ml/min at any 
time during the study will have the study drug permanently 
discontinued. 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 9
25 September 2019
The primary analysis will occur at Week 48 with the primary 
efficacy endpoint being the proportion of subjects with complete 
viral suppression, i.e., plasma HBV DNA level below 29 IU/mL. 
Subjects who permanently discontinue study drug 
(either prematurely or at the end of study [Week 384]) for reasons 
other than HBsAg loss with confirmed seroconversion to anti-HBs
will be followed every 4 weeks for 24 weeks off treatment or until 
initiation of alternative, commercially available HBV therapy, 
whichever occurs first. Use of commercialized therapy is strongly 
encouraged.
Subjects with HBsAg loss, with confirmed seroconversion to 
anti-HBs should discontinue study drug within 3-6 months 
following confirmation of seroconversion to anti-HBs. Subjects 
with HBsAg loss with confirmed seroconversion to anti-HBs prior 
to Week 48 are not permitted to discontinue study drug prior to the 
Week 48 visit. Subjects who discontinue study drug for confirmed 
seroconversion to anti-HBs will be followed off treatment every 
4 weeks for 12 weeks and then per the study visit schedule 
(Appendix 2) through Week 384/ED. Discontinuation of study drug 
for subjects experiencing HBsAg loss with confirmed 
seroconversion, who have known bridging fibrosis or cirrhosis, 
should be considered on a case by case basis.
An external independent multidisciplinary Data Monitoring 
Committee (DMC) will review the progress and safety of this study 
approximately every 24 weeks following randomization of the first 
subject during the double blind period of the study. During the 
open-label duration of the study (Weeks 144 to 384), the DMC will 
convene approximately every 48 weeks. At each meeting, the DMC 
will review routine safety and dual energy x-ray absorptiometry 
(DXA) data, and will make recommendations regarding 
modification of the study treatment.
Number of Subjects 
Planned:
864 subjects (576 subjects TAF 25 mg QD and matched placebo of 
TDF 300 mg QD, and 288 subjects TDF 300 mg QD and matched 
placebo of TAF 25 mg QD). 
For China, approximately 150 additional subjects (100 subjects 
TAF 25 mg QD and matched placebo of TDF 300 mg QD, and 
50 subjects TDF 300 mg QD and matched placebo of 
TAF 25 mg QD) will be enrolled.
Target Population:
Subjects, who are at least 18 years of age and older, with 
HBeAg-positive, chronic hepatitis B


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 10
25 September 2019
Duration of Treatment:
The duration of the double-blind treatment is 144 weeks (96 weeks
under Amendment 2.1). After completing the double-blind period
of treatment, all subjects remaining on treatment will be eligible to 
receive open label TAF 25 mg QD, for up to an additional 
240 weeks (Week 144 through Week 384/ED). Subjects already 
assigned to open label TAF 25 mg QD at Week 96 per 
Amendment 2.1 will continue on open label TAF 25 mg QD 
through Week 384/ED. Subjects who lose HBsAg with confirmed
seroconversion to anti-HBs should discontinue study drug within 
3-6 months following confirmation of seroconversion to anti-HBs,
or after Week 48, if seroconversion occurs prior to this visit. 
Diagnosis and Main 
Eligibility Criteria:
Subjects must meet all of the following inclusion criteria to be 
eligible to participate in the study.
1. Must have the ability to understand and sign a written informed 
consent form, which must be obtained prior to initiation of 
study procedures
2. Male and non-pregnant, non-lactating female subjects, 18 years 
of age and older, based on the date of the screening visit. 
A negative serum pregnancy test at Screening is required for 
female subjects of childbearing potential (as defined in 
Appendix 6).
3. Documented evidence of chronic HBV infection 
(e.g. HBsAg positive for more than 6 months)
4. HBeAg positive, chronic hepatitis B with all of the following:

HBeAg-positive at Screening (if the subject is deemed 
ineligible for this study by HBV serology [i.e. HBeAg-negative 
CHB], this information may be used to determine eligibility for 
GS-US-320-0108 [another Gilead Sciences Phase 3 study in 
HBeAg-negative, CHB subjects; this study must also be 
IRB/EC approved at the participating center])

Screening HBV DNA > 2 × 104 IU/mL

Screening serum ALT level > 60 U/L (males) or > 38 U/L 
(females) and ≤10 × ULN (by central laboratory range)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 11
25 September 2019
5. Treatment-naïve subjects (defined as < 12 weeks of oral 
antiviral treatment with any nucleoside or nucleotide analogue 
OR treatment-experienced subjects (defined as subjects meeting 
all entry criteria [including HBV DNA and serum ALT criteria], 
and with > 12 weeks of previous treatment with any nucleoside 
or nucleotide analogue) will be eligible for enrollment. 
Treatment-experienced subjects receiving oral antiviral 
treatment at Screening must continue their treatment regimen 
until the time of randomization, when it will be discontinued.
6. Any previous treatment with interferon (pegylated or 
non-pegylated) must have ended at least 6 months prior to the 
Baseline visit.
7. Estimated creatinine clearance (CLCr) ≥ 50 mL/min (using the 
Cockcroft-Gault method) based on serum creatinine and actual 
body weight as measured at the Screening evaluation, as 
follows:
(140 – age in years) (body weight [kg])
(72) (serum creatinine [mg/dL])
[Note: multiply estimated rate by 0.85 for women]
8. Normal ECG (or if abnormal, determined by the Investigator 
not to be clinically significant)
9. Must be willing and able to comply with all study requirements.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to 
be enrolled in the study.
1. Pregnant women, women who are breastfeeding or who believe 
they may wish to become pregnant during the course of the 
study.
2. Males and females of reproductive potential who are unwilling 
to use an “effective”, protocol-specified method(s) of 
contraception during the study. For a list of protocol-specified 
contraceptive methods, refer to Appendix 6.
3. Co-infection with HCV, HIV, or HDV
4. Evidence of hepatocellular carcinoma (e.g. as evidenced by 
recent imaging)
5. Any history of, or current evidence of, clinical hepatic 
decompensation (i.e., ascites, encephalopathy or 
variceal hemorrhage). 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 12
25 September 2019
6. Abnormal hematological and biochemical parameters, 
including:

Hemoglobin < 10 g/dL

Absolute neutrophil count < 750/mm3

Platelets ≤50,000/mm3

AST or ALT > 10 × ULN

Total bilirubin > 2.5 × ULN

Albumin < 3.0 g/dL

INR > 1.5 × ULN (unless stable on anticoagulant regimen)
7. Received solid organ or bone marrow transplant
8. Significant renal, cardiovascular, pulmonary, or neurological 
disease in the opinion of the investigator
9. Significant bone disease (e.g., osteomalacia, chronic 
osteomyelitis, osteogenesis imperfecta, osteochrondroses), or 
multiple bone fractures
10. Malignancy within the 5 years prior to Screening, with the 
exception of specific cancers that are cured by surgical resection 
(basal cell skin cancer, etc). Subjects under evaluation for 
possible malignancy are not eligible.
11. Currently receiving therapy with immunomodulators 
(e.g. corticosteroids), investigational agents, nephrotoxic agents, 
or agents capable of modifying renal excretion
12. Known hypersensitivity to study drugs, metabolites, or 
formulation excipients
13. Current alcohol or substance abuse judged by the investigator to 
potentially interfere with subject compliance
14. Any other clinical condition or prior therapy that, in the opinion 
of the investigator, would make the subject unsuitable for the 
study or unable to comply with dosing requirements.
15. Subjects on prohibited concomitant medications 
(See Table 5-1). Subjects on prohibited medications, otherwise 
eligible, will need a wash out period of at least 30 days.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 13
25 September 2019
Study Procedures/
Frequency:
Laboratory analyses (serum chemistry, liver tests, hematology, 
urinalysis, plasma HBV DNA levels, pregnancy testing [for females 
of childbearing potential]), vital signs, adverse events and 
concomitant medications will be performed at Screening, Baseline, 
and every 4 weeks thereafter through Week 48, every 8 weeks 
through Week 96, every 12 weeks through Week 144, and every 
24 weeks through Week 384/Early Discontinuation (ED) visit.
HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex HBsAb) 
will be performed at Screening and Baseline, and every 
12 to 16 weeks until Week 144, and every 24 weeks through 
Week 384/ED and at Follow up Weeks 12 and 24. Quantitative 
serum HBsAg will be assessed at Screening, Baseline, every 
12-16 weeks until Week 144, every 24 weeks until Week 384/ED, 
and at Follow Up visits. Bone and renal biomarker testing will be 
performed at Baseline and then at defined intervals (see Schedule of 
Assessments, Appendix 2) throughout the study. IL28B 
polymorphism genotype, HBV genotyping and vitamin D 
assessments will be performed at Baseline only. Fibrotest® will be
performed at Baseline and every 48 weeks until Week 384/ED. 
Fasting metabolic assessments (fasting glucose and lipid panel) will 
be conducted at Baseline, every 24 weeks until Week 240, and 
every 48 weeks until Week 384/ED visit.
Complete physical examinations will be performed at Screening, 
Baseline, Weeks 24, 48, 72, 96, and 144 and every 48 weeks until 
Week 384/ED. Height assessment will be conducted at Screening 
only. Symptom directed physical exams with body weight 
assessment will be conducted at all other visits. ECG will be 
performed at Screening and every 48 weeks thereafter. At sites in 
China with the capability only, DXA scans of the hip and spine will 
be conducted during the screening period, and should be conducted 
at least 14 days prior to the first dose of study drug, and will be 
subsequently conducted at Weeks 24, 48, 72, 96, 144, and every 
48 weeks until Week 384/ED visit (if not done within the last 
24 weeks of this visit). Hepatic ultrasound for surveillance of 
hepatocellular carcinoma will be performed starting at Week 96 and 
then every 24 weeks until Week 384/ED.


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
CONFIDENTIAL 
Final 
Amendment 3 .4 
Genotypic analysis of the HBV polymerase/reverse transcriptase 
(pol/RT) for resistance surveillance will be perfonned at Baseline 
for all subjects and attempted for all viremic subjects (HBV DNA 
69 IU/mL) at Weeks 48, 96, 144 and every 48 weeks until 
Week 384/ ED. As it may not be known at the time of the visit 
whether a patient is viremic or if it will be their last study visit, a 
separate virology sample for potential resistance surveillance will 
be collected at each study visit. Plasma, serum, and urine will be 
collected at Baseline and at every visit thereafter for storage. 
A single phannacokinetic (PK) blood sample will be collected at all 
study visits Weeks 4 through 48 for all subjects. At the 
Week 4 and 12 visits, dosing will occur in-clinic and a single PK 
blood sample will be collected between 15 minutes and 4 hours 
post-dose. It is preferred that subjects take their study drug 
according to a morning dosing schedule; however, evening dosing 
is allowable. Subjects who elect to dose in evening are not required 
to have in-clinic dosing and the single PK blood sample collection 
at the Week 4 and 12 visits. 
Page 14 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Test Product, Dose, and 
Mode of Administration: 
CONFIDENTIAL 
Double-blind Treatment: 
Final 
Amendment 3 .4 
• 
Tenofovir alafenamide (TAF) 25 mg QD, oral administration or 
matched placebo of Tenofovir DF (TDF) 300 mg QD, 
oral administration 
Open-label Treatment: 
• 
Tenofovir alafenamide (TAF) 25 mg QD, oral administration 
Page 15 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 16
25 September 2019
Reference Therapy, 
Dose, and Mode of 
Administration:
Double-blind Treatment: 

Tenofovir DF 300 mg QD, oral administration or matched 
placebo of Tenofovir alafenamide (TAF) 25 mg QD, 
oral administration
Open-label Treatment: NA
Criteria for Evaluation:
Safety:
Key secondary safety endpoints include the percent change from 
baseline at Week 48 in hip and spine BMD, and change from 
baseline at Week 48 in serum creatinine.
If a subject has confirmed creatinine clearance (CLCr) < 50 ml/min 
and > 20% decline in eGFR by CKD-EPI (cystatin C), at any time 
during the double-blind period of the study, the subject will be 
required to undergo dose modification to every other day dosing of 
study drug. Subjects with confirmed creatinine clearance 
< 30 ml/min at any time during the study will have the study drug 
permanently discontinued.
The proportion of subjects in each treatment arm with tolerability 
failure (defined as an adverse event [AE] leading to permanent 
discontinuation of study drug) at Weeks 48, 96, 144, 240 and 384
will be summarized. Change from baseline in serum creatinine will
be assessed at every visit and summarized through Week 384. 
Change from baseline in BMD by DXA of the spine and hip will be 
assessed at Weeks 24, 48, 72, 96, 120, 144, and every 48 weeks 
until 384/ED. 
Ophthalmologic changes from baseline by fundoscopic examination 
at Weeks 24, 48, 72, 96 and 144 (or ED if prior to Week 144 and 
more than 24 weeks since the last exam) will be summarized for a 
subset of subjects (n=30). In addition, for any subject who develops 
signs or symptoms of posterior uveitis, the investigator should 
contact the Gilead Medical Monitor to discuss the need for 
additional ophthalmologic evaluation including dilated fundoscopy 
and optical coherence tomography (OCT).
Adverse events and clinical laboratory tests will be collected at 
every visit and summarized through Week 144. Additionally, 
summaries of AEs, discontinuations due to AEs, and laboratory 
data including BMD measurements (via DXA scans, serum
creatinine, and creatinine clearance by Cockcroft-Gault) by original 
treatment arms (TAF versus TDF) will continue through Week 384.
Fracture risk assessment will be evaluated at Baseline. In China, 
this fracture risk assessment will be evaluated at sites with DXA 
capability only.


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Final 
Gilead Sciences, lnc. 
Amendment 3.4 
Efficacy: 
The primary efficacy endpoint is the proportion of subjects with 
plasma HBV DNA levels below 29 IU/mL at Week 48. 
Phannacokinetics: 
CONFIDENTIAL 
The key secondary efficacy endpoint is: 
• 
The proportion of subjects with HBeAg seroconversion to 
anti-HBe at Week 48 
Other secondary efficacy endpoints are: 
• 
The proportion of subjects with plasma HBV DNA < 29 IU/mL 
at Weeks 96, 144, 240, and 384 
• 
The proportion of subjects with plasma HBV DNA < 29 IU/mL 
(target not detected) at Weeks 48, 96, 144, 240, and 384 
• 
The proportion of subjects with ALT nonnalization 
(by central laboratory and American Association for the 
Study of Liver Diseases [AASLD] criteria) at 
Weeks 48, 96 and 144, 240, and 384 
• 
The proportion of subjects with HBeAg loss at 
Weeks 48, 96, 144, 240, and 384 
• 
The proportion of subjects with HBeAg seroconversion to 
anti-HBe at Weeks 96, 144, 240, and 384. 
• 
The proportion of subjects with HBsAg loss at 
Weeks 48, 96,144, 240, and 384 
• 
The proportion of subjects with HBsAg seroconversion to 
anti-HBs at Weeks 48, 96 ,144, 240, and 384 
• 
The change from baseline in fibrosis as assessed by FibroTest® 
at Weeks 48, 96, 144, 240, and 384 
• 
The incidence of drug resistant mutations at 
Weeks 48, 96, 144, 240, and 384 
Page 17 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 18
25 September 2019
Statistical Methods:
The primary analysis will be performed when approximately
864 subjects complete 48 weeks of the double-blind treatment 
period or discontinue prematurely. The analysis will compare the 
TAF arm to the TDF arm.
Analysis Methods:
A two-sided 95% confidence interval (CI), based on large sample 
theory adjusted for the randomization stratification factors, for the 
difference (TAF-TDF) between treatments will be used to compare 
treatment groups with respect to the primary efficacy endpoint. A 
missing equals to failure approach will be employed for the primary 
analysis. Non-inferiority will be declared if the lower bound of this 
confidence interval exceeds 0.10 (i.e., 10% non-inferiority 
margin). If non-inferiority is established, the lower bound of the 
95% CI will be compare to 0; if the lower bound of the 95% CI is 
greater than 0, then superiority of TAF over TDF will be 
established using the same CI.
The percent change from baseline in hip and spine BMD at 
Week 48 will be analyzed using an analysis of variance (ANOVA)
model. The model will include treatment group as a fixed effect.
The details are provided in the Statistical Analysis Plan (SAP).
The change from baseline in serum creatinine at Week 48 will be 
analyzed using an analysis of covariance (ANCOVA) model with 
baseline serum creatinine as a covariate, and treatment group as a 
fixed effect. The details are provided in the SAP.
All secondary continuous endpoints will be summarized using an 
8-number summary (n, mean, standard deviation, median, Q1, Q3, 
minimum, and maximum). All categorical secondary endpoints will 
be summarized by number and percentage of subjects who meet the 
endpoint.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 19
25 September 2019
Sample Size:
With respect to the primary efficacy endpoint of proportion of 
subjects with plasma HBV DNA levels below 29 IU/mL at 
Week 48, when the sample sizes are 576 (TAF 25 mg arm) and 
288 (TDF 300 mg arm), a two-group, large-sample normal 
approximation test of proportions with a one-sided 0.025 
significance level will have 84% power to reject the null 
hypothesis, that the TAF 25 mg arm is inferior to the TDF 300 mg 
arm (the difference in proportions [TAF-TDF] having a lower 
bound of the one-sided 97.5% confidence interval of less than 
0.10, ie, 10%) in favor of the alternative hypothesis that the TAF 
25 mg arm is not inferior to the TDF 300 mg arm. This assumes the 
expected difference (TAF-TDF) in proportion of subjects with 
HBV DNA < 29 IU/mL is 0 and the proportion of subjects with 
HBV DNA < 29 IU/mL in the TDF 300 mg arm is 0.69. 
The TDF virologic rate of 0.69 was calculated using the observed 
rate in Study GS-US-174-0103. 
This sample size also provides at least 90% power to detect a 
1% difference in the percent change from baseline in hip BMD at 
Week 48 (assuming a 1.17% change from baseline in the TDF 
300 mg arm and 0.17% change from baseline in the TAF 25 mg 
arm, with a common standard deviation of 2.20% and a two-sided 
α = 0.025); at least 90% power to detect a 1% difference in the 
percentage change from baseline in spine BMD at Week 48 
(assuming a 1.69% change from baseline in the TDF 300 mg arm 
and 0.69% change in the TAF 25 mg arm, with a common 
standard deviation of 3.08% and a two-sided α = 0.025); at least 
85% power to detect a 0.03 mg/dL difference in the change from 
baseline in serum creatinine at Week 48 (assuming a 0.04 mg/dL 
change from baseline in the TDF 300 mg arm and 0.01 mg/dL 
change from baseline in the TAF 25 mg arm, with a common 
standard deviation of 0.12); and 16% power to detect a 
4% difference in HBeAg seroconversion rate (assuming a 
19% HBeAg seroconversion rate in the TDF arm and 23% HBeAg 
seroconversion rate in the TAF arm). These assumptions were 
derived from studies GS-98-437, GS-98-438, GS-US-174-0102, 
GS-US-174-0103, and GS-US-174-0121.
For China, approximately 150 additional subjects (100 subjects 
TAF 25 mg QD and matched placebo of TDF 300 mg QD, and 
50 subjects TDF 300 mg QD and matched placebo of 
TAF 25 mg QD) will be enrolled.
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 20
25 September 2019
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
°C
degrees Celsius
°F
degrees Fahrenheit
AASLD
American Association for the Study of Liver Diseases
ADV
Adefovir dipivoxil
AE
Adverse event
AhR
Aryl hydrocarbon receptor
AK
Adenylate kinase
ALT
Alanine aminotransferase (SGPT)
ANC
Absolute neutrophil counts
ANCOVA
Analysis of coavariance
ANOVA
Analysis of variance
AR
Adverse reaction
AST
Aspartate aminotransferase (SGOT)
AUCinf
Area under the concentration versus time curve extrapolated to infinite time, calculated as 
AUC0last + (Clast/z)
AUCtau
Area under the plasma concentration versus time curve over the dosing interval (tau)
bsAP
Bone specific alkaline phosphatase
BMD
Bone mineral density
CatA
Cathepsin A
CD4
Cluster of differentiation 4 cells
CD8
Cluster of differentiation 8 cells
CES1
Caboxylesterase-1
CHB
Chronic hepatitis B
CI
confidence interval
CKD
Chronic kidney disease
CKD-EPI
Chronic kidney disease epidemiology collaboration
CL/F
Apparent oral clearance after administration of the drug
CLCr
Creatinine clearance
Cmax
The maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
COBI / C
Cobicistat
CRF/eCRF
case report form(s)/electronic case report form(s)
CRO
Contract (or clinical) research organization
CTX
C-type collagen sequence
CYP3A4
Cytochrome P450 3A4
DMC
Data Monitoring Committee
DNA
Deoxyribonucleic acid
DXA
Dual energy x-ray absorptiometry
E2
Estradiol


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 21
25 September 2019
EC
Ethics committee
EudraCT
European clinical trials database
E/C/F
Elvitegravir/cobicistat/emtricitabine
eGFR
Estimated glomerular filtration rate
EFV
Efavienz
EKG / ECG
Electrocardiogram
ETV
Entecavir
EU
European Union
EVG
Elvitegravir
FAS
Full analysis set
FDA
(United States) Food and Drug Administration
FEPO4
Fractional excretion of Phosphate
FSH
Follicle stimulating hormone
FRAX®
Fracture Risk Assessment Tool
FTC
Emtricitabine
GCP
Good Clinical Practice (Guidelines)
GFR
Glomerular filtration rate
GSI
Gilead Sciences, Inc.
GGT
Gamma glutamyl transferase
Hb
Hemoglobin
HBeAb
Hepatitis B e antibody
HBeAg
Hepatitis B e antigen
HBsAb
Hepatitis B surface antibody
HBsAg
Hepatitis B surface antigen
HBV
Hepatitis B virus
HCC
Hepatocellular carcinoma
HCV
Hepatitis C virus
HDV
Hepatitis D virus
HDPE
High-density polyethylene
hERG
Human ether-à-go-go-Related Gene
HIV
Human Immunodeficiency Virus
IC50
50% inhibitory concentration
ICF
Informed Consent Form
ICH
International Conference on Harmonisation
IEC
Independent ethics committee
Ig
Immunoglobulin
IMP
Investigational Medicinal Product
IND
Investigational New Drug (Application)
ITT
Intent-to-treat (analysis or subset)
IRB
Institutional review board


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 22
25 September 2019
IV
Intravenous
IVRS
Interactive voice response system
IWRS
Interactive web response system
IUD
Intrauterine device
LdT
Telbivudine
LAM
Lamivudine
LLN
Lower limit of the normal range
LOCF
Last observation carried forward
MedDRA
Medical Dictionary for Regulatory Activities
mg
Milligram
min
Minute
mmHg
Millimeters mercury
NK
Natural killer cells
NOEL
No observed adverse effect level
NRTI
Nucleoside reverse transcriptase inhibitor
OC
osteocalcin
OCT
Optical coherence tomography
OL
Open-label
PBMC
Peripheral blood mononuclear cells
PCR
Polymerase chain reaction
PD
Pharmacodynamic
P-gp
P-glycoprotein
P1NP
Procollagen type 1 amino-terminal propeptide
pol
Polymerase
PK
Pharmacokinetic
PVE
PXR
Pharmacovigilance and Epidemiology
Pregnane X receptor
PT
Preferred Term
PT/INR
Prothrombin time/ International normalized ratio
QD
Once daily (use only in tables)
RNA
Ribonucleic acid
RPV
Rilpivirine
RT
Reverse transcriptase
SA
Single agent
SAE
Serious adverse event
SAP
Statistical Analysis Plan
sCr
Serum creatinine
SD
Standard deviation
SOC
System Organ Class
SOP
Standard Operating Procedure


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 23
25 September 2019
STR
Single tablet regimen
SUSAR
Suspected Unexpected Serious Adverse Reaction
TAF
Tenofovir Alafenamide, GS-7340
TAF Fumarate
Tenofovir Alafenamide Fumarate, GS-7340-03
TDF
Tenofovir Disoproxil Fumarate
TFV
Tenofovir
TFV-DP
Tenofovir diphosphate
TLOVR
Time to loss of virologic response
Tmax
The time (observed time point) of Cmax
t½
An estimate of the terminal elimination half-life of the drug in serum/plasma/PBMC, 
calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz)
T3
Triiodothyronine
TSH
Thyroid stimulating hormone
UACR
Urine albumin-to-creatinine ratio
UGT1A1
Uridine glucuronosyltransferase 1 family, polypeptide A1 
ULN
Upper limit of the normal range
UPCR
Urine protein-to-creatinine ratio
US
United States
WHO
World Health Organization


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 24
25 September 2019
1.
INTRODUCTION
1.1.
Background
Chronic hepatitis B (CHB) is a serious global health care problem and one of the principal causes 
of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Of the estimated 
2 billion people worldwide who have been acutely infected with the hepatitis B virus (HBV), 
approximately 400 million have developed CHB, and approximately 1 million people die 
annually from complications of CHB {World Health Organization (WHO) 2000}. Despite the 
availability of HBV vaccine programs in many countries, new HBV infections are still common 
even in areas of low endemicity. For example, approximately 80,000 people in the United States 
(US) become acutely infected each year, according to an estimate from the Centers for Disease 
Control and Prevention {Centers for Disease Control and Prevention (CDC) 2003}. Following 
acute HBV infection, approximately 5% to 10% of adults and up to 90% of children fail to 
produce an immune response adequate to clear the infection; these individuals become chronic 
carriers of the virus {Zuckerman 1996}.
Chronic hepatitis B has a broad clinical spectrum, ranging from asymptomatic, slowly 
progressive illness to severe, and more rapidly progressive liver disease. Chronic hepatitis B may 
remain quiescent for many years and represent a risk factor for progression to cirrhosis, liver 
failure, and death within a few years. Approximately 25% of subjects with CHB will ultimately 
develop serious liver disease such as hepatic decompensation, cirrhosis, or HCC {Zuckerman 
1996}. The development of nucleos(t)ide analogues has been a major breakthrough for the 
treatment of CHB, providing effective suppression of viral replication and reducing the risk of 
long term complications. However, if viral replication resumes as a result of resistance mutation 
development, the clinical benefit is lost. The rate of resistance development in treatment-naive 
subjects varies depending on the treatment: up to 70% after 4 years with lamivudine (LAM), up 
to 29% after 5 years with adefovir dipivoxil (ADV), 25%/11% in hepatitis B e antigen 
positive/negative (HBeAg+/) subjects after 2 years with telbivudine (LdT), and 1.2% after 
5 years with entecavir (ETV). To date, resistance to TDF has not been documented {Marcellin 
2011}.
Tenofovir DF (Viread®) 300 mg once daily was first approved for the treatment of CHB in 
Turkey on 28 March 2008, and is currently approved in 101 countries, including the US, Canada, 
and Europe. Approval of TDF for CHB was based primarily on 48 week data from 
375 adult subjects with HBeAg  CHB and 266 subjects with HBeAg+ CHB who enrolled in the 
similarly designed pivotal studies GS-US-174-0102 (HBeAg  subjects) and GS-US-174-0103 
(HBeAg+ subjects). In study GS-US-174-0102, TDF 300 mg once daily was shown to be 
superior to ADV 10 mg once daily for the treatment of HBeAg/antibody to hepatitis B e antigen 
(anti-HBe)-positive (presumed precore mutant) chronic HBV infection. At 48 weeks, 70.8% of 
subjects in the TDF group (n = 250) had a complete response (plasma HBV deoxyribonucleic 
acid [DNA] < 69 IU/mL [400 copies/mL] and histologic improvement characterized by ≥2 point 
reduction in the Knodell necroinflammatory score and no worsening of Knodell fibrosis), 
compared to 48.8% of subjects in the ADV group (n = 125; p < 0.001) {Marcellin 2007}. 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 25
25 September 2019
In study GS-US-174-0103 (HBeAg+ subjects), at 48 weeks, 66.5% of subjects in the TDF group 
(n = 176) had a complete response, compared to 12.2% in the ADV group (n = 90; p < 0.001) 
{Heathcote 2007}. Subjects in both studies who completed the 48-week double-blind treatment 
period (including the end-of-blinded-treatment biopsy) were eligible to continue in an open-label 
(OL) extension phase consisting of treatment with TDF up to Week 480 (Year 10). 
In both Phase 3 studies, for viremic subjects originally randomized to ADV, who rolled over to 
open-label TDF at Week 48, HBV DNA values decreased sharply during the first 16 weeks of 
TDF therapy. At Week 96, the percentages of subjects with plasma HBV DNA < 400 copies/mL 
were not significantly different between treatment groups in both studies. Viral suppression was 
maintained through Week 240 of these 2 pivotal studies in those subjects receiving continued 
treatment with TDF for 240 weeks (TDFTDF group), and in those who received 192 weeks of 
TDF treatment following an initial 48 weeks of treatment with ADV (ADVTDF group). Based 
on results from a pooled histology analysis at Year 5 for these 2 studies, 96.2% of subjects on 
open-label TDF-experienced either improvement or no change in fibrosis (by Ishak fibrosis 
scoring). Further, of the 96 subjects with cirrhosis at baseline (Ishak fibrosis score 5-6), 
25% experienced no change in Ishak fibrosis score while 73% experienced reversal of cirrhosis 
by Week 240 with a reduction in Ishak fibrosis score of at least 2 points (missing = excluded 
[M=E], data after addition of emtricitabine [FTC] included) {Marcellin 2013}. Importantly, viral 
suppression (HBV DNA < 69 IU/mL or < 400 copies/mL was documented in 330/334 (99%) of 
subjects with available histology who were maintained on therapy with an available HBV DNA 
measurement at Week 240. No mutations associated with TDF resistance developed in subjects 
treated with TDF for up to 5 years in the pivotal studies.{Marcellin 2013} No phenotypic 
resistance to TDF has been observed among subjects with virologic breakthrough or who 
developed conserved-site changes in the HBV polymerase (pol)/reverse transcriptase (RT) 
during TDF treatment for up to 5 years. Continued treatment with TDF for 5 years revealed no 
new adverse reactions inconsistent with the known safety profile of TDF. Importantly, these 
results demonstrate that achievement and maintenance of long term viral suppression with TDF 
translates into a histological benefit (i.e. fibrosis regression) in the majority of subjects.
While liver biopsy provides important information regarding severity of necroinflammatory 
activity and fibrosis in diseases such as CHB, it is no longer considered routine in clinical 
practice for ongoing disease monitoring, and the procedure itself is challenging to perform within 
the context of clinical trials. Additionally, liver biopsy is costly and limited by sampling error as 
well as patient reluctance to undergo this invasive procedure. With the availability of 
non-invasive tests, including FibroTest® (also known as FibroSURE in the U.S.) and Fibroscan®, 
which have been shown to correlate with histology in liver diseases such hepatitis B {Poynard 
2005}, hepatitis C {Ngo 2006}, and non-alcoholic fatty liver disease {Poynard 2007}, the need 
for liver biopsy has been largely replaced, particularly for ongoing monitoring of changes in 
fibrosis.
Tenofovir DF is also approved worldwide in many markets for administration in combination 
with other antiretroviral agents for treatment of human immunodeficiency virus (HIV)-1 
infection (first approval in 2001). TDF is also a component of Truvada®
(FTC 200 mg/TDF 300 mg), a marketed fixed-dose combination product for treatment of HIV-1 
infection in combination with other antiretroviral agents. More recently, TDF has been included 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 26
25 September 2019
in single tablet regimens (STRs) for treatment of HIV infection. Three STRs are currently 
approved for once-daily administration in the treatment of HIV-1 infection, efavirenz 
(EFV)/FTC/TDF (Atripla®), FTC/rilpivirine (RPV)/TDF (Complera®/Eviplera), and more 
recently, elvitegravir (E)/cobicistat (C)/emtricitabine (F)/TDF (Stribild™). The newly approved 
Stribild™STR tablet, which contains a fixed-dose combination of E/C/F/TDF 
(150/150/200/300 mg), has been approved in the United States by the Food and Drug 
Administration (FDA) for the treatment of HIV-1 infection in treatment-naïve adults. E/C/F/TDF 
is the first approved STR that combines an integrase strand transfer inhibitor (elvitegravir) with a 
nucleoside reverse transcriptase inhibitor (NRTI) backbone into a once-daily tablet. Since Viread 
was first marketed on 31 October 2001, the overall exposure to TDF upto 31-May 2013 from 
branded Viread®, Truvada®, Atripla®, Complera® and Stribild®, combined upto 31 May 2013, is 
estimated to be in excess of 6 million patient years.
TDF is a preferred oral N(t)RTIs for treatment of CHB infection by all current treatment 
guidelines. For the majority of CHB subjects, life-long treatment is required as only a small 
percentage (< 10%) of subjects experience sustained loss of hepatitis B surface antigen (HBsAg), 
and as a consequence, achieve an effective cure of the disease. Though highly effective, long 
term use of TDF is associated with nephrotoxicity and reduced bone mineral density in some 
subjects {Panel on Antiretroviral Guidelines for Adults and Adolescents 2012}. Thus, alternative 
therapies with high antiviral potency, a high genetic barrier to resistance development, and 
improved long term safety and tolerability are needed in order to further advance treatment of 
chronic HBV infection worldwide.
Tenofovir alafenamide (TAF), a novel “intracellular” prodrug of tenofovir (TFV), has the 
potential to advance treatment of chronic HBV infection. In contrast to TDF, an oral prodrug that 
is rapidly cleaved by esterases in the intestines and plasma to TFV, TAF has been specifically 
synthesized to be more stable in resisting early enzymatic cleavage following oral administration 
and remain mostly intact until penetrating target cells. By virtue of this key distinguishing 
property, TAF when administered at a lower dose than TDF, is capable of efficiently delivering 
active drug (e.g. tenofovir diphosphate [TFV-DP]) to the cells where it is needed 
(e.g. HBV-infected hepatocytes, HIV-infected lymphoid cells) while systemic exposures of TFV 
are greatly reduced in comparison to oral administration of TDF 300 mg. These features are 
hypothesized to translate into the potential for effective suppression of viral replication and an 
improved tolerability and safety profile.
1.2.
Tenofovir Alafenamide (TAF, GS-7340)
1.2.1.
General Information
Tenofovir alafenamide (GS-7340, TAF, or L-alanine, N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-
1-methylethoxy] methyl]/phenoxyphosphinyl]-, 1-methylethyl ester) is a next generation oral 
prodrug of TFV, a nucleotide analog that inhibits reverse transcription in HIV-1 and HBV. TFV
is metabolized intracellularly to the active metabolite, tenofovir diphosphate (TFV-DP), a 
competitive inhibitor of HIV-1 reverse transcriptase (RT) and HBV pol/RT that terminates the 
elongation of the viral DNA chain. In the development of TAF, three forms of the drug substance 
have been used in various studies: GS-7340, synonym for GS-7340 as the free base; 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 27
25 September 2019
GS-7340-02, synonym for TAF monofumarate (1:1); and GS-7340-03 as the hemifumarate (2:1). 
GS-7340-03, also known as TAF fumarate, the form being used in GS-US-292-0102 (Phase 2 
study in HIV subjects) and GS-US-320-0101 (Phase 1b study in HBV subjects), is considered
comparable to GS-7340-02 based on physical/chemical properties of GS-7340-02, the form that
has been used in previous studies and a number of currently ongoing studies. Importantly, both 
GS-7340-03 and GS-7340-02 exist as the free base, TAF (GS-7340), in blood and biological 
fluids.
For further information on TAF, (GS-7340), please refer to the latest Investigator’s Brochure for 
GS-7340.
1.2.2.
Preclinical Pharmacology and Toxicology
1.2.2.1.
Primary Pharmacodynamics
TAF is converted intracellularly by cathepsin A (CatA) and carboxylesterase-1 (CES1) to form 
TFV (i.e, a nucleoside monophosphate analog) which is not dependent on an intracellular 
nucleoside kinase activity for the first step in the conversion to the active metabolite, and is 
subsequently converted to TFV-DP by cellular kinases. The cellular enzymes responsible for 
TFV metabolism to the active diphosphorylated form are adenylate kinase (AK) {Robbins 1995}
and nucleotide diphosphate kinase, which are highly active and ubiquitous. AK exists as multiple 
isozymes (AK1 to AK4), with the phosphorylation of TFV mediated most efficiently by AK2. 
Analysis of primary cells showed that CatA activity varied minimally in both human cluster of 
differentiation 4 (CD4+) T lymphocytes and macrophages. CatA activity was equivalent in 
resting and activated CD4s and approximately 2-fold higher in macrophages. Intracellular 
metabolites of TAF were similar among individual donors in both CD4+ T-cells and 
macrophages. Carboxylesterease-1 (Ces1) which is highly expressed in liver, contributes to TAF 
conversion to TFV, particularly in hepatocytes {Bam 2012, Birkus 2012}.
The intracellular metabolism of TAF and TFV are consistent with the 600-fold enhancement in 
anti-HIV activity in cell culture of TAF over TFV. Metabolism of TAF was also studied in 
different human blood lymphocyte subpopulations, CD4+ and CD8+ T-cells, NK cells, B-cells 
and macrophages/monocytes. TAF is metabolized inside host cells to the active metabolite 
TFV-DP. Concentration of the active metabolite TFV-DP was substantial in all cell populations. 
Additionally, a 24-hour continuous incubation of TAF in primary human hepatocytes in vitro 
resulted in approximately 120- or 5-fold higher levels of TFV-DP compared to incubation of 
TFV or TDF, respectively (AD-120-2017).


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 28
25 September 2019
1.2.2.2.
Safety Pharmacology
TAF monofumarate (GS-7430-02) has been evaluated to determine potential effects on the 
central nervous system (R990188), renal system (R990186), cardiovascular (D2000006) and 
gastrointestinal systems (R990187). Single doses did not induce pharmacologic effects on the 
central nervous system of the rat (1000 mg/kg), the renal system of the rat (1000 mg/kg), or the 
cardiovascular system of the dog (100 mg/kg). GS-7340-02 (at 1000 mg/kg reduced distal transit 
and increased stomach weights starting 2 hours post dosing with reversibility beginning by 
6 hours after dosing. The NOEL for gastrointestinal motility was 100 mg/kg. The IC50 for the 
inhibitory effect of TAF fumarate (GS-7340-03) on hERG potassium current was estimated to be 
greater than 10 μM.
1.2.2.3.
Nonclinical Pharmacokinetics
All nonclinical pharmacokinetic experiments in this section were performed using TAF 
monofumarate (GS-7340-02), and all study data described in this section reflect the dosage of the 
monofumarate. For reference, 100 mg of GS-7340-02 is equivalent to 80 mg of the GS-7340 free 
base (TAF).
Plasma pharmacokinetics of the intact prodrug, TAF, following oral administration of 
GS-7340-02 in dogs and monkeys demonstrated rapid absorption with peak plasma 
concentrations between 0.25 and 0.5 hours. 
Peak TFV plasma concentrations occurred following TAF absorption, with TFV Tmax values 
between 0.25 to 1.7 hours in rats, dogs, and monkeys. TFV plasma concentrations declined with 
a terminal half-life of 11.2 to 16.4 hours in rats (fasted), > 24 hours in dogs (fasted) and 
8.1 to 12.5 hours in rhesus monkeys. 
The tissue distribution and recovery of [14C] radiolabeled GS-7340-02 was examined in beagle 
dogs. Radioactivity was detected in all tissues except brain, with the majority present in the 
contents of the gastrointestinal tract, liver, kidney, and large intestine. Tissue concentrations 
were the highest in kidney, PBMCs, liver, large intestine, and bile. Significant concentrations of 
TFV-related radioactive material were observed in lymph nodes from all 4 sites, suggesting that 
TAF may be selectively cleaved to TFV in the cells of the lymphoreticular system.
The primary route of elimination of TFV is renal excretion of unchanged drug based on 
IV studies of TFV. Following oral administration of GS-7340-02, approximately 15% of a 
radiolabeled dose is recovered in dog urine in 24 hrs. TFV was the major species present in the 
urine (90%), with about 3.4% of TAF also present. Biliary excretion of TFV in dogs and fecal 
elimination of TFV in rats and dogs are negligible.
TFV was the only species found in the intestinal contents and feces. In human systems, TAF is 
metabolized by hydrolytic cleavage and, to a lesser extent, by CYP3A4 catalyzed oxidation 
(AD-120-2004). As a result of the limited metabolism of TAF by CYP3A4, inhibition or 
induction of this enzyme should have little consequence on TAF exposure in vivo. TAF has
limited potential to alter CYP enzyme activity through inhibition and does not inhibit UGT1A1 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 29
25 September 2019
function. In addition, TAF is not an activator of either the aryl hydrocarbon receptor (AhR) or 
human pregnane-X-receptor (PXR). These features combined with the relatively low plasma 
exposures of TAF in humans suggest that the potential of TAF to cause or be affected by 
clinically relevant drug-drug interactions is very low.
The hepatic extraction of TAF was estimated to be 70% suggesting that TAF was rapidly cleaved 
by hepatic hydrolases including Ces1 and CatA {Babusis 2013}. An in vitro study to evaluate 
effects of inhibitors of CatA or Ces1 on TAF metabolism in primary human hepatocytes is 
ongoing. Single and repeat dose dog liver pharmacokinetic studies are planned.
1.2.2.4.
Nonclinical Toxicology
TAF monofumarate (GS-7340-02) was evaluated in mice, rats, dogs, and monkeys for treatment 
periods up to 9 months and was negative in genetic toxicology studies.
In chronic studies in rats, bone (atrophy of metaphyseal cancellous bone) and kidneys 
(karyomegaly) were the primary target organs after 26 weeks of treatment. GS-7340-02 also 
appeared to increase biochemical markers of bone turnover and decrease serum 
1,25-dihydroxy- and 25-hydroxyvitamin D3 at doses of 25 mg/kg/day and above. In chronic 
studies in dogs after 9 months of treatment with GS-7340-02, the primary target organs were 
kidney and bone.  
GS-7430-02 had no discernible electrocardiograph (EKG/ECG) effect at the low dose of 
2 mg/kg/day and slightly prolonged PR intervals at 6 and 18/12 mg/kg/day (started at 
18 mg/kg/day, then reduced to 12 mg/kg/day at Weeks 7-8). Additionally, at Week 39, 
GS-7430-02 appeared to reversibly reduce heart rate with an associated mild QT prolongation. 
At Week 39, decreases in serum T3 were noted for animals receiving 18/12 mg/kg/day but was 
reversible at the 3 month recovery period. Minor hematological and biochemistry parameters 
changes were observed but remained within normal historical ranges with the following 
exceptions: AST (~ 100% increase) and total bilirubin (~ 40% increase). There were no clear 
treatment-related effects observed in monkeys following 28 days of treatment, including no 
changes in mitochondrial function.
The data from the 6-month rat study determined a NOAEL of 25 mg/kg/day 
(tenofovir AUC = 3758 ng•h/mL); the 9-month dog study defined a NOAEL of 2 mg/kg/day 
(tenofovir AUC = 1180 ng•h/mL), and the 28-day nonhuman primate study defined a NOAEL of 
30 mg/kg/day (tenofovir AUC = 5870 ng•h/mL). In conjunction with the nonclinical data with 
TDF and the clinical experience with TDF and TAF, these toxicology studies support studies in 
humans of doses up to 150 mg/day (equivalent to 120 mg free base, the highest anticipated 
human dose) for chronic treatment.
At the time of the rodent toxicity studies, the bioassay could not detect plasma TAF, possibly due 
to instability in the matrix.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 30
25 September 2019
Because of the lack of exposure to the prodrug in mice and rats and achievable TFV exposures 
less than previously tested in chronic and carcinogenicity studies with TDF, carcinogenicity 
studies in mice and rats with TAF are currently not required per agreement with FDA and EMA.
Also, TAF does not need to be evaluated in perinatal-postnatal reproductive toxicology studies
per agreement with FDA and EMA. Reproductive tissues were examined in repeat-dose 
toxicology studies in the rat, dog, and monkey. There were no clearly treatment-related 
histologic alterations or changes in organ weights in the rat and the dog following chronic daily 
dosing, or in the monkey. 
The TAF fumarate (GS-7340-03) oral rat fertility study is ongoing (Report No. TX-120-2012;
report in progress). 
1.2.3.
Clinical Trials of Tenofovir Alafenamide (TAF, GS-7340)
To date, a total of 8 Phase 1 and Phase 1/2 clinical trials of tenofovir alafenamide (TAF) have 
been conducted or are ongoing in 528 subjects. This includes seven HIV studies (total of 
477 subjects; 2 completed Phase 1/2 studies [68 subjects], 3 completed Phase 1 studies 
[83 subjects], and 2 ongoing Phase 2 studies [326 subjects]), and 1 Phase 1b HBV study 
(completed enrollment; 51 subjects). TAF is presently in Phase 3 for treatment of HIV-1, and a 
Phase 1b study has completed enrollment and is nearing completion for treatment of chronic 
HBV. 
Clinical trials entailing the use of TAF (dose[s] studied) for HIV-1 infection and other Phase 1 
studies include:

GS-120-1101, a Phase 1/2 study of the pharmacokinetics and antiviral activity of TAF, 
GS-7340 (50 mg and 150 mg) in HIV-infected subjects (completed)

GS-US-120-0104, a Phase 1b study of the pharmacokinetics and antiviral activity of TAF, 
GS-7340 (8 mg, 25 mg, 40 mg) in HIV-infected subjects (completed)

GS-US-120-0107, a Phase 1, partially-blinded, randomized, placebo- and positive-controlled 
study to evaluate the effect of TAF, GS-7340 (25 mg and 150 mg) on the QT/QTc interval in 
healthy subjects (completed)

GS-US-120-0108, A Phase 1, Open-Label, Parallel-Design Study to Evaluate the 
Pharmacokinetics of TAF, GS-7340 (25 mg) in Subjects with Severe Renal Impairment 
(completed)

GS-US-120-0109, A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism and 
Excretion of TAF, GS-7340 (25 mg [completed])


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 31
25 September 2019
Further details regarding these studies are provided in the table (Table 1-1) below. In Phase 1/2 
studies in HIV-infected subjects (Studies 120-1101 and 120-0104), the short-term 
safety/tolerability, PK, and antiviral activity of TAF when given as a stand alone agent (SA) 
were evaluated over a range of doses. In Study 120-0104, at TAF doses of 25 mg or higher, near-
maximal HIV RNA suppression was observed at Day 10, and importantly, single dose PK 
assessments of TAF (8 mg, 25 mg, or 40 mg) and TDF (300 mg) demonstrated that the 
TAF-generated TFV systemic exposures (AUCinf) were markedly lower (approximately 
90% lower at TAF 25 mg) than the TFV exposure generated with TDF 300 mg. For HIV Phase 2 
(and Phase 3) studies, however, a 10 mg dose of TAF was selected for inclusion as a component 
of the Elvitegravir (E)/Cobicistat (COBI, or “C”)/Emtricitabine(F)/TAF STR in comparison to 
the E/C/F/TDF STR control arm. A reduction in dose from 25 mg to 10 mg of TAF in the 
E/C/F/TAF STR is required based on a drug-drug interaction between TAF and COBI resulting 
in increased exposures of both TAF and TFV which is likely a consequence of Pgp-mediated 
inhibition of TAF and TFV efflux within the gut by COBI. Importantly, the resultant TFV 
exposures when TAF is dosed at 10 mg with COBI in the E/C/F/TAF STR formulation are 
equivalent to TFV exposures generated with TAF 25 mg given as a single agent. Given that TAF 
exposures with E/C/F/TAF 10 mg are comparable to those with 25 mg TAF given alone, safety 
results in HIV trials using this formulation are being assessed at a TAF dose that is considered 
therapeutically equivalent to TAF 25 mg. Thus, HIV studies conducted at TAF exposures similar 
to those expected in HBV provide the basis for supporting safety data for the TAF HBV 
development program.
Table 1-1.
Summary of TAF Phase 1 and Phase 1/2 Studies for HIV Infection
Study #
Population
Design
Dosing/Duration
Rationale
HIV Studies (Phase 1/2)
120-1101
N=30
Treatment naïve
Dose escalation
3 treatment cohorts
TAF 50 mg, 150 mg, TDF 
300 mg; multiple dosing for 14 
days
Short-term proof of concept 
study; safety, PK, and 
antiviral efficacy
120-0104
N=38
Treatment naïve
(no ARV within 
90 days of screening)
Randomized 
(2:2:2:1:2) partially 
blinded
TAF 8 mg, 25 mg, 40 mg, 
TDF 300 mg, or placebo 
(PBO) for 10 days; off 
treatment follow up to Day 21
Confirmatory study for Study 
1101 using a TAF 
reformulation; more rigorous 
design, evaluate lower TAF 
doses
Supportive Phase 1 Studies
120-0107
N=48
Males/females, 
age 18-45
Thorough QT 
(TQT)
TAF 25 mg, 125 mg; each 
subject dosed 3 times for 
37 days (with 10 day wash-out 
period)
Regulatory requirement
120-0108
N=27 
(14 with severe renal 
impairment 
[CrCL 15-29 mL/min] 
and 13 matched 
controls 
[CrCL ≥90 mL/min])
PK in Renal 
impairment
TAF 25 mg single dose with 
14 days of follow up
Characterizing TAF and TFV 
PK in severe 
renal impairment 
(to demonstrate no need for 
TAF dose adjustment)
120-0109
N=8
healthy volunteer, 
male subjects
Mass Balance
Single radio-labeled TAF 
25 mg dose with 21 days of 
follow up
Regulatory requirement


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 32
25 September 2019
Clinical trials entailing the use of TAF for the treatment of CHB virus:

GS-US-320-0101 A Phase 1b Randomized, Open-label, Active-Controlled Study to Assess 
the Safety, Viral Kinetics and Anti-HBV Activity of GS-7340 in Treatment-Naïve Adults 
with Chronic Hepatitis B (CHB) Infection (enrollment and dosing completed)
The two proof-of concept studies, GS-120-1101 and GS-US-120-0104, as well as 
GS-US-292-0101, a STR bioequivalence study, were performed using TAF monofumarate 
(GS-7340-02). All subsequent studies discussed herein were performed using TAF fumarate 
(GS-7340-03). 
GS-120-1101 was a Phase 1/2 randomized double-blind, active-controlled, dose escalation study 
of the safety, tolerance, pharmacokinetics, and antiviral activity of TAF in antiretroviral-naïve 
subjects, who are chronically infected with HIV-1. The subjects were randomized to receive 
14 days of monotherapy, fasting, with GS-7340-02 50 mg (40 mg GS-7340 [free base] 
equivalent) QD, 150 mg (120 mg GS-7340 [free base] equivalent) QD, or tenofovir DF 300 mg 
QD (n = 10 per group). TAF was rapidly absorbed into the systemic circulation, and 
subsequently following attainment of Cmax, was eliminated rapidly with a short plasma half-life 
(20-40 minutes). Compared with TDF, GS-7340-02 50 mg provided a ~16-fold lower TFV Cmax
(207 ng/mL vs 13 ng/mL), about 2-fold longer elimination half-life (26 hours vs 48 hours) and 
lower overall systemic TFV exposure (AUCinf: 1814 ng.h/mL vs 383 ng.h/ml). GS-7340-02
150 mg provided lower Cmax (42 ng/mL), but comparable AUCinf: (1740 ng.h/mL) as TDF. In 
PBMCs, TFV was detected earlier, more frequently, and in higher concentrations following 
dosing of GS-7340-02 as compared to TDF. The intracellular delivery of TFV is approximately 
30-fold greater for GS-7340-02 versus TDF. The decrease from Baseline to Day 14 in plasma 
HIV-RNA levels was greater for groups treated with GS-7340-02 50 mg (p = 0.02757) or 
150 mg (p = 0.0010) than the group that received TDF 300 mg. The median changes from 
baseline in plasma HIV-1 RNA after 14 days of monotherapy were 0.96 log10 copies/mL for 
TDF 300 mg, 1.65 log10 copies/mL for GS-7340-02 50 mg, and 1.68 for GS-7340-02 150 mg. 
A second proof-of-concept study, GS-US-120-0104, evaluated monotherapy, fasting, with three 
lower doses of TAF compared with TDF 300 mg, or placebo, administered for 10 days. Potent 
antiviral activity was achieved with TAF in treatment-naïve HIV-1 infected subjects; mean viral 
load declines for both the 25 mg and 40 mg doses were statistically better than the 8 mg dose. 
TAF exposure (AUC) was best associated with antiviral activity despite its short plasma half-life 
(~ 30 min). TFV AUC values were 97%, 87%, and 80% lower at 8 mg, 25 mg, and 40 mg TAF 
respectively, compared to TDF administration. When compared to 40 mg and historical 120 mg
data, 25 mg TAF provides near maximal anti-HIV-1 activity. From this PK-PD analysis, a target 
dose of 25 mg TAF monotherapy is expected to provide near maximal antiviral activity and 
~ 90% reduction in circulating TFV. 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 33
25 September 2019
Study GS-US-120-0107 is a Phase 1, partially-blinded, randomized, placebo- and 
positive-controlled study to evaluate the effect of TAF on the QT/QTc interval in healthy 
subjects. This was a negative thorough-QTc study. No effect of TAF was observed on the QTcF 
interval (ie, no QTc interval prolongation > 10 msec at any time point post-dose and assay 
sensitivity was confirmed via the positive control [moxifloxacin]). As such, these findings satisfy 
the guidelines set forth in the International Conference on Harmonization (ICH) E14 guidance 
and support the conclusion that there is no significant effect of TAF on the QT/QTc interval.
Study GS-US-120-0108 is a Phase 1, open-label, parallel-design study to evaluate the PK of TAF 
in subjects with severe renal impairment. TAF was well tolerated in the study. Subjects with 
severe renal impairment had < 2-fold higher TAF and 5-6-fold higher TFV systemic exposures as 
assessed by AUC relative to subjects with normal renal function. TFV exposures in subjects with 
severe renal impairment are comparable to those with normal renal function receiving 300 mg
TDF QD. Given the extensive safety data available for TDF at a dose of 300 mg, TFV exposures 
in severely renally impaired subjects similar to those associated with TDF 300 mg are deemed 
appropriate for further study of TAF in HIV-infected subjects without TAF dose modification.
Preliminary results from Study GS-US-120-0109, a Phase 1 PK, metabolism and excretion study 
demonstrated that TAF is eliminated in both feces and urine. TAF and its metabolites are 
eliminated in both feces and urine. The predominant species detected in feces and urine is TFV, 
accounting for 31.4% ± 10.4% and 22.2% ± 4.47% respectively, of the total radioactive dose.
These human data are consistent with the established preclinical profile of TAF. Following
administration of TAF, plasma [14C] radioactivity showed a time dependent profile with TAF as 
the most abundant species in the initial few hours and uric acid, a byproduct of TAF metabolism,
in the remaining period. The whole blood-to-plasma concentration ratio of [14C] radioactivity 
increased from 0.511 at 0.25 hours post dose to 2.32 at 216 hours post dose, suggesting a 
relatively slower clearance of [14C] radioactivity from blood cells relative to the plasma 
[14C] radioactivity time-course. In addition to TFV and uric acid, additional low quantities of 
metabolites were formed, including xanthine, hypoxanthine, and adenine. They are identical to 
the endogenous products of purine metabolism and therefore should not cause any safety risk. 
TAF 25 mg tablets administered together with tracer dose of [14C] radiolabeled TAF as a single 
oral tablet, were well tolerated.
HBV Study – GS-US-320-0101
In HBV subjects, a 28 day Phase 1b study (GS-US-320-0101), was conducted to evaluate 
safety/tolerability, pharmacokinetics, and antiviral activity of TAF at doses of 8 mg, 25 mg, 
40 mg, and 120 mg compared to TDF 300 mg control in 50 subjects (10/cohort). As of 
April 2, 2013, enrollment was completed (n=51) and all subjects have completed study drug 
dosing through day 29.
Preliminary data suggest that all treatment groups were generally well matched and 
representative of the chronic HBV population (Table 1-2). Overall, the majority of subjects were 
male (66.7%), and of Asian descent (56.9%). Of the 51 randomized subjects, 27 (53%) and 
24 (47%) were HBeAg-negative and HBeAg-positive, respectively. Median age ranged among 
groups from 34 years in the 8 mg and 25 mg TAF groups to 40 and 42 years in the 40 mg and 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 34
25 September 2019
120 mg TAF groups, respectively; median age in the TDF group was 34 years. The most 
common HBV genotype at enrollment was genotype C (16/51; 31%), the proportions of other 
genotypes were: A (7/51; 14%), B (10/51; 20%), D (9/51; 18%), and E (9/51; 18%). The 
distribution of HBV genotypes was similar among groups, with the exception of a higher 
proportion (5 of 11 [45.5%]) of subjects in the 40 mg TAF group being genotype B.
Table 1-2.
GS-US-320-0101: Baseline Demographics and Disease Characteristics
TAF 8 mg
(N=10)
TAF 25 mg
(N=10)
TAF 40 mg
(n=11)
TAF 120 mg
(N=10)
TDF 300 mg
(N=10)
Male sex, n (%) 
4 (40%)
8 (80%)
8 (73%)
8 (80%)
6 (60%)
Median (range) age, yr
34 (19 – 57)
34 (23 – 42)
40 (19 −60)
42 (25 −51)
34 (25 −49)
Race, n (%)
Asian
4 (40%)
7 (70%)
8 (73%)
5 (50%)
5 (50%)
Black or African American
4 (40%)
1 (10%)
3 (27%)
2 (20%)
5 (50%)
White
2 (20%)
1 (10%)
0
3 (30%)
0
Native Hawaiian or 
Other Pacific Islander
0
1 (10%)
0
0
0
Median (range) BMI, kg/m2
26.6
(17.9 - 32.3)
25.9
(20.2 – 46.0)
24.1
(21.0 – 31.8)
24.5
(19.8 – 34.0)
25.6
(19.6 – 31.8)
Median (range) body weight, kg
69.7
(49.9 – 94.0)
74.7
(61.0 – 134.4)
62.5
(56.0 – 104.1)
71.2
(54.0 – 110.0)
78.3
(47.2 – 98.8)
Median (range) CLCr, mL/min
107.1
(88.8 −158.0)
121.7
(84.8 −239.1)
117.9
(75.6 −153.8)
107.6
(81.3 −143.5)
127.1
(64.2 −196.4)
Median (range) HBV DNA, 
log10 IU/mL
6.26
(3.73 – 8.98)
6.35
(3.56 – 8.93)
5.37
(3.27 – 8.57)
5.98
(3.71 – 9.74)
4.78
(3.97 – 8.85)
Median (range) HBsAg,
log10 IU/mL
4.10
(1.55 – 4.72)
3.59
(1.47 – 4.72)
3.64
(1.67 – 4.72)
3.84
(2.64 – 4.72)
3.93
(2.95 – 4.72)
Median (range) ALT, U/L
41.0
(23 −83)
52.5
(33 −106)
50.0
(11 −169)
43.0
(26 −114)
27.5
(11 −107)
HBeAg-negative, n (%)
5 (50%)
4 (40%)
8 (73%)
5 (50%)
5 (50%)
HBV genotype, n (%)
A
1 (10%)
1 (10%)
1 (9%)
1 (10%)
3 (30%)
B
1 (10%)
2 (20%)
5 (45%)
1 (10%)
1 (10%)
C
2 (20%)
4 (40%)
3 (27%)
3 (30%)
4 (40%)
D
3 (30%)
2 (20%)
1 (9%)
3 (30%)
0
E 
3 (30%)
1 (10%)
1 (9%)
2 (20%)
2 (20%)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 35
25 September 2019
Preliminary safety results are summarized in the table below. Overall, TAF was safe and well 
tolerated in HBV subjects. No subjects experienced a serious adverse event (SAE), or 
Grade 3 or 4 treatment emergent adverse event, and no subjects required treatment 
discontinuation for an AE. Treatment emergent AEs were generally mild and included 
gastrointestinal complaints (nausea, vomiting, diarrhea, epigastric discomfort), fatigue, lethargy, 
headache, and dizziness. Grade 3 laboratory abnormalities were seen in 3 subjects in the TAF 
40 mg group (1 subject each with creatine kinase elevation, glycosuria, and hematuria), 
2 subjects in the TAF 120 mg group (1 subject each with elevated transaminases [both AST 
and ALT] - described below, and amylase elevation), and in 1 subject in the TDF arm 
(amylase elevation). The subject with Grade 3 glycosuria in the TAF 40 mg group, experienced 
this abnormality at Day 29 which was associated with a corresponding serum glucose elevation 
(212 mg/dL); the subject also had a history of diabetes mellitus.
Table 1-3.
GS-US-320-0101: Treatment-Emergent Adverse Events and 
Laboratory Abnormalities: Overall Summary, Safety Analysis Set
TAF 8 mg
(N=10)
TAF 25 mg
(N=10)
TAF 40 mg
(n=11)
TAF 120 mg
(N=10)
TDF 300 mg
(N=10)
Subjects Experiencing Any
Treatment-Emergent Adverse Event
7 (70%)
6 (60%)
6 (55%)
8 (80%)
5 (50%)
Subjects Experiencing Any 
Treatment-Emergent 
Study-Drug-Related Adverse Event
2 (20%)
4 (40%)
3 (27%)
4 (40%)
5 (50%)
Subjects Experiencing Any 
Grade 2, 3 or 4 Treatment-Emergent 
Adverse Event
1 (10%)
1 (10%)
0
4 (40%)
2 (20%)
Subjects Experiencing Any 
Grade 2, 3 or 4 Treatment-Emergent 
Study-Drug Related Adverse Event
0
0
0
3 (30%)
1 (10%)
Subjects Experiencing Any 
Grade 3 or 4 Treatment-Emergent 
Adverse Event
0
0
0
0
0
Subjects Experiencing Any 
Grade 3 or 4 Treatment-Emergent 
Laboratory Abnormality
0
0
3 (27%)
2 (20%)
1 (10%)
Subjects Experiencing Any 
Treatment-Emergent Serious 
Adverse Event
0
0
0
0
0
Subjects Experiencing Any 
Treatment-Emergent Adverse Event 
Leading to Premature Study Drug 
Discontinuation
0
0
0
0
0


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 36
25 September 2019
Given the significantly smaller declines in creatinine clearance (CLCr) observed at Week 24 with 
TAF relative to TDF in the HIV Phase 2 study (GS-US-209-0102; Section 1.2.4), changes in 
CLCr were also assessed in HBV subjects participating in GS-US-320-0101. After 4 weeks of 
dosing, numerically smaller changes in CLCr at Day 29 were seen in HBV subjects receiving 
TAF compared with TDF (Figure 1-1). At Day 29, median (range) change from baseline in 
CLCr was 2.0 ( 13.2, 9.6) mL/min for the TAF 25 mg group compared with a change of 
10.4 ( 35.7, 13.0) mL/min in the TDF group. Further, there were no notable differences in CLCr
change among the two lowest dose groups (TAF 8 mg and TAF 25 mg), and the highest dose 
group (120 mg). An early decline in CLCr, similar to that observed in the TDF group was noted 
in the TAF 40 mg group; however, by Day 29 the change in CLCr was similar to the other TAF 
groups. These results are consistent with findings in HIV subjects receiving the E/C/F/TAF 
10 mg STR and provide additional evidence to support the concept that lower TFV exposures 
with TAF relative to TFV exposures with TDF are associated with notable differences in renal 
function change as determined by estimated CLCr.
Figure 1-1.
Median Change (Q1, Q3) from Baseline in Creatinine Clearance 
(Cockcroft-Gault Method) in GS-US-320-0101
Baseline is defined as Day 1.
Over 28 days of study drug treatment, similar median declines in HBV DNA levels were 
observed among treatment groups (Figure 1-2). Overall, viral decay results among subjects who 
received treatment with TAF demonstrated the absence of a dose effect. In addition, the HBV 
30 
20 
10 
" 
.!: 
ai 
(/) 
It! 
Ill 
E -10 
.g 
" 
Cl 
C 
It! 
.c -20 
u 
-30 
-40 
-50 
BL 
8-MG GS-7340 QD: 
10 
10 
25-MG GS-7340 QD: 
10 
40-MG GS-7340 QD: 
11 
11 
120-MG GS-7340 QD: 
10 
300-MG TDF QD: 
10 
10 
-- --::----::::-
- -
10 
15 
19 
22 
Analysis Visit (Study Days) 
10 
10 
10 
10 
0 = 8-MG GS-7340 QD 
• 
= 25-MG GS-7340 QD 
I', = 40-MG GS-7340 QD 
= 120-MG GS-7340 QD 
= 300-MG TDF QD 
-----
29 
10 
10 
11 
9 
10 
30 
20 
10 
-10 
-20 
-30 
-40 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 37
25 September 2019
DNA declines with TAF (n = 41) over 28 days of dosing were similar to HBV DNA declines 
observed in the TDF 300 mg group (n = 10). A summary of change from baseline in HBV DNA 
results at Day 15 and Day 29 is provided in the table below (Table 1-4) below. Among TAF 
groups, median change from baseline in HBV DNA at Day 29 ranged from 1.98 log10 IU/mL 
for the TAF 40 mg group to 2.76 log10 IU/mL for the TAF 8 mg group. For TAF 25 mg, the 
change from baseline in HBV DNA at Day 29 was 2.67 log10 IU/mL. Consistently smaller 
declines in HBV DNA over time, and slightly lower median change from baseline in HBV DNA 
were observed in the TAF 40 mg group at Day 29. The reason for this is unclear and possibly 
related to a lower median HBV DNA value at Baseline (Table 1-4). In this group, 
5/11 (45.5%) subjects had a baseline HBV DNA value below 5.0 log10 IU/mL. In comparison to 
TAF groups, the change from baseline in HBV DNA at Day 29 was 2.60 log10 IU/mL with 
TDF 300 mg. 
Figure 1-2.
GS-US-320-0101: Median Change (Q1, Q3) from Baseline HBV DNA 
(log10 IU/mL) by Treatment Group
Baseline is defined as Day 1/pre-dose.
0.5 
0.0 
'.J -0.5 
0 
- 1.0 
C) 
0 
-=-
<{ 
-1 .5 
z 
0 
> -2.0 
Ill 
I 
.E 
GJ 
-2.5 
.E 
-.; 
Ill 
"' 
-3.0 
Ill 
E 
0 .::: 
-3.5 
GJ 
Cl 
C: 
"' 
-4.0 
.s:: u 
-4.5 
-5.0 
8-MG GS-7340 QD: 
25-MG GS-7340 QO: 
40-MG GS-7340 QO: 
120-MG GS-7340 QD : 
300-MG TDF QD: 
0.5 
0.0 
-0.5 
-1 .5 
-2.0 
-2.5 
-3.0 
0 = 8-MG GS-7340 QD 
-3.5 
• 
= 25-MG GS-7340 QD 
[':,. = 40-MG GS-7340 QD 
-4.0 
= 120-MG GS-7340 QD 
= 300-MG TDF QD 
-4.5 
'-.---.---,---,---,---,----,----,--,---,---,--,---.---,---,---,---,----,----,--,---,---,--.---.---,---,---,---,----,----,--,-' -5.0 
BL 
10 
10 
10 
10 
10 
10 
10 
11 
11 
10 
11 
10 
10 
10 
10 
10 
10 
10 
11 
10 
10 
15 
Visit (Day) 
10 
10 
9 
10 
10 
19 
10 
9 
11 
10 
22 
10 
10 
11 
10 
10 
29 
10 
10 
9 
10 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 38
25 September 2019
Table 1-4.
GS-US-320-0101: HBV DNA Results: Median Change from Baseline 
at Day 15 and Day 29 by Treatment Group
TAF 8 mg
(N = 10)
TAF 25 mg
(N = 10)
TAF 40 mg
(n = 11)
TAF 120 mg
(N = 10)
TDF
(N = 10)
HBV DNA (Log10 IU/mL) 
at Baseline (Day 1), 
Median (Q1, Q3), [Min, Max]
6.26
(5.01, 8.50)
[3.73, 8.98]
6.35
(4.10, 7.68)
[3.56, 8.93]
5.37
(3.42, 7.78)
[3.27, 8.57]
5.98
(4.34, 8.83)
[3.71, 9.74]
4.78
(4.11, 6.86)
[3.97, 8.85] 
n =
10
10
9
10
10
Change from Baseline in 
HBV DNA (Log10 IU/mL) at 
Day 15, Median (Q1, Q3), 
[Min, Max]
-2.41
(-2.63, -2.03)
[-3.03, -1.42]
-2.14
(-2.48, -1.76)
[-3.07, -1.27]
-1.84
(-2.18, -1.68)
[-2.81, -0.98]
-2.43
(-2.58, -2.25)
[-3.03, -1.91]
-2.55
(-2.69, -1.87)
[-2.99, -1.75]
n =
10
10
9
9
10
Change from Baseline in 
HBV DNA (Log10 IU/mL) at 
Day 29, Median (Q1, Q3), 
[Min, Max]
-2.76
(-3.17, -2.48)
[-3.57, - 1.88]
-2.67
(-3.23, -2.12)
[-3.32, -1.49]
-1.98
(-2.65, -1.82)
[-3.11, -1.67]
-2.70
(-2.92, -2.56)
[-3.88, -2.16]
-2.60
(-2.99, -2.52)
[-3.44, -1.99]
Plasma concentration-time profiles were generated after intensive pharmacokinetic sampling 
following a single dose on Day 1 for subjects who were randomized to receive TAF 8, 25, 40, or 
120 mg, or TDF 300 mg (N=51). The respective plasma concentration-versus-time profiles are 
shown in Figure 1-3 (TAF) and Figure 1-4 (TFV). Pharmacokinetic parameters were calculated 
via non-compartmental analysis. 
TAF Pharmacokinetic Results
In general, the concentration-time profiles for TAF over the range of doses studied in CHB 
subjects were consistent with previous results in the healthy volunteers and HIV subjects 
receiving TAF either as a single agent or as a component of the E/C/F/TAF STR.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 39
25 September 2019
Figure 1-3.
GS-US-320-0101: Mean (SD) Plasma Concentrations vs. Time on 
Day 1: TAF (GS-7340), Linear Scale
TAF plasma pharmacokinetic parameters are summarized in Table 1-5. Day 1 pharmacokinetic 
results in CHB subjects participating in GS-US-320-0101 are consistent with previously reported 
results in the HIV Phase 1/2 study GS-US-120-0104, which evaluated TAF single-dose 
pharmacokinetics following doses of 8 mg (n=9), 25 mg (n=8), and 40 mg (n=8), versus TDF 
300 mg (n=6). In GS-US-120-0104, mean (%CV) AUC0-last was 38.4 (80.6) ng∙h/mL, 
139.7 (57.8) ng∙h/mL, and 322.1 (42.0) ng∙h/mL after single doses of TAF 8 mg, 25 mg, and 
40 mg, respectively. Other parameters assessed on Day 1 (Cmax, Tmax, and t1/2) in 
GS-US-320-0101 were similar to the results generated in GS-US-120-0104.
Similar findings to the present study were also observed when TAF pharmacokinetic parameters 
were assessed after multiple doses at steady-state in the ongoing Phase 2 study, 
GS-US-292-0102, which compares STRs of E/C/F/TAF 10 mg to E/C/F/TDF 300 mg in HIV-1 
infected, treatment-naive subjects. Mean (%CV) AUClast, and Cmax values for TAF at the 10 mg 
dose in combination with COBI were 230.4 (47.3) ng∙h/mL and 232.8 (64.6) ng/mL, 
respectively. As TAF exposures at the 10 mg dose, when included as a component of the 
E/C/F/TAF STR, have been shown to be comparable to those with TAF 25 mg given as the 
stand-alone agent, these results indicate similar TAF exposures in both subjects infected with 
HIV and those infected with HBV.  
1600 
1500 
1400 
1300 
:::, 1200 
i 
] 
900 
800 
C: ., 
(.) 
C: 
0 u 
8-MG GS-7340 QD (n=): 
25-MG GS-7340 QD (n=): 
40-MG GS-7340 QD (n=): 
120-MG GS-7340 QD (n=): 
700 
600 
500 
400 
300 
200 
100 
0 
0 
2 
10 10 10 
10 
9 
10 
11 
11 
11 
10 10 10 
3 
4 
6 
10 10 
10 
10 10 
10 
11 
11 
11 
10 10 
10 
8 
10 
9 
11 
10 
12 
0 = 8-MG GS-7340 QD 
• 
= 25-MG GS-7340 QD 
6 = 40-MG GS-7340 QD 
= 120-MG GS-7340 QD 
Time (h) 
24 
10 
10 
10 
9 
Note: Plasma concentration below limit of quantltatlon was treated as 0 for summary purpose and was treated as missing for log-transformed data. 
Data Extracted: CRF data: 25APR2013 
Source: ... \draft2\prog\t-pkconc.sas v9.2 Output file: g-pconc1-mn.out 01 MAY2013:16:12 
1600 
1500 
1400 
1300 
1200 
1100 
1000 
900 
800 
700 
600 
500 
400 
300 
200 
100 
0 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 40
25 September 2019
Table 1-5.
GS-US-320-0101: Single Dose Pharmacokinetic Results for TAF on 
Day 1
TAF PK Parameter
TAF 8 mg
(N = 10)
TAF 25 mg
(N = 10)
TAF 40 mg
(N = 11)
TAF 120 mg
(N = 10)
AUC0-last (ngh/mL)
59.2 (54.1)
153.0 (41.1)
328.1 (58.4)
832.4 (39.1)
AUCinf (ngh/mL)
60.6 (52.8)
154.4 (41.0)
329.8 (58.1)
834.6 (38.9)
Cmax (ng/mL))
83.2 (46.3)
249.5 (45.9)
527.4 (50.6)
1128.7 (33.7)
Tmax (h) median
0.5
0.5
0.5
0.5
T1/2 (h)
0.36 (23.8)
0.51 (32.6)
0.59 (30.7)
0.76 (30.8)
All results expressed as mean (%CV) unless otherwise stated
TFV Pharmacokinetic Results
Mean (SD) plasma concentration versus time profiles for TFV following single dose 
administration of ascending doses of TAF and TDF 300 mg are shown in Table 1-4. At each 
TAF dose evaluated, plasma TFV concentrations resulting from TAF administration were lower 
than plasma TFV concentrations following TDF administration. The TFV concentrations 
achieved from all TAF dose levels in HBV subjects in GS-US-320-0101 are comparable to TFV 
concentrations achieved after TAF administration in the HIV program.
Figure 1-4.
GS-US-320-0101: Mean (SD) Plasma Concentrations vs. Time on 
Day 1: Tenofovir, Linear Scale
400 
::::; 300 
E 
c, 
..s 
C 
0 
:;::; 200 
C: 
(I) 
0 
C 
0 u 100 
0 
0 
2 
8-MG GS-7340 ao (n=): 
10 
10 10 
25-MG GS-7340 QD (n=): 
10 
9 
10 
40-MG GS-7340 QD (n=): 
11 
11 
11 
120-MG GS-7340 QD (n=): 
10 
10 10 
300-MG TDF QD (n•): 
9 
9 
10 
3 
4 
6 
10 
10 
10 
10 
10 
10 
11 
11 
11 
10 
10 
10 
10 
10 
10 
8 
10 
9 
11 
10 
10 
0 = 8-MG GS-7340 ao 
• 
= 25-MG GS-7340 ao 
6 = 40-MG GS-7340 ao 
0 = 120-MG GS-7340 ao 
= 300-MG TDF ao 
12 
Time (h) 
24 
10 
10 
11 
9 
8 
Note: Plasma concentration below limit of quantltation was treated as O for summary purpose and was treated as missing for log-transformed data. 
Data Extracted: CRF data: 25APR2013 
Source: ... ldralt2\proglt-pkconc.sas v9.2 Output file: g-pconc2-mn.out 01MAY2013:16:12 
400 
300 
200 
100 
0 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 41
25 September 2019
Tenofovir (TFV) plasma pharmacokinetic parameters are summarized in Table 1-6. As with 
TAF, Day 1 TFV pharmacokinetic results in CHB subjects participating in GS-US-320-0101 are 
consistent with those previously reported in the HIV Phase 1/2 study GS-US-120-0104, which 
evaluated TAF single-dose pharmacokinetics following doses of 8 mg (n=9), 25 mg (n=8), and 
40 mg (n=8), versus TDF 300 mg (n=6). In GS-US-120-0104, mean (%CV) AUCinf for TFV 
were 49.4 (30.3) ng∙h/mL, 195.9 (27.2) ng∙h/mL, and 287.3 (33.7) ng h/mL after single doses of 
TAF 8 mg, 25 mg, and 40 mg, respectively. Mean (%CV) AUCinf for TFV following TDF 
300 mg was 1719.2 ng∙h/mL. Other parameters assessed on Day 1 (Cmax, Tmax, and t1/2) in 
GS-US-320-0101 were similar to results seen in HIV subjects in GS-US-120-0104. As stated 
earlier, When TAF is included as a component of the E/C/F/TAF STR, a reduced dose (10 mg) is
required due to a drug-drug interaction (inhibition of P-gp in the gut by cobicistat) that results in
increased exposures of both TAF and TFV (see Section 1.2.4).
The following Section 1.2.4 provides a summary of experience with TAF in HIV-1 infection, 
including the final Week 24 analysis results for TAF when used as a component of the 
E/C/F/TAF STR in the HIV Phase 2 study GS-US-292-0102. Because TAF exposures in this 
ongoing trial are similar to those expected in the TAF HBV development program, these results 
provide importing supporting safety data.
Table 1-6.
GS-US-320-0101: Single Dose Pharmacokinetic Results for TFV on 
Day 1
TFV PK Parameter
TAF 8 mg
(n=10)
TAF 25 mg
(n=10)
TAF 40 mg
(n=11)
TAF 120 mg
(n=10)
TDF 300 mg
(n=10)
AUC0-last (ngh/mL)
32.9 (35.0)
90.6 (25.8)
213.4 (40.2)
607.7 (35.4)
1682.1 (28.0)
AUCinf (ngh/mL),
74.0 (41.2)
171.4 (29.9)
444.6 (43.0)
1572.0 (47.2)
2309.8 (27.9)
Reduction in AUCinf, 
TAF/TDF (%)
97
93
81
32
N/A
Cmax (ng/mL),
3.0 (34.5)
8.3 (41.6)
20.3 (43.2)
61.0 (33.5)
306.8 (24.5)
Reduction in Cmax, 
TAF/TDF (%)
99
97
93
80
N/A
Tmax (h) median
1.25
1.0
1.0
1.0
1.0
t1/2 (h)
26.7 (23.4)
20.7 (39.6)
26.3 (33.8)
31.4 (38.6)
10.8 (17.4)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 42
25 September 2019
1.2.4.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
Phase 1 and 2 clinical trials using TAF, coformulated into the E/C/F/TAF STR for the treatment 
of HIV-1 infection include:

GS-US-292-0101, a Phase 1 healthy volunteer study evaluating the relative bioavailability of 
EVG, FTC, TFV, and COBI when administered as E/C/F/TAF STR relative to E/C/F/TDF or 
TAF (completed)

GS-US-292-0103, a Phase 1 healthy volunteer study to evaluate the pharmacokinetics and 
relative bioavailability of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg (STR) or 25 mg SA (completed)

GS-US-292-0102, a Phase 2 randomized, double-blinded study of the safety and efficacy of 
E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, antiretroviral treatment-naive 
adults (ongoing)
1.2.4.1.
Summary of Phase 1 Studies (Study GS-US-292-0101, GS-US-292-0103)
Study GS-US-292-0101 is a Phase 1 study of 40 subjects evaluating the relative bioavailability 
of two different formulations of E/C/F/TAF STR, each with TAF dose of 25 mg or 40 mg, versus 
E/C/F/TDF STR or TAF 25 mg alone. Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolayer or bi-layer). In 
contrast, TAF exposures were ~2.2-fold higher (and corresponding tenofovir exposures ~ 3-fold 
higher) when administered as E/C/F/TAF (25 mg) vs TAF SA 25 mg for both formulations of the 
E/C/F/TAF. This is likely mediated by inhibition of Pgp-mediated intestinal secretion of TAF by 
COBI and consistent with data from Study GS-US-311-0101 described below. 
Study GS-US-292-0103 is a completed Phase 1 healthy volunteer study which evaluated the PK 
and relative bioavailability of the E/C/F/TAF STR relative to the individual components at TAF 
doses of 10mg (as STR) or 25 mg SA. Results indicate that when dosed as the E/C/F/TAF 10 mg
STR, TAF and TFV exposures were comparable to those observed with TAF 25 mg dosed alone. 
Exposures of EVG, COBI, and FTC were also comparable between the STR and individually 
dosed formulations. 
1.2.4.2.
Week 24 Summary of Phase 2 Study (Study GS-US-292-0102)
GS-US-292-0102 is an ongoing Phase 2, randomized, double-blind, multicenter, 
active-controlled study to assess the safety and efficacy of E/C/F/TAF STR versus E/C/F/TDF in 
HIV-1 infected, antiretroviral treatment-naive adults with plasma HIV-1 RNA levels 
≥5,000 copies/mL at screening. 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 43
25 September 2019
Eligible subjects were randomized in a 2:1 ratio to 1 of the following 2 treatment arms and 
randomization was stratified by HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL) 
at screening:

Treatment Arm 1: STR of EVG 150 mg/ COBI 150 mg/ FTC 200 mg/ TAF 10 mg
(E/C/F/TAF) + placebo-to-match STR of EVG 150 mg/ COBI 150 mg/ FTC 200 mg/ TDF 
300 mg (E/C/F/TDF) once daily (n = 100)

Treatment Arm 2: STR of EVG 150 mg/COBI 150 mg/ FTC 200 mg/ TDF 300 mg
(E/C/F/TDF) + placebo-to-match STR EVG 150 mg/ COBI 150 mg/ FTC 200 mg/ 
TAF 10 mg (E/C/F/TAF) once daily (n = 50)
The Independent Data Monitoring Committee (IDMC) reviewed the safety and study conduct at 
week 12 and determined that no changes were required for study GS-US-292-0102. Interim data 
at week 24 is presented below.
1.2.4.3.
Week 24 Subject Disposition and Demographics
A total of 170 subjects were randomized and treated in this study: 112 subjects in the E/C/F/TAF 
group and 58 subjects in the E/C/F/TDF group. The full analysis set (FAS) and safety analysis 
set (SAS) each included all randomized and treated subjects from each group. 
 
 At the time of the 
Week 24 data analysis, 6 subjects (2.4%) had been discontinued from treatment and 4 subjects 
(2.4%) had been discontinued from study. 
Of the 170 subjects in the FAS and SAS, 165 (97.1%) were male; 115 (67.6%) were white and 
50 (29.49%) were black; and the mean age was 36 years (range: 18 to 71 years). Demographic 
and baseline disease characteristics were similar between the 2 treatment groups.
1.2.4.4.
Week 24 Efficacy Results
Proportion of Subjects with Plasma HIV-1 RNA < 50 copies/mL at Week 24
The proportion of subjects who achieved HIV-1 RNA < 50 copies/mL at Week 24 was 86.6% in 
the E/C/F/TAF group and 89.7% in the E/C/F/TDF group, with a stratum-adjusted difference in 
the response rate between the 2 treatment groups of 4.9% (95% CI: 15.7% to 5.9%; p = 0.36).
Results of the secondary efficacy endpoint confirmed those of the primary analysis. The 
proportion of subjects with suppression of plasma HIV-1 RNA < 50 copies/mL at Week 24 
(time-to-loss of virologic-response [TLOVR] analysis) was 88.4% (99/112) in the E/C/F/TAF 
group and 84.5% (49/58) in the E/C/F/TDF group. The stratum-adjusted difference in the 
response rate between the 2 treatment groups was 0.1% (95% CI: 10.4% to 10.2%; p = 0.99).
The mean increase in CD4 cell count from baseline to Week 24 was 163 cells/μL in the 
E/C/F/TAF group and 177 cells/μL in the E/C/F/TDF group (-6 difference in LSM, 
95% CI 44 to 33).
CCI-


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
1.2.4.5. 
1.2.4.6. 
1.2.4.6.1. 
Week 24 Phannacokinetic Results 
Week 24 Safety Results 
Overall Safety 
Final 
Amendment 3 .4 
At the time of the 24-week interim analysis, 112 subjects had been treated with E/C/F/f AF for a 
median duration of21.1 weeks and 58 subjects had been treated with E/C/F/fDF for a median 
duration of 21.3 weeks. The overall subject incidence of treatment-emergent adverse events 
(AEs) was balanced between treatment groups (81.3% E/C/F/f AF, 81.0% E/C/F/TDF) 
(Table 1-7). The most frequent treatment-emergent AEs (> 10% in either treatment group) were 
(E/C/F/TAF, E/C/F/TDF) nausea (17.9%, 12.1 %), diarrhea (11.6%, 12.1 %), fatigue 
(11.6%, 8.6%), upper respiratory tract infection (7.1 %, 12.1 %), and headache (9.8%, 10.3%), 
respectively. 
Most treatment-emergent AEs were assessed as Grade 1 or Grade 2 in severity. The incidence of 
Grade 3 or 4 A Es was higher in the E/C/F ff AF group (7 .1 %) compared to the E/C/F/TDF group 
(3.4%). No Grade 3 or 4 event occurred in > 1 subject; the system organ class (SOC) with the 
highest subject incidence of Grade 3 or 4 events was Nervous System Disorders 
(2.7% E/C/F/TAF, 0% E/C/F/TDF). The only Grade 3 or 4 event that was considered by the 
investigator to be related to investigational product was Grade 3 diarrhea in 1 subject (0.9%) in 
the E/C/F/TAF group; there were no treatment-related Grade 3 or 4 AEs in the E/C/F/fDF 
group. Based on these data, there do not appear to be any signature, higher grade AEs associated 
with the use of E/C/F/TAF through 24 weeks of treatment. 
More subjects in the E/C/F/TAF group compared to the E/C/F/TDF group also had 
treatment-emergent serious AEs (SAEs) (5.4% vs 3.4%) or AEs leading to premature treatment 
discontinuation (3.6% vs 0). None of these events occurred in> 1 subject, and none of the SAEs 
were considered by the investigator to be related to treatment with investigational product. The 
system organ class (SOC) with the highest subject incidence of treatment-emergent SAEs was 
Infections and Infestations (4.5% E/C/F/f AF, 0% E/C/F/TDF). No deaths or pregnancies 
occurred. 
CONFIDENTIAL 
Page 44 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 45
25 September 2019
Table 1-7.
GS-US-292-0102: Treatment-Emergent Adverse Events: 
Overall Summary, Safety Analysis Set
E/C/F/TAF
(N=112)
E/C/F/TDF
(N=58)
Subjects Experiencing Any Treatment-Emergent Adverse Event
91 (81.3%)
47 (81.0%)
Subjects Experiencing Any Grade 2, 3, or 4 Treatment-Emergent Adverse Event
42 (37.5%)
17 (29.3%)
Subjects Experiencing Any Grade 3 or 4 Treatment-Emergent Adverse Event
8 (7.1%)
2 (3.4%)
Subjects Experiencing Any Treatment-Emergent Study-Drug-Related 
Adverse Event
38 (33.9%)
15 (25.9%)
Subjects Experiencing Any Grade 2, 3, or 4 Treatment-Emergent 
Study-Drug-Related Adverse Event
6 (5.4%)
1 (1.7%)
Subjects Experiencing Any Grade 3 or 4 Treatment-Emergent 
Study-Drug-Related Adverse Event
1 (0.9%)
0
Subjects Experiencing Any Treatment-Emergent Serious Adverse Event
6 (5.4%)
2 (3.4%)
Subjects Experiencing Any Treatment-Emergent Study-Drug-Related 
Serious Adverse Event
0
0
Subjects Experiencing Any Treatment-Emergent Adverse Event Leading to 
Premature Study Drug Discontinuation
4 (3.6%)
0
Subjects who had Treatment-Emergent Death
0
0
Treatment-emergent death refers to a death occurring between the first dose date and the last dose date plus 30 days (inclusive).
At least 1 treatment-emergent laboratory abnormality (ie, at least 1 grade level increase in graded 
abnormality) was reported for 103/111 subjects (92.8%) in the E/C/F/TAF group and 
46/58 subjects (79.3%) in the E/C/F/TDF group. The majority of laboratory abnormalities were 
Grade 1 or 2 in severity. Subject incidence of Grade 3 or 4 treatment-emergent laboratory 
abnormalities is summarized in Table 1-8.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 46
25 September 2019
Table 1-8.
GS-US-292-0102: Treatment-Emergent Grade 3 or 4 Laboratory 
Abnormalities, Safety Analysis Set
E/C/F/TAF
(N = 112)
E/C/F/TDF
(N = 58)
Maximum Post-Baseline Toxicity Grade 3 or 4
19 (17.1%)
8 (13.8%)
Neutrophils
5 (4.5%)
1 (1.7%)
WBC
1 (0.9%)
0
Amylase
2 (1.8%)
1 (1.7%)
Creatine Kinase (CK)
6 (5.4%)
2 (3.4%)
Lipase
0
1 (12.5%)
Serum Glucose (Hyperglycemia)
0
1 (1.7%)
Total Cholesterol (Fasting, Hypercholesterolemia)
1 (0.9%)
0
Triglycerides (Fasting)
1 (0.9%)
1 (1.7%)
LDL (Fasting)
7 (6.4%)
2 (3.4%)
Urine Protein (Proteinuria)
1 (0.9%)
0
Urine RBC (Hematuria, Quantitative)
1 (0.9%)
0
Denominator for percentage is the number of subjects in the SAS set with at least 1 post-baseline laboratory value (for the test).
Subjects were counted once for the maximum post-baseline severity for each laboratory test.
Lipase test was only performed for subjects with serum amylase > 1.5 x upper limit of normal.
Urine RBC (hematuria, quantitative) was graded based on DAIDS grading scale (with the modification of urine RBC 
> 75 cells/HPF as Grade 3).
For Urinalysis (i.e., urine glucose, urine protein, and urine RBC), the highest grade is up to Grade 3.
No clinically significant changes in mean thyroid function tests (TSH, free T3, free T4) or serum 
immunoglobulins (IgG and IgM) were observed.
1.2.4.6.2.
Renal Safety
On multiple objective laboratory tests of renal function, subjects receiving E/C/F/TAF had a 
lower magnitude of change than subjects receiving E/C/F/TDF through 24 weeks.  
The change from baseline in serum creatinine (SCr) was lower in the E/C/F/TAF group
compared to the E/C/F/TDF group at most assessments through Week 24. At Week 24, median 
change from baseline in serum creatinine was 0.07 mg/dL (range through Week 24: 0.05 mg/dL 
to 0.08 mg/dL) for the E/C/F/TAF group and 0.11 mg/dL (range through Week 24: 0.08 mg/dL 
to 0.11 mg/dL) for the E/C/F/TDF group (Week 24 p = 0.016).
Accordingly, the decrease from baseline in estimated glomerular filtration rate (GFR) by 
Cockcroft-Gault formula for CLCr was lower in the E/C/F/TAF group compared to the 
E/C/F/TDF group at most assessments through Week 24 (Figure 1-5). At baseline, the mean 
(SD) estimated GFRC-G was similar between groups (120.1 [30.22] (mL/min) for subjects in the 
E/C/F/TAF group and 114.7 [21.68] (mL/min) for subjects in the E/C/F/TDF group. At Week 24, 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
median change from baseline estimated GFRc-G was 6.6 mL/min for the E/C/F/TAF group and 
10.6 mL/min for the E/C/F/TDF group (p = 0.009). At Week 24, 3 (5.2%) subjects in the 
E/C/F/TDF group would be classified as new Stage 3 CKD (eGFR 30-59 mL/min) vs. 
1 (1.0%) subjects in the E/C/F/TAF group, and 15 (14.4%) subjects in the E/C/F/TAF group 
would be classified as new Stage 2 CKD (eGFR 60-89 mL/min) vs. 20 (34.5%) subjects in the 
E/C/F/TDF group. 
Figure 1-5. 
GS-US-292-0102: Median (Ql, Q3) of Change from Baseline in 
Estimated GFR by Cockcroft-Gault by Visit, Safety Analysis Set 
-
10 
10 
C 
s 
""' 
::::, 
ro 
(!) 
0 
0 
() 
-" 
() 
0 u 
>, 
.0 
a:: 
u. 
(!) 
"O -10 
2 ro .s 
iii 
w 
-~ 
Q) 
-~ 
5l -20 
&l 
E 
0 
.): 
Q) 
Ol 
C ro 
.s::: 
-10 
-20 
U 
-30 
BL 
2 
4 
EVG/0081/FTCITAF (n=): 112 
109 
109 
<> 
STB (n=t. 
58 
54 
58 
8 
110 
58 
12 
107 
58 
16 
Week 
107 
58 
24 
104 
58 
32 
18 
11 
At Week 24, a trend towards reduced proteinuria was observed in the E/C/F/TAF group. By 
urine dipstick, the frequency of maximum post-baseline proteinuria (any grade) was 13.5% in 
E/C/F/TAF vs. 20.7% in E/C/F/TDF. The median change from baseline in urine albmn in to 
creatinine ratio (UACR) was 0.84 mg/g in E/C/F/TAF vs 0.07 in EICIF!TDF. The median 
change from baseline in urine protein to creatinine ratio (UPCR was 5.6 m 
and 1.6 mglg in 
the E/C/F/T AF and E/C/F/TDF 
ou s res ectivel . 
At Wee 24, me mn c ange om ase me 
beta-2-microglobulin to creatinine ratio was 35.9 µgig for EICIF!TAF vs 1.1 µgig for 
E/C/F/TDF (p = 0.004), and median change from baseline in retinol binding protein to creatinine 
ratio was 0.7 µgig for E/C/F/TAF vs 11.9 µgig for E/C/F/TDF (p = 0.006). 
CONFIDENTIAL 
Page 47 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
A treatment difference for other laboratory markers of kidney function were not observed, 
including median change from baseline for serum phosphate and fractional excretion of 
phosphate (FEPO4 [fractional excretion of phosphate] using adjusted sCr). 
1.2.4.6.3. 
Bone Safety 
DXA scans of the spine and hip were perfonned at the Baseline and Week 24 visits (and at the 
early study drug discontinuation visit, if applicable) to measure changes from baseline in BMD. 
The percent changes from baseline in BMD values in the lmnbar spine and hip are smmnarized 
in Table 1-9. The median percentage decrease from baseline was significantly less for subjects in 
the E/C/F/T AF group compared with that for subjects in the E/C/F/TDF group for both spine 
(p = 0.002) and hip (p < 0.001) BMD. 
The categorical distribution of subjects in each treatment group with percentage changes in BMD 
from baseline within specified ranges at Week 24 is smmnarized for spine and hip in Table 1-10. 
At Week 24, a significantly higher proportion of subjects in the E/C/F/T AF group than in the 
E/C/F/TDF group had no decreases in BMD at the hip (40.6% vs 22.8%; p < 0.001) and spine 
(37.5% vs 12.1 %; p = 0.003). Substantially fewer subjects in the E/C/F/TAF group had decreases 
in BMD of >3% at the hip than in the E/C/F/TDF group (3.0% vs 31.6%) at Week 24. 
Table 1-9. 
Spine 
Mean (SD) 
Median (QI, Q3) 
Min, Max 
Hip 
Mean (SD) 
Median (QI, Q3) 
Min, Max 
GS-US-292-0102: Percent Change from Baseline in Lumbar Spine 
and Hip Bone Mineral Density at Week 24, DXA Analysis Set 
E/C/F/fAF3 
E/C/F/TDF3 
E/C/F/TAF vs E/C/F/fDF 
(N =101-104) 
(N = 57-58) 
p-value 
-0.84(3.411) 
-2.48(2.519) 
0.002 
-0.92 (-3.00, 0.99) 
-2.34 (-3.65, -0.33) 
-8.49, 17.12 
- 10.37, 2.43 
-0.30 (1.774) 
-2.03 (2.677) 
< 0.001 
-0.42 (- 1.44, 0.71) 
-2.08 (-3.60, -0.48) 
-4.68, 7.84 
-8.55, 4.86 
P-values were from the Wile.axon rank sum test. 
a 
CONFIDENTIAL 
Page 48 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
Table 1-10. 
GS-US-292-0102: Percent Change in Bone Mineral Density by 
Gradation at Week 24, DXA Analysis Set 
E/C/F/TAF3 
E/C/F/TDF3 
E/C/F/TAF vs E/C/F/fDF 
(N = 101-104) 
(N = 57-58) 
p-value 
Spine 
No Decrease 
39/ 104 (37.5%) 
7/58 (12.1%) 
0.003 
> 0 to <= I% Decrease 
14/ 104 ( I 3 .5%) 
11/58 (19.0%) 
> I to <= 3% Decrease 
25/ 104 (24.0%) 
17/58 (29.3%) 
> 3 to <= 5% Decrease 
18/ 104 (17.3%) 
15/58 (25.9%) 
> 5% Decrease 
8/ 104 (7.7%) 
8/58 (13.8%) 
Hip 
No Decrease 
41/ 101 (40.6%) 
13/57 (22.8%) 
< 0.001 
> 0 to <= I% Decrease 
23/ 101 (22.8%) 
7 /57 ( 12.3%) 
> I to <= 3% Decrease 
34/ 101 (33.7%) 
19/57 (33.3%) 
> 3 to <= 5% Decrease 
3/ 101 (3.0%) 
12/57 (21.1%) 
> 5% Decrease 
OIi O I 
6/57 ( I 0.5%) 
P-value was from the CMH test for ordinal data (row mean scores differ statistic was used). 
a 
Clinical BMD status was assessed using BMD T-scores. Changes from baseline in BMD status 
at Week 24 were detennined using T-scores. At Week 24, 6 of 99 subjects (6.1 %) in the 
E/C/F/TAF group and 2 of 58 subjects (3.4%) in the E/C/F/TDF group showed a deterioration 
from baseline in spine BMD T-score category, and 1 of 99 subjects (1.1 %) in the E/C/F/TAF 
group and 5 of 54 subjects (9.3%) in the E/C/F/TDF group showed a deterioration from baseline 
in hip BMD T-score category. In the E/C/F/TAF group at Week 24, 5 subjects had improvement 
in spine BMD T-score category and 1 subject had improvement in hip BMD T-score category. 
One subject in the E/C/F/TDF group showed improvement in the hip BMD T-score category. As 
a continuous variable, median decrease from baseline BMD T-score was significantly less for 
E/C/F/TAF vs E/C/F/TDF at both spine (-0.08 vs. 0.22, p = 0.005) and hip ( 0.03 vs 0.14, 
p < 0.001). 
Bone turnover markers, including one for bone resorption (C-type collagen sequence [CTX]) and 
three for fonnation (bone specific alkaline phosphatase [bsAP], osteocalcin [OC], and 
procollagen type 1 N-tenninal propeptide [Pl NP]), were assessed to support the BMD data. 
Comparisons of percent change from baseline for each bone turnover marker at Weeks 12 and 24 
demonstrated statistically significantly less change in the E/C/F/T AF ann, and provide evidence 
of less bone turnover at both timepoints in the E/C/F/TAF ann vs the E/C/F/TDF ann 
(Table 1-11 ). These results are consistent with the observations made in the BMD analyses. 
CONFIDENTIAL 
Page 49 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 50
25 September 2019
Table 1-11.
GS-US-292-0102: Percentage Change from Baseline in Bone Turnover 
Markers, Safety Analysis Set
E/C/F/TAF
(N = 112)
E/C/F/TDF
(N = 58)
E/C/F/TAF vs E/C/F/TDF
p-value
Week 12
CTx, % change in mean (SD)
37.9 (62.0)
103.7 (109.1)
<0.001
bsAP, % change in mean (SD)
-13.4 (16.0)
2.0 (16.3)
<0.001
OC, % change in mean (SD)
22.0 (32.5)
46.9 (49.1)
<0.001
P1NP, % change in mean (SD)
2.6 (32.2)
30.1 (36.1)
<0.001
Week 24
CTx, % change in mean (SD)
39.2 (79.2)
94.8 (107.9)
<0.001
bsAP, % change in mean (SD)
4.1 (17.2)
25.3 (24.9)
<0.001
OC, % change in mean (SD)
30.3 (43.5)
71.0 (74.3)
<0.001
P1NP, % change in mean (SD)
10.6 (38.7)
58.8 (61.4)
<0.001
P-values were from the Wilcoxon rank sum test; CTx = Type 1 collagen crosslinked C-telopeptide; 
bsAP = serum bone specific alkaline phosphatase; OC = osteocalcin; P1NP = procollagen Type 1 N-terminal propeptide.
1.2.4.6.4.
Week 24 Conclusions
Key conclusions from the Week 24 analysis of Study GS-US-292-0102 included the following:

The proportion of subjects with plasma HIV-1 RNA < 50 copies/mL at Week 24 was similar 
between treatment groups

Treatment was generally well tolerated as most AEs were mild and not associated with 
treatment discontinuation. No new or unexpected adverse events occurred.

The data shows that subjects taking E/C/F/TAF had more modest changes in creatinine and 
in bone mineral density than subjects taking E/C/F/TDF. The differences were statistically 
significant and may have important clinical relevance for individual subjects.
Other than renal lab abnormalities and biomarkers and bone biomarkers, the frequency and type 
of laboratory abnormalities was comparable between the two treatment arms.
1.3.
Rationale for This Study
1.3.1.
Tenofovir Alafenamide (TAF) for Treatment of Chronic Hepatitis B
Approximately one-third of the world’s population has serological evidence of past or present 
HBV infection with over 350 million people globally who are chronic HBV surface antigen 
(HBsAg) carriers. The disease burden for HBV varies regionally, with greater than 50% of all 
subjects residing in Asian countries with the highest prevalence (e.g. China, India, Vietnam, 
Indonesia, South Korea, Taiwan, the Philippines, and Pakistan). The primary goal of treatment is 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 51
25 September 2019
to achieve and maintain virologic suppression, without resistance, which has been shown to 
translate to improvement in liver disease outcomes. Current guidelines recommend treatment for 
subjects with evidence of ongoing viral replication along with liver injury based on elevated 
levels of serum alanine aminotransaminase (ALT). 
TDF and ETV are highly potent first line therapies for CHB; however, each has specific 
limitations. TDF has a potential to cause renal- and bone-related toxicities in a subset of subjects. 
ETV has reduced activity in drug-treated populations, specifically LAM-experienced/resistant 
subjects {Baldick 2008, Tenney 2009}. The latter is a key limitation for ETV use as LAM 
remains one of the most commonly prescribed HBV treatments in most regions of the world. 
Thus, despite the availability of effective treatments there remains a clear need for newer oral 
HBV agents that are safe and well tolerated for long term use, and capable of achieving high 
rates of viral suppression with little or no potential for resistance development.
Tenofovir alafenamide (TAF), a novel prodrug of TFV, has the potential to further advance the 
treatment of CHB infection. In contrast to TDF, an agent that is rapidly and completely cleaved 
by intestinal and plasma esterases to TFV, TAF is a more stable prodrug that efficiently resists 
early enzymatic cleavage following oral administration and remains more fully intact until it is 
taken up by target cells. As a consequence, TAF, when given at a lower dose than TDF, is 
capable of efficiently delivering active drug (e.g. TFV-DP) to the virally-infected cells 
(e.g. HBV-infected hepatocytes and HIV-infected lymphoid cells) while systemic exposures of 
TFV are reduced compared with oral administration of TDF 300 mg. These features are 
hypothesized to translate into the potential for effective suppression of viral replication, and an 
improved tolerability and safety profile.
Results from GS-US-320-0101, a Phase 1b study evaluating the short-term (28 day) safety, 
efficacy (HBV DNA suppression), and PK of TAF at 4 dose levels (8 mg, 25 mg, 40 mg, and 
120 mg) compared to TDF 300 mg, has shown no dose effect in regard to viral suppression, and 
similar short-term safety and tolerability compared with TDF. Intensive PK results show 
93% or greater reductions in TFV exposures with doses of TAF 25 mg or lower compared to the 
TFV exposures generated seen with TDF 300 mg. These results, taken together with 24 weeks 
safety results from the HIV Phase 2 study GS-US-292-0102, which directly compares TAF to 
TDF (each included as a component of an STR), suggest that TAF is safe and well tolerated and 
may have a lower potential for renal- and bone-related AEs compared to TDF. Importantly, TFV 
exposures for E/C/F/TAF 10 mg are comparable to TFV exposures generated with TAF 25 mg
given as a standalone agent.
1.3.2.
Rationale for the Current Study
TDF and ETV are highly potent first line therapies for chronic HBV; however, each has specific 
limitations. TDF has a potential to cause renal- and bone-related toxicities in a subset of subjects. 
ETV has reduced activity in drug-treated populations, specifically lamivudine 
(LAM)-experienced/resistant subjects. Thus, despite the availability of effective treatments there 
remains a clear need for newer oral HBV agents that are safe and well tolerated for long term 
use, and capable of achieving high rates of viral suppression with little or no potential for 
resistance development. TAF has the potential to address each of these requirements. 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 52
25 September 2019
The current study is designed to evaluate non-inferiority of TAF compared to TDF in regard to 
the proportion of subjects with HBV DNA levels below 29 IU/mL at Week 48. The durability of 
TAF compared to TDF in regard to the proportion of subjects with HBV DNA < 29 IU/mL at 
Weeks 96 and 144 will also be assessed in a double-blind fashion. In addition to treatment-naïve 
subjects, treatment-experienced CHB subjects who are viremic and with elevated ALT levels at 
screening are included. This is based on results from GS-US-174-0106 (ADV suboptimal 
responders) and GS-US-174-0121 (LAM-resistant subjects) which demonstrated in viremic 
patients comparable rates of HBV DNA suppression, as described below, in comparison to 
results in mostly treatment-naïve subjects participating in pivotal studies GS-US-174-0102 
(HBeAg-negative subjects) and GS-US-174-0103 (HBeAg-positive subjects). Given the unique 
properties of TAF (efficient delivery of the active moiety, TFV-DP, to HBV-infected 
hepatocytes with reduced systemic TFV exposures), this study will also evaluate the potential 
safety differences (e.g. renal- and bone-related complications) of TAF relative to TDF at 
Week 48 and long term comparative safety at Week 144, after which subjects will be further 
evaluated for safety and efficacy of TAF in an open-label TAF 25 mg QD extension phase 
through Week 384. The extension phase is important as it will enable the evaluation of subjects 
treated for the entire 384 week period with TAF as well as those who received 144 weeks of 
TDF initially in a double-blinded fashion followed by an additional 240 weeks of open-label 
TAF. The latter group will allow an ongoing assessment, including possible resolution, of any 
potential bone- and/or renal-related (or other) complications during TAF treatment that might 
have arisen under initial treatment with TDF.
The primary endpoint of this study is the proportion of subjects with HBV DNA < 29 IU/mL at 
Week 48; the lowest limit of susceptibility of the polymerase chain reaction (PCR) assay to be 
employed (Roche COBAS® Taqman® HBV test for use with the High Pure System). A
histological component of treatment response is not included. Alternatively, non-invasive means 
(i.e. Fibrotest®) will be used to assess the degree of fibrosis at baseline and the change in fibrosis 
on an annual basis for all subjects participating in the trial. In support of this, 48 week results 
from studies, GS-US-174-0102 and GS-US-174-0103, which formed the basis for TDF approval 
for CHB, showed TDF to be superior to ADV based on a “complete response” to treatment 
(a composite endpoint of HBV DNA suppression (< 69 IU/mL) and histologic improvement 
based on repeat liver biopsy). In GS-US-174-0103, conducted in 266 HBeAg-positive subjects, 
66.5% and 12.2% of subjects randomized to TDF and ADV, respectively, achieved a complete 
response at Week 48 (treatment difference: 54.1%; p < 0.001). Of the components, HBV DNA 
suppression (proportion < 69 IU/mL) was achieved in 76.1% and 13.3% (treatment difference: 
63.1%; p < 0.001), while histologic improvement was achieved in 74.4% and 67.8% 
(treatment difference: 5.8%; p = 0.320) of TDF- and ADV-treated subjects, respectively. Thus, 
the greater potency of TDF relative to ADV resulting in a significantly higher rate of viral 
suppression was the primary element associated with the superior treatment response at 48 weeks
{Marcellin 2007, Marcellin 2008}. Similar findings were observed in HBeAg-negative subjects 
in GS-US-174-0102.
After 48 weeks, subjects in GS-US-174-0102 and GS-US-174-0103 were eligible to continue 
open-label treatment with TDF. At Year 5 (Week 240), 331/641 (52%) of subjects on TDF 
(without addition of FTC) underwent a repeat liver biopsy, and regression of fibrosis 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 53
25 September 2019
(improvement in Ishak fibrosis score of ≥1 point) was seen in 52% (172/331) of subjects. 
Furthermore, in 94/331 (28%) subjects with cirrhosis (Ishak score ≥5) at baseline, 73% (69/94) 
were no longer cirrhotic at year 5 (≥1 unit decrease in Ishak score). These results confirm the 
benefits of long term viral suppression with TDF in terms of regression of fibrosis and reversal 
of cirrhosis in the majority of TDF-treated subjects {Marcellin 2011}.
The efficacy of TDF in viremic treatment-experienced CHB populations has been shown to be 
similar to treatment naïve subjects. In a prospective, randomized (1:1), double-blind, Phase 3b 
study (GS-US-174-0121) which compared TDF alone to the combination of FTC/TDF in 
280 HBeAg-positive and HBeAg-negative subjects receiving treatment with LAM and having 
HBV DNA > 3 log10 IU/mL with documented LAM-resistance (rtM204I/V ± rtL180M 
mutation[s]), 89.4% of TDF-treated subjects vs. 86.3% treated with FTC/TDF had HBV DNA 
< 69 IU/mL at Week 96 (primary endpoint, missing equals failure analysis; p = 0.43). BMD was 
also assessed in GS-US-174-0121, and small declines in BMD (< 2%) of both hip and spine were 
seen with equal frequency in both groups which occurred by Week 24 (spine) and Week 72 
(hip). In another prospective, randomized, double-blind study of TDF vs. FTC/TDF in 
105 HBeAg-positive and HBeAg-negative subjects with a prior suboptimal response to ADV 
(GS-US-174-0106), no differences in HBV DNA suppression (proportion less than 69 IU/mL) 
were seen between treatment groups (82.4% TDF vs. 84.0% FTC/TDF; ITT, non-completer 
equals failure; p= 0.78). Taken together, these studies support the efficacy of TDF in treatment-
experienced subjects as being similar to results seen in treatment naïve subjects.
1.3.3.
Rationale for Dose Selection
In the phase 1b study GS-US-320-0101, which has completed enrollment, 4 doses 
(8, 25, 40, and 120 mg) of TAF monotherapy, and TDF 300 mg were evaluated in 
51 treatment naïve CHB subjects. To date, all subjects have completed the 28 day dosing period. 
Results demonstrate that TAF when given in doses over a range of 8 to 120 mg results in similar
HBV DNA declines over 28 days. Furthermore, HBV DNA suppression with TAF is comparable 
to that of TDF 300 mg. In GS-US-320-0101, increased rates of viral suppression were not 
observed with higher TAF doses (40 mg, 120 mg) relative to lower TAF doses 
(8 mg and 25 mg), and similar safety profiles were observed among TAF treatment groups. PK 
results demonstrate a 93% reduction in TFV exposures relative to TDF 300 mg when TAF is 
dosed at 25 mg. These results in CHB subjects are consistent with data in healthy volunteers and 
HIV-infected subjects given TAF 25 mg as a stand alone agent. Importantly, the TFV exposures 
seen with TAF 25 mg in CHB subjects are therapeutically comparable to those in HIV patients 
receiving E/C/F/TAF 10 mg (due to an inhibitory drug-drug interaction between TAF and COBI
when these agents are included in the E/C/F/TAF STR) which provide safety data (from Phase 2 
study GS-US-292-0102) supporting the development of TAF for hepatitis B at the 25 mg dose 
level. Further, in CHB subjects participating in the Phase 1b study who were dosed at the lowest 
TAF dose (8 mg), a 97% reduction in TFV exposures relative to TDF 300 mg was observed, an 
incremental reduction in TFV exposure of only 5% at this dose level relative to TAF 25 mg.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 54
25 September 2019
Importantly, as previously stated, the TFV exposures at a 25 mg dose when given alone are 
consistent with TAF exposures generated with the E/C/F/TAF 10 mg STR currently in Phase 3 
development for the treatment of HIV infection. Thus, the efficacy and safety of TAF in HIV is 
also being evaluated at a dose level that is therapeutically equivalent to the dose selected for 
study GS-US-320-0110.
Final Week 24 results from GS-US-292-0102, a phase 2 study being conducted in HIV-1 
treatment-naïve subjects, demonstrated similar safety and tolerability of TAF vs. TDF when each 
is included as a component of STRs containing elvitegravir, cobicistat, and emtricitabine. At 
Week 24, significant differences were noted between arms in regard to smaller declines in hip 
BMD, estimated CLCr (Cockcroft-Gault), and changes in various biomarkers of bone and renal 
function which are suggestive or differences in bone and renal tolerability of TAF vs. TDF. 
Similar assessments will be included in the present trial in chronic HBV subjects, and the study 
is sufficiently powered to demonstrate a potentially superior safety profile for TAF relative to 
TDF in regard to these bone and renal parameters.
In summary, a 25 mg dose was selected for TAF for use in this non-inferiority trial based upon 
the safety profile for TAF in treatment naïve HIV-1-infected subjects from GS-US-292-0102, 
which utilizes a therapeutically equivalent TAF dose (10 mg as a component of the E/C/F/TAF 
STR), the viral suppression results in chronic HBV subjects in GS-US-320-0101 showing 
comparable rates of HBV DNA decline for a TAF 25 mg dose compared to TDF 300 mg
(the approved dose for treatment of HBV), and the reduced systemic TFV exposures (~93%) 
seen with TAF relative to TDF 300 mg, when dosed at this level.
1.4.
Compliance
This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory requirements.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 55
25 September 2019
2.
OBJECTIVES
The primary objectives of this study are as follows:

To compare the efficacy of tenofovir alafenamide (TAF) 25 mg QD versus 
tenofovir disoproxil fumarate (TDF) 300 mg QD for the treatment of HBeAg-positive, 
chronic hepatitis B at Week 48 in treatment naïve and treatment-experienced subjects. The 
primary efficacy parameter is the proportion of subjects with plasma HBV DNA levels below 
29 IU/mL 

To compare the safety and tolerability of TAF 25 mg QD versus TDF 300 mg QD for the 
treatment of HBeAg-positive, chronic hepatitis B at Week 48 in treatment-naïve and 
treatment-experienced subjects
The key secondary safety objectives of this study are as follows: 

To compare the safety of TAF 25 mg QD versus TDF 300 mg QD as determined by the 
percent change from baseline in hip and spine BMD at Week 48

To compare the safety of TAF 25 mg QD versus TDF 300 mg QD as determined by the 
change from baseline in serum creatinine at Week 48
The key secondary efficacy objective of this study is as follows:

To compare the serological response (loss of HBeAg with seroconversion to anti-HBe) of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Week 48
Other secondary objectives of this study are as follows:

To compare the efficacy of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, chronic hepatitis B in regard to the proportion of subjects with plasma HBV 
DNA levels below 29 IU/mL at Weeks 96, and 144

To compare the efficacy of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, chronic hepatitis B in regard to the proportion of subjects with plasma HBV 
DNA levels below 29 IU/mL (target not detected) at Weeks 48, 96, and 144

To compare the biochemical (ALT normalization by central laboratory and AASLD criteria) 
response of TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, 
chronic hepatitis B at Weeks 48, 96, and 144

To compare the serological response (loss of HBeAg with seroconversion to anti-HBe) of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, 
chronic hepatitis B at Weeks 96, and 144


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 56
25 September 2019

To compare the serological response (loss of HBsAg with seroconversion to anti-HBs) of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Weeks 48, 96, and 144

To compare the change in fibrosis as assessed by FibroTest® of TAF 25 mg QD versus TDF 
300 mg QD for the treatment of HBeAg-positive, chronic hepatitis B at 
Weeks 48, 96, and 144

To compare the incidence of drug resistant mutations of TAF 25 mg QD versus TDF 300 mg 
QD at Weeks 48, 96, and 144

To compare the change from baseline, in ophthalmologic findings by fundoscopic 
examination of TAF 25 mg QD versus TDF 300 mg QD at Weeks 24, 48, 72, 96, and 144 
(or ED visit if prior to Week 144 and more than 24 weeks since prior exam) in a subset of 
subjects 

To characterize the pharmacokinetics of TAF and tenofovir (TFV) and determine 
intracellular concentrations of tenofovir diphosphate (TFV-DP) within peripheral blood 
mononuclear cells (PBMCs) in subjects receiving TAF or TDF

To evaluate the comparative open-label efficacy, safety, and drug resistance mutations of 
TAF 25 mg QD in subjects initially randomized to TAF 25 mg QD and in subjects 
sequentially treated with TDF 300 mg QD and then switched to open-label TAF 25 mg QD


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 57
25 September 2019
3.
STUDY DESIGN
3.1.
Endpoints
The primary efficacy endpoint of this study is:

The proportion of subjects with HBV DNA < 29 IU/mL at Week 48
3.1.1.
Secondary Endpoints
The key secondary safety endpoints are:

The percent change from baseline at Week 48 in hip BMD

The percent change from baseline at Week 48 in spine BMD

The change from baseline at Week 48 in serum creatinine 
The key secondary efficacy endpoint is:

The proportion of subjects with HBeAg loss and seroconversion to anti-HBe at Week 48
3.1.2.
Other Endpoints of Interest

The proportion of subjects with plasma HBV DNA < 29 IU/mL at Weeks 96, 144 and 240, 
and 384

The proportion of subjects with plasma HBV DNA < 29 IU/mL (target not detected) at 
Weeks 48, 96, 144, 240, and 384

The proportion of subjects with ALT normalization (by central laboratory and 
AASLD criteria) at Weeks 48, 96, 144, 240, and 384

The proportion of subjects with HBsAg loss at Weeks 48, 96, 144, 240, and 384

The proportion of subjects with HBeAg loss at Weeks 48, 96, 144, 240, and 384

The proportion of subjects with HBsAg seroconversion to anti-HBs at 
Weeks 48, 96¸144, 240 and 384  

The proportion of subjects with HBeAg seroconversion to anti-HBe at 
Weeks 96, 144, 240, and 384

The change from baseline in fibrosis as assessed by FibroTest® at 
Weeks 48, 96, 144, 240, and 384

The incidence of drug resistant mutations at Weeks 48, 96, 144, 240 and 384

The change from baseline in ophthalmologic findings by fundoscopic examination at 
Weeks 24, 48, 72, 96, 144, 240, and 384 in a subset of subjects


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 58
25 September 2019
3.2.
Study Design
This is a randomized, double-blind, non-inferiority study to compare the antiviral activity of 
TAF 25 mg versus TDF 300 mg QD. Approximately 864 subjects will be randomized in a 
2:1 ratio (A: B) to the treatment arms for 144 weeks (96 weeks, under Amendment 2.1), and will 
be stratified by plasma HBV DNA level (> 8 log10 IU/mL vs. < 8 log10 IU/mL) and oral antiviral 
treatment status (treatment-naïve vs. treatment-experienced). 
For China, approximately 150 additional subjects will be randomized in a 2:1 ratio (A: B) to the 
treatment arms for 96 weeks, and will be stratified by plasma HBV DNA level (≥8 log10 IU/mL 
vs. < 8 log10 IU/mL) and oral antiviral treatment status (treatment-naïve vs. 
treatment-experienced). 
A centralized randomization procedure via an Interactive Voice/Web Response System 
(IVRS/IWRS) will be used for this study, whereby study treatment will be assigned to subjects 
according to the randomization schedule. A unique subject number will be provided during 
randomization. If the subject is deemed ineligible for this study by HBV serology 
(i.e. HBeAg negative CHB), this information may be used to determine eligibility for 
GS-US-320-0108 (another Gilead Sciences Phase 3 study in HBeAg negative, CHB subjects; 
this study must also be IRB/EC approved at the participating center).
At Week 144, all subjects will be switched to the open label TAF 25 mg QD extension period for 
an additional 240 weeks (Week 144 through Week 384). Subjects already assigned to open-label 
TAF 25 mg QD at Week 96 per Amendment 2.1 will continue on open-label TAF 25 mg QD 
through Week 384/ED. All subjects who complete the double-blind period of treatment are 
eligible for participation in the open label TAF 25 mg QD extension period. Subjects who 
permanently discontinue study drug for reasons other than HBsAg loss with confirmed 
seroconversion to anti-HBs (either prematurely [ED] or at the end of study [Week 384]) will be 
followed every 4 weeks for 24 weeks off treatment or until initiation of alternative, commercially 
available HBV therapy, whichever occurs first. 
Subjects with a history of or current diagnosis of compensated cirrhosis are eligible for 
enrollment. Acceptable diagnostic criteria for cirrhosis include a Metavir or Knodell fibrosis 
score ≥ 4 or Ishak fibrosis score ≥ 5 by liver biopsy, or previous Fibroscan result > 12kPa 
(in countries where locally approved). Available information regarding the presence or absence 
of cirrhosis by these criteria will be captured in the electronic case report forms at Baseline, and 
any other time during the trial should an investigator opt to undertake additional studies. 
Importantly, the change in fibrosis as assessed by Fibrotest® will be performed in all subjects 
participating in the trial at Baseline, and annually thereafter through Week 384/ED.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 59
25 September 2019
Figure 3-1.
Study Schema
3.3.
Study Treatments
The two treatment arms which will be evaluated in this study are:
Treatment Arm A: 576 subjects TAF 25 mg QD and matched placebo of TDF 300 mg QD
Treatment Arm B: 288 subjects TDF 300 mg QD and matched placebo of TAF 25 mg QD
For China, approximately 150 additional subjects (100 in Treatment Arm A and 50 in 
Treatment Arm B) will be enrolled for local registration purposes.
TAF, TDF, and their matched placebo tablets are packaged in white, high density polyethylene 
(HDPE) bottles. Each bottle contains 30 tablets and a silica gel desiccant and polyester coil. All 
labels for study drug bottles to be distributed to centers in the US, EU and the rest of the 
countries will meet all applicable requirements of the US Food and Drug Administration (FDA) 
and Annex 13 of Good Manufacturing Practices: Manufacture of Investigational Medicinal 
Products (July 2010) and/or other local regulations as applicable.
I 
Screening 
I 
Randomization 2:1 (A:B), 
I 
I 
Arm A: TAF 25 mg QD and placebo tio 
Arm. B: TDF 300 mg QD and placebo tio 
matich of TDF 300 mg QD 
match ofTAF 25 mg QD 
I 
I 
Week 96 Open Label TAF 25 mg QD ,(Amendment 2.1), 
Week 144 Open Label TAF 25 mg QU ,(Amendment 3.1) 
I 
Week 384 / Early Discontinuation Visit 
Follow up,-
EverJ 4 TI eeks for 2-4 weeks off treatment or up to initiation of alternative, 
commerdallJ available HBV therapy. whichever occurs first 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 60
25 September 2019
3.4.
Duration of Treatment
The duration of double-blind treatment is 144 weeks (96 weeks under Amendment 2.1). At 
Week 144, all subjects remaining on blinded treatment will be switched to the open-label TAF 
25 mg QD extension period for an additional 240 weeks (Week 144 through Week 384/ED). 
Subjects already assigned to open-label TAF 25 mg QD at Week 96 per Amendment 2.1 will 
continue on open-label TAF 25 mg QD through Week 384/ED. All subjects who complete the 
double-blind period of treatment are eligible for participation in the open-label TAF 25 mg QD
extension period. Subjects who permanently discontinue study drug (either prematurely [ED] or 
at the end of study [Week 384]) for reasons other than HBsAg loss with confirmed 
seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks off treatment or until 
initiation of alternative, commercially available HBV therapy, whichever occurs first. 
3.5.
Discontinuation Criteria
Study medication may be discontinued in the following instances:

Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree

Unacceptable toxicity, as defined in the toxicity management section of the protocol, or 
toxicity that, in the judgment of the investigator, compromises the ability to continue 
study-specific procedures or is considered to not be in the subject’s best interest

Subjects with confirmed creatinine clearance of < 30 mL/min will have their study drug 
permanently discontinued

Lack of efficacy (virologic failure) 

HBsAg loss with sero-conversion to anti-HBs. These subjects should discontinue study drug 
within 3-6 months following confirmation of seroconversion to anti-HBs. Subjects with 
HBsAg loss with confirmed seroconversion before Week 48 are not permitted to discontinue 
study drug prior to the Week 48 visit

Discontinuation of study drug for subjects experiencing HBsAg loss with confirmed 
seroconversion to anti-HBs, who have known bridging fibrosis or cirrhosis, should be 
considered on a case by case basis

Subject request to discontinue for any reason

Subject noncompliance

Pregnancy during the study; refer to Appendix 6

Discontinuation of the study at the request of Gilead Sciences, a regulatory agency or an 
institutional review board or independent ethics committee (IRB/IEC)


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
3.6. 
3.6.1. 
Biomarker Testing 
Biomarker Samples to Address the Study Objectives 
to mcrease 10w e ge an un erstanding 
of the biology of chronic hepatitis B. The specific analyses will include, but will not be limited 
to, the biomarkers and assays listed below. Because biomarker science is a rapidly evolving area 
of investigation, and adverse events in particular are difficult to predict, it is not possible to 
specify prospectively all tests that will be done on the specimens provided. The testing outlined 
below is based upon the current state of scientific knowledge. It may be modified during or after 
the end of the study to remove tests no longer indicated and/or to add new tests based upon the 
growing state of art knowledge. 
• 
Blood sample for bone biomarkers - including, but not limited to, C-type collagen sequence 
(CTX) and procollagen type 1 N-tenninal propeptide (PlNP) 
• 
Urine sample for renal biomarkers - including, but not limited to, retinol binding protein and 
beta-2-microglobulin 
These specimens will be collected from all subjects in a fasted state. 
3.6.2. 
uired to document a subject's agreemen-
. From subjects who agree to 
participate 
a blood sample will be obtained. This 
sample should be collected at the Baseline visit, prior to the first dose of study drug, but may be 
collected at any time durin the stud or at a se arate unscheduled study visit, if necessary. The 
specimens collected 
will be used to identify or validate 
genetic markers that may increase our knowledge and understanding of the biology of the study 
disease and related diseases and to study the association of genetic markers with disease 
pathogenesis, progression and/or treatment outcomes includin efficac adverse events 
rocesses of dru abso tion and dis 
The 
collection and analysis of 
specimens will facilitate the rational design of 
new phannaceutical agents and the development of diagnostic tests, which may allow for 
individualized drug therapy for subjects in the future. 
3.7. 
CONFIDENTIAL 
Page 61 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Subjects partici 
to provide a 
evaluate 
(TFV). 
3.8. 
CONFIDENTIAL 
Page 62 
Final 
Amendment 3 .4 
will also be asked 
1 will be used to 
tenofovir 
An exam should be 
e past 24 weeks. 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 63
25 September 2019
4.
SUBJECT POPULATION
4.1.
Number of Subjects and Subject Selection
Approximately 864 subjects with active chronic hepatitis B will be randomized 2:1 to receive 
either blinded TAF 25 mg and TDF 300 mg matched placebo (n=576), or TDF 300 mg and TAF 
25 mg matching placebo (n=288) for 144 weeks (96 weeks under Amendment 2.1).
For China, approximately 150 subjects with active chronic hepatitis B will be randomized 2:1 to 
receive either blinded TAF 25 mg and TDF 300 mg matched placebo (n=100), or TDF 300 mg 
and TAF 25 mg matching placebo (n=50) for 96 weeks.
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study:
1. Must have the ability to understand and sign a written informed consent form, which must be 
obtained prior to initiation of study procedures.
2. Male and non-pregnant, non-lactating female subjects, 18 years of age and older, based on 
the date of the screening visit. A negative serum pregnancy test at Screening is required for 
female subjects of childbearing potential (as defined in Appendix 6).
3. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 
6 months)
4. HBeAg positive, chronic hepatitis B with all of the following:

HBeAg-positive at Screening (if the subject is deemed ineligible for this study by HBV 
serology [i.e. HBeAg-negative CHB], this information may be used to determine 
eligibility for GS-US-320-0108 [another Gilead Sciences Phase 3 study in 
HBeAg-negative, CHB subjects; this study must also be IRB/EC approved at the 
participating center]) 

Screening HBV DNA ≥ 2 × 104 IU/mL 

Screening serum ALT level 60 U/L (males) or > 38 U/L (females) and ≤10 ULN 
(by central laboratory range)
5. Treatment-naïve subjects (defined as < 12 weeks of oral antiviral treatment with any 
nucleoside or nucleotide analogue) OR treatment-experienced subjects (defined as subjects 
meeting all entry criteria [including HBV DNA and serum ALT criteria] and with 
> 12 weeks of previous treatment with any nucleoside or nucleotide analogue) will be 
eligible for enrollment. Treatment-experienced subjects receiving oral antiviral treatment at 
Screening must continue their treatment regimen until the time of randomization, when it will 
be discontinued.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 64
25 September 2019
6. Any previous treatment with interferon (pegylated or non-pegylated) must have ended at 
least 6 months prior to the baseline visit. 
7. Estimated creatinine clearance (CLCr) ≥ 50 mL/min (using the Cockcroft-Gault method) 
based on serum creatinine and actual body weight as measured at the Screening evaluation, 
as follows:
(140 – age in years) (body weight [kg])
(72) (serum creatinine [mg/dL])
[Note: multiply estimated rate by 0.85 for women]
8. Normal ECG (or if abnormal, determined by the investigator not to be clinically significant)
9. Must be willing and able to comply with all study requirements
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
1. Pregnant women, women who are breastfeeding or who believe they may wish to become 
pregnant during the course of the study.
2. Males and females of reproductive potential who are unwilling to use an “effective”, protocol 
specified method(s) of contraception during the study. For a list of protocol specified 
contraceptive methods, refer to Appendix 6.
3. Co-infection with HCV, HIV, or HDV
4. Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging)
5. Any history of, or current evidence of, clinical hepatic decompensation 
(i.e., ascites, encephalopathy or variceal hemorrhage)
6. Abnormal hematological and biochemical parameters, including:

Hemoglobin < 10 g/dL

Absolute neutrophil count < 750/mm3

Platelets ≤50,000/mm3

AST or ALT > 10 × ULN

Total Bilirubin > 2.5 × ULN

Albumin < 3.0 g/dL

INR > 1.5 × ULN (unless stable on anticoagulant regimen)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 65
25 September 2019
7. Received solid organ or bone marrow transplant
8. Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the 
investigator
9. Significant bone disease (eg, osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, 
osteochrondroses), or multiple bone fractures
10. Malignancy within the 5 years prior to screening, with the exception of specific cancers that 
are cured by surgical resection (basal cell skin cancer, etc). Subjects under evaluation for 
possible malignancy are not eligible
11. Currently receiving therapy with immunomodulators (e.g. corticosteroids), investigational
agents, nephrotoxic agents, or agents capable of modifying renal excretion
12. Known hypersensitivity to study drugs, metabolites, or formulation excipients
13. Current alcohol or substance abuse judged by the investigator to potentially interfere with 
subject compliance
14. Any other clinical condition or prior therapy that, in the opinion of the investigator, would 
make the subject unsuitable for the study or unable to comply with dosing requirements.
15. Subjects on prohibited concomitant medications (See Table 5-1). Subjects on prohibited 
medications, otherwise eligible, will need a wash out period of at least 30 days.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 66
25 September 2019
5.
INVESTIGATIONAL MEDICINAL PRODUCTS
5.1.
Randomization, Blinding and Treatment Codes
A centralized randomization procedure via an Interactive Voice/Web Response System 
(IVRS/IWRS) will be used for this study, whereby study treatment will be assigned to subjects 
according to the randomization schedule. A unique subject number will be provided during 
randomization. If the subject is deemed ineligible for this study by HBV serology 
(i.e. HBeAg negative CHB), this information may be used to determine eligibility for 
GS-US-320-0108 (another Gilead Sciences Phase 3 study in HBeAg negative, CHB subjects; 
this study must also be IRB/EC approved at the participating center). Eligible subjects will be 
randomized 2:1 to receive either blinded TAF 25 mg and TDF 300 mg matched placebo or TDF 
300 mg and TAF 25 mg matched placebo for 144 weeks (96 weeks under Amendment 2.1). 
Subjects will be stratified by screening plasma HBV DNA level (≥8 log10 IU/mL vs. 
< 8 log10 IU/mL) and oral antiviral treatment status (treatment-naïve vs. treatment-experienced). 
At Week 144, all subjects will be switched to open-label TAF 25 mg QD for up to an additional
240 weeks (Week 144 through Week 384/ED). Subjects already assigned to open-label TAF 
25 mg QD at Week 96 per Amendment 2.1 will continue on open-label TAF 25 mg QD through 
Week 384/ED. For the entire duration of the study, subjects and investigators will remain blinded 
to the initial treatment regimen to which the subjects were randomized.
5.1.1.
Procedures for Breaking Treatment Codes
In the event of a medical emergency where breaking the blind is required to provide medical care 
to the subject, the investigator may obtain treatment assignment directly from the IVRS/IWRS
for that subject. Gilead recommends but does not require that the investigator contact the 
Gilead Medical Monitor before breaking the blind. Treatment assignment should remain blinded 
unless that knowledge is necessary to determine subject emergency medical care. The rationale 
for unblinding must be clearly explained in source documentation and on the electronic case 
report form (eCRF), along with the date on which the treatment assignment was obtained. The 
investigator is requested to contact the Gilead Medical Monitor promptly in case of any 
treatment unblinding.
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by the subject.
Gilead Pharmacovigilance and Epidemiology (PVE) may independently unblind cases for 
expedited reporting of suspected unexpected serious adverse reactions (SUSARs).


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 67
25 September 2019
5.2.
Description and Handling of Tenofovir Alafenamide (TAF), Tenofovir 
Disoproxil Fumarate (TDF) and Matched Placebos
5.2.1.
Formulation
5.2.1.1.
Tenofovir Alafenamide (TAF) Tablets
TAF 25 mg tablets contain 28 mg of tenofovir alafenamide fumarate, which is equivalent to 
25 mg of tenofovir alafenamide (TAF). The tablets are yellow, round-shaped, and film-coated.
The tablets are debossed with “GSI” on one side and “25” on the other side. In addition to the 
active ingredient, each film-coated tablet contains the following inactive ingredients: 
lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, 
polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.
5.2.1.2.
Placebo to match TAF tablets
Placebo tablets to match TAF 25 mg are yellow, round-shaped, and film-coated. The tablets are 
debossed with “GSI” on one side and “25” on the other side. Each tablet contains the following 
inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, 
magnesium stearate, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and 
yellow iron oxide. 
5.2.1.3.
Tenofovir Disoproxil Fumarate (Viread®, Tenofovir DF, TDF)
TDF 300 mg tablets contain 300 mg of tenofovir disoproxil fumarate (TDF), which is equivalent 
to 245 mg of tenofovir disoproxil. The tablets are light blue, almond-shaped, plain-faced, and 
film-coated. Each tablet contains the following inactive ingredients: microcrystalline cellulose, 
lactose monohydrate, pregelatinized starch, croscarmellose sodium, and magnesium stearate. The 
film coating contains lactose monohydrate, hypromellose (hydroxypropyl methylcellulose), 
glycerol triacetate, titanium dioxide, and indigo carmine aluminum lake.
5.2.1.4.
Tenofovir Disoproxil Fumarate (Viread®, Tenofovir DF, TDF) to be used in 
Developing Markets
TDF 300 mg tablets to be used in developing markets contain 300 mg of tenofovir disoproxil 
fumarate (TDF), which is equivalent to 245 mg of tenofovir disoproxil. The tablets are white, 
almond-shaped, film-coated tablets, debossed with “GILEAD” and “4331” on one side and 
plain-faced on the other side. Each tablet contains the following inactive ingredients: 
microcrystalline cellulose, lactose monohydrate, pregelatinized starch, croscarmellose sodium, 
and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, triacetin 
and titanium dioxide.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 68
25 September 2019
5.2.1.5.
Placebo to match TDF Tablets
Placebo tablets to match tenofovir DF 300 mg are light blue, almond shaped, plain faced, 
film-coated tablets. Each tablet contains the following inactive ingredients: denatonium 
benzoate, lactose monohydrate, pregelatinized starch, croscarmellose sodium, and magnesium 
stearate. The film coating contains the following inactive ingredients: lactose monohydrate, 
hypromellose (hydroxypropyl methylcellulose), triacetin, titanium dioxide, and indigo carmine 
aluminum lake.
5.2.1.6.
Placebo to Match TDF Tablets to be used in Developing Markets
Placebo tablets to match TDF 300 mg for developing markets are white, almond-shaped, 
film-coated tablets, debossed with “GILEAD” and “4331” on one side and plain-faced on the 
other side. Each tablet contains the following inactive ingredients: denatonium benzoate, lactose 
monohydrate, pregelatinized starch, croscarmellose sodium, and magnesium stearate. The film 
coating contains the following inactive ingredients: lactose monohydrate, hypromellose, 
triacetin, and titanium dioxide. 
5.2.2.
Packaging and Labeling
TAF, TDF and their matched placebo tablets are packaged in white, high density polyethylene 
(HDPE) bottles. Each bottle contains 30 tablets and a silica gel desiccant and polyester coil. Each 
bottle is enclosed with a white, continuous-thread, child-resistant polypropylene screw cap fitted 
with an induction-sealed, and aluminum-faced liner. 
To ensure stability of the tablets and proper product identification, the drug should not be stored 
in a container other than the container in which it is supplied.
All labels for study drug bottles to be distributed to centers in the US, EU and the rest of the 
countries will meet all applicable requirements of the US Food and Drug Administration (FDA) 
and Annex 13 of Good Manufacturing Practices: Manufacture of Investigational Medicinal 
Products (July 2010) and/or other local regulations as applicable.
5.2.3.
Storage and Handling
TAF, TDF, and their matched placebo tablets should be stored at a controlled room temperature 
of 25 °C (77 °F); excursions are permitted between 15 °C and 30 °C (59 °F and 86 °F). Measures 
that minimize drug contact with the body should always be considered during handling, 
preparation, and disposal procedures.
5.3.
Dosage and Administration of TAF and TDF
Subjects will be randomly assigned (2:1) to receive one of the following treatments in a blinded 
fashion:
Treatment Arm A: 576 subjects TAF 25 mg QD and matched placebo of TDF 300 mg QD
Treatment Arm B: 288 subjects TDF 300 mg QD and matched placebo of TAF 25 mg QD


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 69
25 September 2019
For China, approximately 150 additional subjects will be randomized 2:1 to receive either 
Treatment A (n = 100) or Treatment B (n = 50) for 144 weeks (96 weeks under Amendment 2.1).
After 144 weeks of blinded randomized treatment (96 weeks under Amendment 2.1), each 
subject will switch to open-label TAF 25 mg QD for up to an additional 240 weeks
(Week 144 through Week 384/ED). Subjects already assigned to open-label TAF 25 mg QD at 
Week 96 per Amendment 2.1 will continue on open-label TAF 25 mg QD until Week 384/ED.
It is preferred that subjects take their study drug according to a morning dosing schedule; 
however, evening dosing is allowable.
All study drugs should be taken at approximately the same time each day with food.
Observed in-clinic study drug dosing is required at Weeks 4 and 12 visits. It is preferred that 
subjects take their study drug according to a morning dosing schedule; however, evening dosing 
is allowable. Subjects who elect to dose in evening are not required to have in-clinic dosing and 
the single PK blood sample collection at the Weeks 4 and 12 visits. Study drug should be 
administered after assessing adverse events and concomitant medication(s).
5.4.
Prior and Concomitant Medications
Concomitant/previous medications taken within 30 days of screening, up to and including the 
date of the visit 4 weeks after discontinuation of study treatment, need to be recorded in the 
source documents and eCRFs.
Concomitant use of some medications including herbal/natural products/therapies and over the 
counter medications with TAF may result in PK interactions.
Should subjects have a need to initiate treatment with any excluded concomitant medication, 
including herbal/natural products/therapies, and over the counter medications, the 
Gilead Sciences Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
investigator must notify Gilead Sciences as soon as he/she is aware of the use of the excluded 
medication.
The following medications are excluded while subjects are participating in the study. These 
medications are prohibited during the screening period and for a minimum of 30 days prior 
to the Baseline/Day 1 visit through the end of treatment:
The following medications are excluded while subjects are participating in this study:

Nephrotoxic agents (e.g., aminoglycosides, amphoterecin B, vancomycin, cidofovir, 
foscarnet, cisplatin, pentamidine, cyclosporine, tacrolimus)

Probenecid


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 70
25 September 2019

Agents which reduce renal function or compete for active tubular secretion with tenofovir 
(e.g., cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir)

Systemic chemotherapeutic agents, systemic corticosteroids (except short term use of 
prednisone as a steroid burst [< 1 week of use], immunosuppressant, or 
immunomodulating agents

Bisphosphonates

Investigational agents (unless approved by Gilead Sciences)

Medications excluded due to the potential for drug-drug interaction with TAF (Table 5-1)
Treatment-experienced subjects (defined as subjects meeting all entry criteria [including HBV 
DNA and serum ALT criteria] and with ≥12 weeks of previous treatment with any nucleoside or 
nucleotide analogue) receiving oral antiviral treatment at Screening must continue their treatment 
regimen until the time of randomization/Baseline/Day 1, when it will be discontinued.
Table 5-1.
List of medications that are prohibited or to be used with caution due 
to the potential for drug-drug interaction with Study Medication
Medication Class
Prohibited Medications
Medications to be used with caution
Analeptic
Modafinil
Antiarrhythmics
Amiodarone, Quinidine: may increase 
concentration of TAF and/or TFV
Antibacterials
Clarithromycin: may increase concentration of 
TAF and/or TFV
Anticonvulsants
Carbamazepine, Oxcarbazepine, 
Phenobarbital, Phenytoin
Antifungals
Voriconazole
Itraconazole, Ketoconazole: may increase 
concentration of TAF and/or TFV
Antimycobacterials
Rifapentine, Rifabutin, Rifampin
Calcium channel blockers
Diltiazem, Felodipine, Verapamil: may 
increase concentration of TAF and/or TFV
Digoxin
Digoxin: concomitant use may result in an 
increased or decreased level; use with caution 
and with appropriate monitoring of serum 
digoxin levels. Digoxin therapy should be 
initiated at the lowest dose, and the dose 
should be titrated to clinical response.
Herbal/Natural Supplements
St. John’s Wort, Echinacea, 
Milk thistle (i.e., silymarin), 
Chinese herb sho-saiko-to 
(or Xiao-Shai-Hu-Tang)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 71
25 September 2019
5.5.
Accountability for Tenofovir Alafenamide (TAF), Tenofovir Disoproxil 
Fumarate (TDF) and Matched Placebos
The investigator or designee (e.g., pharmacist) is responsible for ensuring adequate 
accountability of all used and unused investigational medicinal product (IMP) kits and/or bottles. 
This includes acknowledgement of receipt of each shipment of IMP (quantity and condition). All 
used and unused IMP kits and/or bottles dispensed to subjects must be returned to the site.
IMP accountability records will be provided to each study site to:

Record the date received and quantity of IMP kits and/or bottles.

Record the date, subject number, subject initials, the IMP kit number dispensed.

Record the date, quantity of used and unused IMP kits and/or bottles returned, along with the 
initials of the person recording the information.
5.5.1.
Investigational Medicinal Product Return or Disposal
At the start of the study, the study monitor will evaluate each study center’s study drug disposal 
procedures and provide appropriate instruction for return or destruction of unused study drug 
supplies. If the site has an appropriate Standard Operating Procedure (SOP) for drug destruction, 
the site may destroy used (empty kits and/or bottles) and unused study drug supplies performed 
in accordance with the site’s (hospital/pharmacy) SOP. If the site does not have acceptable 
procedures in place for drug destruction, arrangements will be made between the site and 
Gilead Sciences (or Gilead Sciences’ representative) for return of unused study drug supplies. A 
copy of the site’s SOP will be obtained for central files. Where possible, study drug will be 
destroyed at the site. Upon study completion, a copy of the Investigational Drug Accountability 
records must be filed at the site. Another copy will be returned to Gilead Sciences. If drug is 
destroyed on site, the investigator must maintain accurate records for all study drug kits and/or 
bottles destroyed. Records must show the identification and quantity of each unit destroyed, the 
method of destruction, and person who disposed of the drug. All study drug records must be 
maintained at the site and copies must be submitted to Gilead Sciences at the end of the study. 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 72
25 September 2019
6.
STUDY PROCEDURES
The study procedures to be conducted for each subject enrolled in the study are presented in 
tabular form in Appendix 2 and described in the text that follows. 
The investigator must document any deviation from protocol procedures and notify the sponsor 
or contract research organization (CRO).
6.1.
Subject Enrollment and Treatment Assignment
It is the responsibility of the investigator to ensure that subjects are eligible to participate in the 
study prior to enrollment. Once consent has been obtained, all screening tests and procedures 
have been completed, and study eligibility has been confirmed, subjects will be randomized
within 45 days using an IVRS/IWRS. Subjects will receive study drugs within their assigned 
treatment group as described in Section 5.1. Candidates who fail to meet eligibility criteria by 
screening evaluations may be re-screened once after the initial screen if there is a reasonable 
expectation that the candidate will be eligible after repeat screening.
Retesting of exclusionary laboratory values during the Screening period is permitted only if in 
the Principal Investigator’s opinion, there is reason to believe the retest value will be within 
accepted parameters; if the initial value was deemed to be inaccurate, inconsistent with the 
subject’s previous result(s); in error (e.g. mishandled sample); or due to an extenuating 
circumstance.
6.2.
Pretreatment Assessments
6.2.1.
Screening Visit
Subjects will be screened within 45 days before Baseline to determine eligibility for participation 
in the study. The following will be performed and documented during the screening period:

Obtain written informed consent

Review of inclusion/exclusion criteria

Obtain medical history, including HBV history

Review concomitant medications

Record any serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form

Complete physical examination including vital signs (blood pressure, pulse, respiration rate 
and temperature), body weight, and height


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
• 
ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to 
the recording) 
• 
DXA scan of spine and hip (at sites in China with capability only). DXA scan will be 
perfonned during Screening and should be completed at least 14 days prior to the first dose 
of the study drug, in order to ensure an acceptable pre-dose DXA scan . 
• 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex 
HBsAb), HIV-1, HDV, HCV, serum pregnancy test (for females of child-bearing potential), 
a-fetoprotein (AFP) and INR. An AFP > 50 ng/mL at Screening must have an appropriate 
evaluation (e.g. CT scan) in order to rule out HCC prior to being pennitted to enter the study 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Urine sample for urinalysis 
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 45 days for randomization into the study. (if the subject is deemed ineligible for this 
study by HBV serology (i.e. HBeAg-negative CHB), this infonnation may be used to detennine 
eligibility for GS-US-320-0108 [another Gilead Sciences Phase 3 study in HBeAg negative, 
CHB subjects; this study must also be IRB/EC approved at the participating center). 
From the time of obtaining infonned consent through the first administration of investigational 
medicinal product, record all SAEs, as well as any AEs related to protocol-mandated procedures 
on the adverse events case report fonn (CRF/eCRF). All other m1toward medical occurrences 
observed during the screening period, including exacerbation or changes in medical history are to 
be captured on the medical history CRF/eCRF. See Section 7, Adverse Events and Toxicity 
Management for additional details. 
6.2.2. 
Baseline Assessments 
All baseline tests and procedures must be completed prior to the receipt of the first dose of study 
drug. Subjects screened within 45 days before Baseline will be eligible to participate in the 
study. Initiation of treatment with study drug should take place on the day of the Baseline visit. 
The following will be perfonned at the Baseline visit: 
• 
Review of inclusion/exclusion criteria and confinn medical history 
• 
Complete physical examination including, vital signs (blood pressure, pulse, respiration rate 
and temperature), and body weight 
CONFIDENTIAL 
Page 73 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
• 
Review concomitant medications 
• 
Review adverse events 
Final 
Amendment 3 .4 
• 
Assess future risk of bone fracture using the Fracture Risk Assessment tool (FRAX®; at sites 
in China with DXA capability only) 
• 
Randomization 
• 
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at 
least 8 hours prior to blood collection 
• 
Fasting urine sample for renal biomarkers 
• 
Dispense blinded study drugs 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and 
reflex HBsAb ), HBV genotyping (A-H), virology (resistance surveillance), serum and 
plasma for storage, IL28B genotype, and vitamin D assessment 
• 
Cystatin C testing for estimated glomerular filtration rate (eGFR) by CKD-EPI 
(Chronic Kidney Disease Epidemiology Collaboration) 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Blood sample for Fibrotest® 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
• 
6.3. 
6.3.1. 
Treatment Assessments 
Double-blind Visits (Including Amend 2.1 Open-label Visits 
Weeks 108 through 144) 
Study visits Weeks 4 - 44 and Weeks 56 - 88 should be completed ± 3 days of the protocol 
specified visit date, based on the Baseline Visit. 
Study visit Week 48 visit should be completed within 14 days of the protocol specified visit 
date, based on the Baseline Visit. 
Study visits Weeks 96, 108, 120, and 132, and 144 should be completed ± 14 days of the 
protocol specified visit date, based on the Baseline Visit. 
CONFIDENTIAL 
Page 74 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
6.3.1.1. 
Week4 
• 
Symptom directed physical exam 
• 
Body weight 
• 
Vital signs: blood pressure, pulse, respiration rate, and temperature 
• 
Review concomitant medications 
• 
Review adverse events 
• 
Perfonn study drug accountability 
• 
Fasting blood sample for bone biomarkers 
• 
Fasting urine sample for renal biomarkers 
• 
• 
Dispense blinded study drugs 
Final 
Amendment 3 .4 
• 
Dose in clinic and collect single blood sample for plasma PK between 15 minutes to 4 hours 
post-dose (subjects who elect to dose in the evening the previous day are not required to have 
in-clinic dosing and provide a single PK sample) 
CONFIDENTIAL 
Page 75 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
plasma PK, virology (resistance surveillance), and serum and plasma for storage 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
6.3.1.2. 
Week8 
• 
Symptom directed physical exam 
• 
Body weight 
• 
Vital signs: blood pressure, pulse, respiration rate, temperature 
• 
Review concomitant medications 
• 
Review adverse events 
• 
Perfonn study drug accountability 
• 
• 
Dispense blinded study drugs 
CONFIDENTIAL 
Page 76 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
plasma PK, virology (resistance surveillance), and serum and plasma for storage 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and storage 
6.3.1.3. 
Week 12 
• 
Symptom directed physical exam 
• 
Body weight 
• 
Vital signs: blood pressure, pulse, respiration rate, and temperature 
• 
Review concomitant medications 
• 
Review adverse events 
• 
Perfonn study drug accountability 
• 
Fasting blood sample for bone biomarkers 
• 
Fasting urine sample for renal biomarkers 
• 
CONFIDENTIAL 
Page 77 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 78
25 September 2019

Dispense blinded study drugs

Dose in clinic and collect single plasma PK sample between 15 minutes to 4 hours post-dose
(subjects who elect to dose in the evening the previous day are not required to have in-clinic 
dosing and provide a single PK sample)

Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
plasma PK, serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and 
reflex HBsAb), virology (resistance surveillance), and serum and plasma for storage   

Estimated creatinine clearance (using the Cockcroft-Gault method)

Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage
6.3.1.4.
Weeks 16, 20, 28, 32, 40 and 44

Symptom directed physical exam

Body weight 

Vital signs: blood pressure, pulse, respiration rate, and temperature

Review concomitant medications

Review adverse events 

Perform study drug accountability

Dispense blinded study drugs

Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
plasma PK, virology (resistance surveillance), and serum and plasma for storage 

Estimated creatinine clearance (using the Cockcroft-Gault method)

Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage
6.3.1.5.
Week 24

Complete physical examination including, vital signs (blood pressure, pulse, respiration rate 
and temperature), and body weight

DXA scan of spine and hip (within +/- 14 days of the expected visit date; at sites in China 
with capability only)

Review concomitant medications


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
• 
Review adverse events 
• 
Perfonn study drug accountability 
Final 
Amendment 3 .4 
• 
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at 
least 8 hours prior to blood collection 
• 
Fasting urine sample for renal biomarkers 
• 
Dispense blinded study drugs 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex 
HBsAb), plasma PK, virology (resistance surveillance), and serum and plasma for storage 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
• 
6.3.1.6. 
Week 36 
• 
Symptom directed physical exam 
• 
Body weight 
• 
Vital signs: blood pressure, pulse, respiration rate, and temperature 
• 
Review concomitant medications 
• 
Review adverse events 
• 
Perfonn study drug accountability 
• 
Dispense blinded study drugs 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex 
HBsAb), plasma PK, virology (resistance surveillance), and serum and plasma for storage 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
CONFIDENTIAL 
Page 79 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
6.3.1.7. 
Week48 
Final 
Amendment 3 .4 
• 
Complete physical exam including, vital signs (blood pressure, pulse, respiration rate and 
temperature), and body weight 
• 
ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to 
the recording) 
• 
DXA scan of spine and hip (within - 14 days of the expected visit date; at sites in China with 
capability only) 
• 
Review concomitant medications 
• 
Review adverse events 
• 
Perfonn study drug accountability 
• 
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at 
least 8 hours prior to blood collection 
• 
Fasting urine sample for renal biomarkers 
• 
Dispense blinded study drugs 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex 
HBsAb), plasma PK, virology (resistance surveillance), and serum and plasma for storage 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Blood sample for Fibrotest® 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
• 
6.3.1.8. 
Weeks 56 and 88 
• 
Symptom directed physical exam 
• 
Body weight 
• 
Vital signs: blood pressure, pulse, respiration rate, and temperature 
CONFIDENTIAL 
Page 80 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 81
25 September 2019

Review concomitant medications

Review adverse events 

Perform study drug accountability

Dispense blinded study drugs

Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
virology (resistance surveillance), and serum and plasma for storage 

Estimated creatinine clearance (using the Cockcroft-Gault method)

Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage
6.3.1.9.
Weeks 64, 80, 108, and 132

Symptom directed physical exam

Body weight 

Vital signs: blood pressure, pulse, respiration rate, and temperature

Review concomitant medications

Review adverse events 

Retrieve study drug and perform study drug accountability

Dispense blinded study drugs (subjects already assigned to open-label TAF 25 mg QD at 
Week 96 per Protocol Amendment 2.1 will be dispensed open-label TAF 25 mg QD at all 
subsequent visits)

Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and 
reflex HBsAb), virology (resistance surveillance), and serum and plasma for storage 

Estimated creatinine clearance (using the Cockcroft-Gault method)

Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
6.3.1.10. 
Week 72 
Final 
Amendment 3 .4 
• 
Complete physical exam including, vital signs (blood pressure, pulse, respiration rate and 
temperature), and body weight 
• 
DXA scan of spine and hip (within ± 14 days of the expected visit date; at sites in China with 
capability only) 
• 
Review concomitant medications 
• 
Review adverse events 
• 
Perfonn study drug accountability 
• 
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at 
least 8 hours prior to blood collection 
• 
Fasting urine sample for renal biomarkers 
• 
Dispense blinded study drugs 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
virology (resistance surveillance), and serum and plasma for storage 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
• 
6.3.1.11. 
Weeks 96 and 120 
• 
Complete physical exam including, vital signs (blood pressure, pulse, respiration rate and 
temperature), and body weight 
• 
Hepatic ultrasound for surveillance of hepatocellular carcinoma 
• 
ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to 
the recording) [Week 96 only] 
• 
DXA scan of spine and hip to be perfonned (within ± 14 days of the expected visit date; at 
sites in China with capability only) 
• 
Review concomitant medications 
CONFIDENTIAL 
Page 82 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
• 
Review adverse events 
• 
Retrieve study drug and perfonn study drug accom1tability 
Final 
Amendment 3 .4 
• 
Dispense blinded study drug (Week 120 only: subjects already assigned to open-label 
TAF 25 mg QD at Week 96 per Protocol Amendment 2.1 will be dispensed open-label 
TAF25 mg QD) 
• 
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at 
least 8 hours prior to blood collection 
• 
Fasting urine sample for renal biomarkers 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex 
HBsAb), virology (resistance surveillance), and serum and plasma for storage 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Blood sample for Fibrotest® [Week 96 only] 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
• 
6.3.1.12. 
Week 144 Visit 
• 
Complete physical exam including, vital signs (blood pressure, pulse, respiration rate and 
temperature), and body weight 
• 
Hepatic ultrasound for surveillance of hepatocellular carcinoma 
• 
ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to 
the recording) 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
DXA scan of spine and hip to be perfonned (within ± 14 days of the expected Week 144 visit 
date; at sites in China with capability only) 
• 
Review concomitant medications 
CONFIDENTIAL 
Page 83 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
• 
Review adverse events 
• 
Retrieve study drug and perfonn study drug accom1tability 
• 
Dispense open-label T AF 
Final 
Amendment 3 .4 
• 
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at 
least 8 hours prior to blood collection 
• 
Fasting urine sample for renal biomarkers 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex 
HBsAb), virology (resistance surveillance), and serum and plasma for storage 
• 
Blood sample for Fibrotest® 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage 
• 
6.3.2. 
Open-label Visits 
Study visits Weeks 168 through 384/ED should be completed within ± 28 days of the protocol 
specified visit date, based on the Baseline Visit. 
6.3.2.1. 
Weeks 168,216,264,312, and 360 
• 
Symptom directed physical exam 
• 
Hepatic ultrasound for surveillance of hepatocellular carcinoma 
• 
Body weight 
• 
Vital signs: blood pressure, pulse, respiration rate, and temperature 
• 
Review concomitant medications 
• 
Review adverse events 
• 
Perfonn open-label study drug accountability 
• 
Dispense open-label T AF 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex 
CONFIDENTIAL 
Page 84 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 85
25 September 2019
HBsAb), virology (resistance surveillance), and serum and plasma for storage.  For China 
only, the serum and plasma samples for storage are not being collected.

Estimated creatinine clearance (using the Cockcroft-Gault method)

Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage. For China only, 
the urine sample for storage are not being collected.
6.3.2.2.
Weeks 192, 240, 288, 336, and 384/ED
The ED Visit should be performed within 72 hours (visit window is + 3 days) of the last 
study drug dose.

Symptom directed physical exam (At Week 240 and 384/ED, a complete physical exam 
should be performed) 

Hepatic ultrasound for surveillance of hepatocellular carcinoma
At ED visit, hepatic ultrasound should be performed only if not done within the last 
24 weeks

Body weight

Vital signs: blood pressure, pulse, respiration rate, and temperature

ECG (subjects must rest quietly in the supine position for a minimum of 5 minutes prior to 
the recording)

DXA scan of spine and hip to be performed (within ± 28 days of the expected visit date; at 
sites in China with capability only)
At ED visit, DXA scan should be performed only if not done within the last 24 weeks

Review concomitant medications

Review adverse events

Retrieve study drug and perform study drug accountability 

Dispense Open-label TAF (no study drug will be dispensed at the Week 384/ ED visit)

Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL, direct LDL, and triglycerides]) - no food or drinks, except water, at 
least 8 hours prior to blood collection 

Fasting urine sample for renal biomarkers


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Final 
Amendment 3 .4 
• 
Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology (HBeAg, reflex HBeAb, HBsAg, and reflex 
HBsAb), virology (resistance surveillance), and serum and plasma for storage. For China 
only, the serum and plasma samples for storage are not being collected. 
• 
Estimated creatinine clearance (using the Cockcroft-Gault method) 
• 
Blood sample for Fibrotest® 
• 
Urine sample for urinalysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy test will be done), and for storage. For China only, 
the urine sample for storage is not being collected . 
• 
6.4. 
6.4.1. 
Post-treatment Assessments 
HBsAg Loss and Seroconversion Subjects 
Subjects who discontinue study drug due to HBsAg loss with confirmed seroconversion to 
anti-HBs on or after the Week 48 visit, will be followed off treatment every 4 weeks for 
12 weeks and then per the original study visit schedule through Week 384/ED (excluding drug 
dispensation and accountability). 
6.4.2. 
All other subjects who discontinue study drug 
Subjects who have received at least one dose of study drug and pennanently discontinue study 
drug for reasons other than HBsAg loss with confinned seroconversion to anti-HBs will be 
followed every 4 weeks for 24 weeks off treatment or up to initiation of alternative, 
c01mnercially available HBV therapy, whichever occurs first. 
6.4.3. 
Follow up visit assessments (all subjects) 
Treatment-free Follow up Visits should be completed ±7 days from the protocol-specified visit 
date, detennined by the date the subject discontinued the study drug. 
• 
Symptom directed physical exam 
• 
Body weight 
• 
Vital signs: blood pressure, pulse, respiration rate, and temperature 
• 
Review concomitant medications 
• 
Review adverse events 
CONFIDENTIAL 
Page 86 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 87
25 September 2019

Blood sample for serum chemistry and liver function tests, hematology, plasma HBV DNA, 
HBV serology (HBeAg, reflex HBeAb, HBsAg and reflex HBsAb) at Follow-up visits 
Weeks 12 and 24), quantitative serum HBsAg and serum for storage. For China only, the 
serum sample for storage is not being collected.

Estimated creatinine clearance (using the Cockcroft-Gault method)

Urine for urinalysis
6.5.
Early Discontinuation (ED) from Study
If a subject discontinues study dosing for reasons other than HBsAg loss with confirmed 
seroconversion to anti-HBs (for example, as a result of an AE), every attempt should be made to 
keep the subject in the study and continue to perform the required study-related follow-up and 
procedures (see Section 6.6, Criteria for Discontinuation of Study Treatment. If this is not 
possible or acceptable to the subject or investigator, the subject may be withdrawn from the 
study. Early discontinuation assessments are described in Section 6.3.2.2.
6.6.
Criteria for Discontinuation of Study Treatment
Study medication may be discontinued in the following instances:

Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree

Unacceptable toxicity, as defined in the toxicity management section of the protocol, or 
toxicity that, in the judgment of the investigator, compromises the ability to continue 
study-specific procedures or is considered to not be in the subject’s best interest

Subjects with confirmed creatinine clearance of < 30 mL/min at any time during the study 
will have their study drug permanently discontinued

Lack of efficacy (virologic failure) 

HBsAg loss with sero-conversion to anti-HBs. These subjects should discontinue study drug 
within 3-6 months following confirmation of seroconversion to anti-HBs. Subjects with 
HBsAg loss with confirmed seroconversion before Week 48 are not permitted to discontinue 
study drug prior to the Week 48 visit

Discontinuation of study drug for subjects experiencing HBsAg loss with confirmed 
seroconversion to anti-HBs, who have known bridging fibrosis or cirrhosis, should be 
considered on a case by case basis

Subject request to discontinue for any reason

Subject noncompliance


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
• 
Pregnancy during the study; refer to Appendix 6 
Final 
Amendment 3 .4 
• 
Discontinuation of the study at the request of Gilead Sciences, a regulatory agency or an 
institutional review board or independent ethics committee (IRB/IEC) 
6.7. 
Subjec 
visit. S 
Details 
will be 
documented in the Phannacokinetic Sample Collection, Processing, Storage, and Shipment 
Manual. 
6.8. 
Urine, Serum and Plasma for Storage 
A portion of the blood samples collected at each visit starting at Baseline (for China only, 
through Week 144) will be frozen and stored. These stored blood samples may be used by the 
Sponsor or its research partners for HBV genotyping/phenotyping assays or their development, 
for retestin the amom1t of HBV in the blood for measurement of antiviral dru levels in the 
blood, or 
to provide additional safety data. No human genetic testing on this 
sample will be perfonned. 
CONFIDENTIAL 
Page 88 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
A portion of the urine samples collected at each visit startin 
throu h Week 144 will be frozen and stored. 
6.9. 
Resistance Surveillance 
Final 
Amendment 3 .4 
Genotypic sequence analysis of the HBV polymerase/reverse transcriptase (pol/RT) for 
resistance mutations will be conducted at Baseline for all subjects, and attempted for all viremic 
subjects (HBV DNA ~ 69 IU/mL) at Week 48, and every 48 weeks until Week 384/ED visit. 
At Baseline, genotypic analysis will be conducted by INNO-LiPA Multi-DR v3 (hmogenetics), 
which will detennine the presence of HBV pol/ RT mutations known to confer resistance to 
lamivudine, adefovir, entecavir, clevudine, and/or telbivudine. 
Every 48 weeks post baseline (if viremic), resistance surveillance will be conducted by 
population sequencing of the HBV pol/RT. 
As it may not be known at the time of the visit whether a subject is viremic or if it will be their 
last study visit, a separate virology sample for potential resistance surveillance will be collected 
at each study visit. 
6.10. 
Hepatic Ultrasound for Hepatocellular Carcinoma Surveillance 
Subjects will undergo hepatic ultrasound assessments for HCC surveillance, beginning at 
Week 96, at 24 week intervals. Subjects who have completed the Week 96 visit 
(under Amendment 2.1) should begin ultrasound assessments at the next visit at which an 
ultrasom1d assessment is included (see Appendix 2 and Section 6 of the Protocol). 
6.11. 
End of Study 
The end of this study will be the last subject's last observation ( or visit) 
CONFIDENTIAL 
Page 89 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 90
25 September 2019
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1.
Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical study subject 
administered a medicinal product, which does not necessarily have a causal relationship with the
treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease 
temporally associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may also include pre- or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severity or change in nature during or 
as a consequence of participation in the clinical study will also be considered AEs.
An AE does not include the following:

Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion.
The condition that led to the procedure may be an adverse event and must be reported.

Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the 
screening visit that do not worsen

Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery, social and/or convenience admissions)

Overdose without clinical sequelae (see Section 7.6.1)

Any medical condition or clinically significant laboratory abnormality with an onset date 
before the consent form is signed and not related to a protocol-associated procedure is not an 
AE. It is considered to be pre-existing and should be documented on the medical history 
CRF.
7.1.2.
Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

Death

Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it were more severe.)

In-patient hospitalization or prolongation of existing hospitalization


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 91
25 September 2019

Persistent or significant disability/incapacity

A congenital anomaly/birth defect

A medically important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may 
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medically important event and subject to expedited reporting 
requirements.
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities are usually not recorded as AEs or SAEs. However, laboratory 
abnormalities (eg, clinical chemistry, hematology, and urinalysis) that require medical or surgical 
intervention or lead to IMP interruption, modification, or discontinuation must be recorded as an 
AE, as well as an SAE, if applicable. In addition, laboratory or other abnormal assessments 
(eg, electrocardiogram, x-rays, vital signs) that are associated with signs and/or symptoms must 
be recorded as an AE or SAE if they meet the definition of an AE or SAE as described in 
Sections 7.1.1and 7.1.2. If the laboratory abnormality is part of a syndrome, record the syndrome 
or diagnosis (eg, anemia), not the laboratory result (ie, decreased hemoglobin).
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments.
7.2.1.
Assessment of Causality for Study Drugs and Procedures
The investigator or qualified sub-investigator is responsible for assessing the relationship to IMP 
therapy using clinical judgment and the following considerations:

No: Evidence exists that the adverse event has an etiology other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre-existing condition, underlying disease, 
intercurrent illness, or concomitant medication).

Yes: There is reasonable possibility that the event may have been caused by the 
investigational medicinal product.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 92
25 September 2019
It should be emphasized that ineffective treatment should not be considered as causally related in 
the context of adverse event reporting. 
The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) 
should be assessed using the following considerations:

No: Evidence exists that the adverse event has an etiology other than the study procedure.

Yes: The adverse event occurred as a result of protocol procedures, (eg., venipuncture)
7.2.2.
Assessment of Severity
Severity of adverse events is to be determined based on GSI Grading Scale for Severity of 
Adverse Events and Laboratory Abnormalities (Appendix 5). A distinction should be drawn 
between seriousness and severity of AEs. An AE that is assessed as Grade 4 
(potentially life-threatening) should not be confused with an SAE. Severity is a category utilized 
for rating the intensity of an event: both AEs and SAEs can be assessed as Grade 4. An event is 
defined as “serious” when it meets one of the predefined outcomes described above in 
Section 7.2.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead or CRO
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study medication, the following types of events 
should be reported on the case report form (CRF/eCRF): all serious adverse events (SAEs) and 
adverse events related to protocol-mandated procedures.
Adverse Events
Following initiation of study medication, collect all AEs, regardless of cause or relationship, 
until 4-weeks after last administration of study IMP. AEs must be reported to the CRF/eCRF 
database as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up 
period.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occurs after the subject first consents to 
participate in the study (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol-required post treatment follow-up period, must be reported to the 
CRF/eCRF database and Gilead Pharmacovigilance and Epidemiology (PVE) as instructed. This 
also includes any SAEs resulting from protocol-associated procedures performed after informed 
consent is signed. Any SAEs and deaths, regardless of causality, that occur during the post 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 93
25 September 2019
treatment follow-up period or within 30 days of the last dose of study drug, when subject 
transitions to alternative, commercially available HBV therapy, should also be reported.
Investigators are not obligated to actively seek SAEs after the protocol defined follow up period.
However, if the investigator learns of any SAEs that occur after study participation has 
concluded and the event is deemed relevant to the use of IMP, he/she should promptly document 
and report the event to Gilead PVE.

All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined 
in the CRF/eCRF completion guideline. 

At the time of study start, SAEs may be reported using a paper serious adverse event 
reporting form, but sites will transition to an electronic SAE (eSAE) system. Gilead will 
notify sites in writing and provide training and account information prior to implementing an 
eSAE system.
Serious Adverse Event Paper Reporting Process

All SAEs will be recorded on the serious adverse event report form and submitted by faxing 
or emailing the report form within 24 hours of the investigator’s knowledge of the event to 
the attention of Gilead PVE or to the designated CRO.
Electronic Serious Adverse Event (eSAE) Reporting Process 

Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead PVE within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.

If for any reason it is not possible to record the SAE information electronically, ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours as described above.

As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.

If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Safety: 
Medical Monitor: 
CONFIDENTIAL 
North America - PRA 
Email: PPD 
________ 
_, 
Fax: PPD 
Final 
Amendment 3 .4 
Euro e (including Russian Federation Asia Pacific - PRA 
Email: PPD 
Fax: PPD 
India - KlinEra 
Email: PPD 
----------
ChinLl Vietnam - I VIA 
PPD 
Fax: PPD 
...----
Japan - CMIC 
Email: PPD 
Fax: PPD 
North America - PRA 
Tel: PPD 
Tel: PPD 
Fax: PPD 
Fax: PPD 
Email: 1-'l-'LJ 
----------
-------
Fax: PPD 
Europe (includin2 Russian Federation), Asia Pacific - PRA 
Phone: PPD 
FaxP PD 
Emai : 1-'l-'LJ 
---------
India - KlinEra 
PPD 
Phone: PPD 
Fax: PPD 
China Vietnam - I VIA 
PPD 
Phone: PPD 
Mobile: PPD 
Fax: PPD 
Email: 1-'l-'LJ 
----------
Japan- CMIC 
PPD 
Phone: PPD 
Email: 1-'l-'LJ 
-----------
Page 94 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 95
25 September 2019

For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other 
documents are also to be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.

Additional information may be requested to ensure the timely completion of accurate safety 
reports.
Any medications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
7.4.
Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country-specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by Gilead using reference safety 
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safety letter notifying them of relevant SUSAR reports. The 
investigator should notify the IRB or IEC of SUSAR reports as soon as is practical, where this is 
required by local regulatory agencies, and in accordance with the local institutional policy. 
7.5.
Toxicity Management

All clinical and clinically significant laboratory toxicities will be managed according to 
uniform guidelines detailed in Appendix 4.

Grade 3 and 4 clinically significant laboratory abnormalities should be confirmed by repeat 
testing within 3 calendar days of receipt of results and before investigational medicinal 
product discontinuation, unless such a delay is not consistent with good medical practice.

Clinical events and clinically significant laboratory abnormalities will be graded according to 
the Table for GSI Grading Scale for Severity of Adverse Events and Laboratory 
Abnormalities (Appendix 5).

When restarting investigational medicinal product following resolution of the adverse event, 
the investigational medicinal product should be restarted at full dose or modified dose that is 
dependent upon discussion with the Gilead Sciences Medical Monitor.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 96
25 September 2019

Any recurrence of the investigational medicinal product-related Grade 3 or 4 clinical or 
clinically significant laboratory adverse event following dose interruption mandates 
permanent discontinuation of investigational medicinal product.

Administration of study drug may be discontinued due to a clinical or laboratory event. The 
Gilead Medical Monitor should be consulted prior to dose discontinuation of study drug 
unless the investigator believes that immediate action is warranted to ensure the continued 
safety of subject.

Any questions regarding toxicity management should be directed to the Gilead Sciences 
Medical Monitor.
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event

Continue investigational medicinal product at the discretion of the investigator.
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event

For Grade 3 clinically significant laboratory abnormality or clinical event, investigational 
medicinal product may be continued if the event is considered to be unrelated to 
investigational medicinal product.

For a Grade 3 clinical event, or clinically significant laboratory abnormality confirmed by 
repeat testing, that is considered to be related to investigational medicinal product, 
investigational medicinal product should be withheld until the toxicity returns to ≤Grade 2.

If a laboratory abnormality recurs to ≥Grade 3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product should be permanently discontinued and the subject 
managed according to local practice. Recurrence of laboratory abnormalities considered 
unrelated to investigational medicinal product may not require permanent discontinuation.
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event

For a Grade 4 clinical event or clinically significant Grade 4 laboratory abnormality 
confirmed by repeat testing that is considered related to investigational medicinal product, 
investigational medicinal product should be permanently discontinued and the subject 
managed according to local practice. The subject should be followed as clinically indicated 
until the laboratory abnormality returns to baseline or is otherwise explained, whichever 
occurs first. A clinically significant Grade 4 laboratory abnormality that is not confirmed by 
repeat testing should be managed according to the algorithm for the new toxicity grade.

Investigational medicinal product may be continued without dose interruption for a clinically 
non-significant Grade 4 laboratory abnormality (e.g., Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medically managed) or a clinical event 
considered unrelated to investigational medicinal product.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 97
25 September 2019
7.5.4.
Management of Bone Evaluation
As there is uncertainty surrounding the clinical significance and management of decreases in 
bone mineral density for chronic HBV- infected patients, Gilead recommends that any subject 
who has a DXA scan that demonstrates a decrease from baseline of > 5% in bone mineral density 
of the spine region or the hip region be followed per local medical practice at the discretion of 
the investigator.
7.5.5.
Management of Potential Nephrotoxicity
Creatinine clearance (CLCr), estimated according to the Cockcroft-Gault formula, will be 
followed post-baseline during the study. All subjects with estimated CLCr < 50 mL/min must 
have serum creatinine measured again within 3 calendar days of receipt of results. At the time of 
this repeat serum creatinine assessment, Cystatin C will also be measured and the estimated 
glomerular filtration rate (eGFR) by CKD-EPI (cystatin C) will be calculated and compared with 
the baseline measurement of this parameter. During the double-blind period, any subject who has 
a confirmed CLCr estimated by the Cockroft-Gault formula < 50 mL/min and also experiences a 
> 20% reduction in eGFR by CKD-EPI (cystatin C) from baseline, will be managed as described 
below:
CKD-EPI (cystatin C) formula adjusted for age and sex:
eGFR (mL/min/1.73m2) = 133 × min(Scys/0.8, 1)−0.499 × max (Scys/0.8, 1)−1.328 ×
0.996Age [× 0.932 if female],
where Scys is serum cystatin C (mg/L), min (Scys/0.8,1) indicates the minimum of
Scys/0.8 or 1, and max (Scys/0.8,1) indicates the maximum of Scys/κ or 1.
Subjects meeting the above eGFR criteria (i.e. confirmed CLCr < 50 mL/min by Cockcroft-Gault 
equation and >20% reduction from baseline in eGFR by CKD-EPI equation) will be managed as 
follows:

If the CLCr is confirmed to be ≥ 30 mL/min and < 50 mL/min, the subject will be required to 
undergo dose modification to every other day dosing of study drug during the double-blind 
period only.

If the CLCr is confirmed ≥ 30 mL/min to < 50 mL/min and the subject has undergone dose 
modification to every other day dosing of study drug and subsequently develops a confirmed 
CLCr ≥50 mL/min, the subject may revert to once daily dosing of study drug after discussion 
with the Gilead Medical Monitor.

If the CLCr is confirmed to be < 30 mL/min at any time during the study, the subject will be 
required to permanently discontinue study drug


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 98
25 September 2019

All subjects with a change from baseline serum creatinine of ≥ 0.4 mg/dL must have serum 
creatinine repeated, with a concurrent urinalysis and urine chemistry, within two weeks of 
receipt of results. The following management will be required dependent upon the 
corresponding creatinine clearance value:
If creatinine clearance is < 50 ml/min, or the subject has other clinical and/or laboratory 
evidence of acute renal failure, the subject will be managed according to the guidance 
described above.
If creatinine clearance is ≥ 50 ml/min and the repeat testing of serum creatinine confirms 
a Grade1 or Grade 2 serum creatinine elevation, it is recommended that subject be 
monitored weekly until the serum creatinine level returns to a value within the normal 
laboratory range.

All subjects with negative or trace proteinuria at baseline that develop ≥1+ proteinuria on 
urinalysis must have a urinalysis repeated, with a concurrent urinalysis and urine chemistry, 
within two weeks of receipt of results. Upon confirmation of new proteinuria, subjects will 
be asked to return to the clinic for a scheduled or unscheduled follow up visit for evaluation. 
It is recommended that the investigator contact the Gilead Medical Monitor to discuss if 
further consultation with a nephrologist is clinically warranted.
7.5.6.
On-Treatment ALT Flare and Post-Treatment Exacerbation of Hepatitis 
Management
On-Treatment ALT Flare is defined as:

Confirmed (within 3 days of receipt of results) serum ALT > 2 baseline value and
> 10 ULN, with or without associated symptoms
7.5.6.1.
Management of ALT Flare in Subjects Receiving Study Medication
If laboratory results indicate elevation of ALT 2 × baseline and 10 × ULN, the following is 
recommended:

Schedule the subject to return to the clinic as soon as possible and (ideally within 3 days after 
the initial labs were drawn). During the visit, perform a clinical assessment of the subject. 
The assessment should include a physical examination and evaluation of the subject’s mental 
status. 

Check the following laboratory parameters: serum ALT and AST, total bilirubin, INR and 
serum albumin.

If the ALT elevation is confirmed, the central clinical laboratory will conduct reflex testing 
for plasma HBV DNA, serology for HBV (HBsAg, HBsAb, HBeAg and HBeAb), HDV, 
HAV IgM, HCV, and HEV


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 99
25 September 2019
Based on the results of the confirmatory tests, the following treatment modifications are 
recommended:
Elevated Liver Enzymes, Normal or Stable Relative to Baseline Liver Function Tests
If ALT levels are elevated (i.e., > 2 × baseline and > 10 × ULN), with normal or stable total 
bilirubin and INR relative to baseline, the subject may remain on study medication and should be 
monitored every week until ALT values return to normal or baseline levels. 
During monitoring, if the ALT values remain persistently elevated, the investigator should 
discuss with the Gilead Medical Monitor if the study drug should be discontinued.
For subjects with bridging fibrosis or cirrhosis, study drug discontinuation with treatment-free
follow-up is to be avoided due to the potential risk of exacerbation of hepatitis in the setting of 
low hepatic reserve which could lead to decompensation. Subjects with bridging fibrosis or 
cirrhosis should be placed on commercially available HBV therapy following study drug 
discontinuation.
Elevated Liver Enzymes, Elevated Liver Function Tests
If ALT values are elevated (i.e., > 2 × baseline and > 10 × ULN), total bilirubin is confirmed 
2 × baseline value, and INR is 0.5 above baseline, provided both are > ULN, the investigator 
should consider discontinuing study medication (upon discussion with the 
Gilead Medical Monitor, unless the safety of the subject is of immediate concern). 
The subject should be monitored weekly as long as ALT, total bilirubin and INR values remain 
elevated or above baseline values.
During monitoring, if the ALT and the liver function tests remain persistently elevated, the 
investigator should discuss with the Gilead Medical Monitor if the study drug should be 
discontinued.
For subjects with bridging fibrosis or cirrhosis, study drug discontinuation with treatment-free
follow-up is to be avoided due to the potential risk of exacerbation of hepatitis in the setting of 
low hepatic reserve which could lead to decompensation. Subjects with bridging fibrosis or 
cirrhosis should be placed on commercially available HBV therapy following study drug 
discontinuation.
7.5.6.2.
Management of Exacerbation of Hepatitis in Subjects who have Discontinued 
Study Medication
If laboratory results indicate (1) an ALT elevation > 2 × baseline and > 10 × ULN alone OR 
associated with (2) abnormal laboratory parameters suggestive of worsening hepatic function 
(total bilirubin 2 × baseline, INR 0.5 above baseline, provided both are > ULN) and the subject is 
on no post-study therapy for HBV, the following is recommended:


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 100
25 September 2019

Schedule the subject to return to the clinic as soon as possible (ideally no later than 3 days 
after the initial labs were drawn). During the visit, perform a clinical assessment of the 
subject. 

Check the following laboratory parameters: serum ALT and AST, total bilirubin, INR, and 
albumin.

If the ALT elevations are confirmed, the Central Clinical Laboratory will conduct reflex 
testing for plasma HBV DNA, serology for HBV (HBsAg, HBsAb, HBeAg and HBeAb), 
HDV, HAV IgM, HCV and HEV. If serum plasma HBV DNA is increasing, the investigator 
should consider immediate initiation of approved therapy. 

The subject should be followed until laboratory parameters (ALT, total bilirubin, INR) return 
to normal or baseline up to a maximum of 6 months after the initial occurrence of the event.
7.5.7.
Management of Potential Posterior Uveitis Cases
In a nine-month toxicology study conducted in dogs, some animals administered the highest dose 
of TAF (12-18mg/kg) had minimal mononuclear cell infiltration in the posterior uvea, 
considered secondary to general debilitation; this finding did not occur in animals given lower 
doses and it has not occurred in other animal studies. This pre-clinical finding has also not been 
observed in humans where the dose administered is lower than that given in the dog study, nor 
have there been reports of posterior uveitis in human clinical studies thus far. Nonetheless, if any 
subject develops signs or symptoms of posterior uveitis, investigators should contact the 
Gilead Medical Monitor to discuss the need for additional ophthalmologic evaluation including 
dilated fundoscopy and optical coherence tomography (OCT).
7.6.
Special Situations Reports
7.6.1.
Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, lack of 
effect reports and pregnancy reports regardless of an associated AE. Also includes reports of
adverse reactions in infants following exposure from breastfeeding, and reports of adverse 
reactions associated with product complaints and reports arising from occupational exposure.
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer. 
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a 
subject.
Misuse is defined as any intentional or inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 101
25 September 2019
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in 
question). In cases of a discrepancy in drug accountability, overdose will be established only 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Lack of effect is defined as a situation where there is apparent failure of the medicinal product or
medical technology to bring about the intended beneficial effect on the individual in a defined 
population with a given medical problem, under ideal conditions of use. 
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
7.6.2.
Instructions for Reporting Special Situations
7.6.2.1.
Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study subjects that are identified after
initiation of study medication and throughout the study, including the post study drug follow-up 
period, to the Gilead PVE using the pregnancy report form within 24 hours of becoming aware 
of the pregnancy. Refer to Section 7.3 and the CRF/eCRF completion guidelines for full 
instructions on the mechanism of pregnancy reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.
Any premature termination of pregnancy (e.g., a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underlying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is always considered to be an SAE and will be reported as described in 
Sections 7.1.1 and 7.1.2. Furthermore, any SAE occurring as an adverse pregnancy outcome post 
study must be reported to Gilead PVE.
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome should be reported to the CRO Safety Dept. using the pregnancy 
outcome report form. If the end of the pregnancy occurs after the study has been completed, the 
outcome should be reported directly to Gilead PVE. Gilead PVE contact information is as 
follows: Email: Safety_FC@gilead.com and Fax: +1 (650) 522-5477. 
Refer to Appendix 6 for Pregnancy Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Recommendations.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 102
25 September 2019
7.6.2.2.
Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to the CRO Safety Dept within 24 hours of the investigator becoming aware of the 
situation. These reports must consist of situations that involve study IMP, but do not apply to 
concomitant medications. Special situations involving non-Gilead concomitant medications does 
not need to be reported on the special situations report form, however, for special situations that 
result in AEs due to a non-Gilead concomitant medication, the AE should be reported on the AE 
form. Any inappropriate use of concomitant medications prohibited by this protocol should not 
be reported as “misuse,” but may be more appropriately documented as a protocol deviation.
Refer to Section 7.3 and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the symptoms 
and signs, clinical management, and outcome will be reported, when available.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 103
25 September 2019
8.
STATISTICAL CONSIDERATIONS
8.1.
Analysis Objectives and Endpoints
8.1.1.
Analysis Objectives
The primary objectives of this study are as follows:

To compare the efficacy of tenofovir alafenamide (TAF) 25 mg QD versus tenofovir 
disoproxil fumarate (TDF) 300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Week 48 in treatment-naïve and treatment-experienced subjects. The primary 
efficacy parameter is the proportion of subjects with plasma HBV DNA levels below 
29 IU/mL 

To compare the safety and tolerability of TAF 25 mg QD versus TDF 300 mg QD for the 
treatment of HBeAg-positive, chronic hepatitis B at Week 48 in treatment-naïve and 
treatment-experienced subjects
The key secondary safety objectives of this study are as follows: 

To compare the safety of TAF 25 mg QD versus TDF 300 mg QD as determined by the 
percent change from baseline in hip and spine BMD at Week 48

To compare the safety of TAF 25 mg QD versus TDF 300 mg QD as determined by the 
change from baseline in serum creatinine at Week 48
The key secondary efficacy objective of this study is as follows:

To compare the serological response (HBeAg seroconversion to anti-HBe) of TAF 25 mg 
QD versus TDF 300 mg QD for the treatment of HBeAg-positive, chronic hepatitis B at 
Week 48
Other secondary objectives of this study are as follows:

To compare the efficacy of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, chronic hepatitis B in regard to the proportion of subjects with plasma 
HBV DNA levels below 29 IU/mL at Weeks 96, and 144

To compare the efficacy of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, chronic hepatitis B in regard to the proportion of subjects with plasma 
HBV DNA levels below 29 IU/mL (target not detected) at Weeks 48, 96, and 144

To compare the biochemical (ALT normalization) response of TAF 25 mg QD versus TDF 
300 mg QD for the treatment of HBeAg-positive, chronic hepatitis B at 
Weeks 48, 96, and 144


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 104
25 September 2019

To compare the serological response (loss of HBeAg with seroconversion to anti-HBe) of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Weeks 96, and 144

To compare the serological response (loss of HBsAg with seroconversion to anti-HBs) of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, chronic 
hepatitis B at Weeks 48, 96, and 144

To compare the change in fibrosis as assessed by FibroTest® of TAF 25 mg QD versus TDF 
300 mg QD for the treatment of HBeAg-positive, chronic hepatitis B at 
Weeks 48, 96, and 144

To compare the incidence of drug resistant mutations of TAF 25 mg QD versus 
TDF 300 mg QD at Weeks 48, 96, and 144

To compare the change from baseline, in ophthalmologic findings by fundoscopic 
examination of TAF 25 mg QD versus TDF 300 mg QD at Weeks 24, 48, 72, 96, and 144 in 
a subset of subjects 

To characterize the pharmacokinetics of TAF and tenofovir (TFV) and determine 
intracellular concentrations of tenofovir diphosphate (TFV-DP) within peripheral blood 
mononuclear cells (PBMCs) in a subset of subjects receiving TAF or TDF

To evaluate the comparative open-label efficacy, safety, and incidence of drug resistance 
mutations of TAF 25 mg QD in subjects initially randomized to TAF 25 mg QD and in 
subjects sequentially treated with TDF 300 mg QD and then switched to open-label TAF
25 mg QD
8.1.2.
Primary Endpoint
The primary efficacy endpoint is the proportion of subjects with plasma HBV DNA < 29 IU/mL 
at Week 48.
8.1.3.
Secondary Endpoints
The key secondary safety endpoints are:

The percent change from baseline at Week 48 in hip BMD 

The percent change from baseline at Week 48 in spine BMD 

The change from baseline at Week 48 in serum creatinine 
The key secondary efficacy endpoint is:

The proportion of subjects with HBeAg seroconversion to anti-HBe at Week 48


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
8.1.4. 
Other Endpoints of Interest 
Final 
Amendment 3 .4 
• 
The proportion of subjects with plasma HBV DNA < 29 IU/mL at Weeks 96, 144, 
240, and 384 
• 
The proportion of subjects with plasma HBV DNA < 29 IU/mL (target not detected) at 
Weeks 48, 96, 144, 240, and 384 
• 
The proportion of subjects with ALT nonnalization (by central laboratory and 
AASLD criteria) at Weeks 48, 96 144, 240, and 384 
• 
The proportion of subjects with HBsAg loss at Weeks 48, 96, 144, 240, and 384 
• 
The proportion of subjects with HBeAg loss at Weeks 48, 96, 144, 240, and 384 
• 
The proportion of subjects with HBsAg seroconversion to anti-HBs at Weeks 48, 96, 144, 
240, and 384 
• 
The proportion of subjects with HBeAg seroconversion to anti-HBe at Weeks 96, 144, 240, 
and 384 
• 
The change from baseline in fibrosis as assessed by FibroTest® at Weeks 48, 96, 144, 240, 
and 384 
• 
The incidence of drug resistant mutations at Weeks 48 and 96, 144, 240, and 384 
• 
• 
The proportion of subjects with treatment-emergent proteinuria (by dipstick) at 
Weeks 48, 96, 144, 240, and 384 
8.2. 
8.2.1. 
8.2.1.1. 
Analysis Conventions 
Analysis Sets 
Efficacy 
The primary analysis set for efficacy analysis is the Full Analysis Set (FAS), defined as all 
randomized subjects who receive at least one dose of study drug. Subjects will be analyzed 
according to the randomized treatment assignment. 
CONFIDENTIAL 
Page 105 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
8.2.1.2. 
Safety 
Final 
Amendment 3 .4 
The primary analysis set for safety analyses is the Safety Analysis Set (SAS), defined as all 
randomized subjects who receive at least one dose of study drug. Subjects will be analyzed 
according to the treatment actually received. 
All data collected during treatment will be included in the safety summaries. Data collected 
during treatment free follow-up will be smmnarized or listed separately. 
8.2.1.3. 
Phannacokinetics 
The PK analysis set will include all subjects who are randomized and have received at least 
one dose of study medication and for whom concentration data of any analytes of interest 
( e.g., T AF and TFV) are available. The PK analysis set will be used for analyses of general 
phannacokinetics. 
8.2.1.4. 
Biomarkers 
The Biomarker analysis set will include all subjects who have evaluable biomarkers data. 
8.3. 
Data Handling Conventions 
For the primary endpoint and the key secondary efficacy endpoint, missing data will be handled 
using a missing = failure approach, m1less otherwise specified. 
For key secondary safety endpoints, missing data will be handled via a Last Observation Carried 
Forward (LOCF) method. 
For other categorical secondary efficacy endpoints, missing data will be handled using a 
missing = failure approach. For the drug resistant mutations endpoint, a missing = excluded 
approach will be employed. 
Sensitivity analyses will be perfonned as warranted. 
8.4. 
Multiplicity Adjustments 
The primary hypothesis of non-inferiority between TAF 25 mg QD and TDF 300 mg QD with 
respect to the proportion of subjects with HBV DNA < 29 IU/mL will be tested first. If 
non-inferiority is established, then multiplicity adjustments will be perfonned for the secondary 
endpoints with a fallback procedure using the following weights: 
a) Hip BMD (weight = 0.4) 
b) Spine BMD (weight = 0.2) 
CONFIDENTIAL 
Page 106 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 107
25 September 2019
c) Serum creatinine (weight = 0.4)
d) HBeAg seroconversion (weight = 0)
8.5.
Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized using standard descriptive 
methods by treatment group and overall.
Demographic summaries will include sex, race/ethnicity, geographical region, randomization 
stratification group, and age.
Is hip HMD statistically 
differentbenveen TAF 
and TDF? (a = 0.02) 
Is spine BMD statistically 
different benveen T AF 
and TDF? (a = 0.03) 
Yes 
Is serum 
creatinine 
statistically 
different 
between TAF 
and TDF? 
(a = 0.05) 
Yes 
0 
STOP 
Is HBeAg 
seroconvers10n 
statistically 
different between 
TAF and TDF? 
(a = 0.05) 
0 
Is serum 
creatinine 
statistically 
different 
betweenTAF 
and TDF? 
(a = 0.02) 
Yes 
0 
STOP 
Is HBeAg 
seroconvers10n 
statistically 
different between 
TAF and TDF? 
( a = 0.02) 
Is spine BMD statistically 
different benveen T AF 
and TDF? (a = 0.01) 
Yes 
Is serum 
creatinine 
statistically 
different 
between TAF 
and TDF? 
(a = 0.03) 
Yes 
Is HBeAg 
seroc-onverston 
statistically 
different benveen 
TAF and TDF? 
( a = 0.03) 
0 
Is serum 
creatinine 
statistically 
different 
between TAF 
and TDF? 
(a = 0.02) 
Yes 
0 
STOP 
Is HBeAg 
seroconvers10n 
statistically 
different between 
TAF andTDF? 
(a = 0.02) 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 108
25 September 2019
Baseline data will include a summary of body weight, height, body mass index, log10 HBV DNA 
level, years positive for HBV, ALT level (≤ ULN, > ULN), previous oral nucleoside/nucleotide 
treatment experience, previous interferon experience, and genotype.
8.6.
Efficacy Analysis
8.6.1.
Primary Analysis
The primary efficacy analysis will be conducted when approximately 864 randomized subjects
complete 48 weeks of the double-blind treatment period or discontinue prematurely. A two-sided 
95% confidence interval, based on the large sample theory adjusted for the randomization 
stratification factors (the adjusted Mantel-Haenszel proportions), for the difference (TAF – TDF) 
in the proportion of subjects who achieved HBV DNA < 29 IU/mL will be used to compare the 
treatment groups. A non-inferiority will be declared if the lower bound of this confidence 
interval exceeds a non-inferiority margin of –0.10. If non-inferiority is established, the lower 
bound of the 95% CI will be compared to 0; if the lower bound of the 95% CI is greater than 0, 
then superiority of TAF over TDF will be established using the same confidence interval. Details 
will be provided in the statistical analysis plan.
8.6.1.1.
Justification of the non-inferiority margin
At Week 48 in study GS-US-174-0103, the proportion of subjects with HBV DNA < 29 IU/mL 
in the TDF arm was 68.8%. At Week 48 in study GS-98-437, the proportion of subjects with 
HBV DNA < 29 IU/mL in the placebo arm was 0%. The non-inferiority margin of 10% would 
preserve more than 83% of the lower bound of the 95% confidence interval of the difference 
between TDF and placebo.
NTDF
NPBO
Response rate 
in TDF
Response rate 
in PBO
Difference
95% confidence interval
lower bound
176
167
68.8%
0%
68.8%
62.0%
Preserve at least 83% 
of lower bound
10%
Furthermore, at Week 48 in study GS-US-174-0103, the proportion of subjects with HBV DNA 
< 29 IU/mL in the TDF arm was 68.8% and the proportion of subjects with HBV DNA 
< 29 IU/mL in adefovir (ADV) arm was 8.9%. The non-inferiority margin of 10% would 
preserve more than 80% of the lower bound of the 95% confidence interval of the difference 
between TDF and adefovir (ADV).
NTDF
NADV
Response rate 
in TDF
Response rate 
in ADV
Difference
95% confidence interval 
lower bound
Study 174-0103
176
90
68.8%
8.9%
59.9%
50.8%
Preserve at least 80% 
of lower bound
10%


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 109
25 September 2019
8.6.2.
Key Secondary Efficacy Analyses
The proportion of subjects with HBeAg seroconversion to anti-HBe at Week 48 will be 
summarized and compared between the two groups using the Mantel-Haenszel test, controlling
for the randomization strata. A missing = failure approach will be employed. The details are
provided in the SAP.
8.6.3.
Analyses of Other Endpoints of Interest
Continuous secondary endpoints will be summarized using conventional descriptive statistics 
(n, mean, standard deviation, median, Q1, Q3, minimum, and maximum) by treatment group and 
overall. A Wilcoxon rank sum test will be used to compare the treatment groups, in an 
exploratory manner.
Categorical secondary endpoints will be summarized by number and percentage of subjects that 
meet the endpoint. A two-sided Mantel-Haenszel test, controlling for the randomization strata,
will be used to compare the treatment groups, in an exploratory manner. Missing data will be 
handled by the missing = failure approach. For the incidence of drug resistant mutations, the 
missing = excluded approach will be employed.
An analysis of the China subpopulation will also be conducted when approximately 
150 randomized and treated China subjects complete 48 weeks of double-blind treatment or 
discontinue prematurely to examine the consistency of the responses between the China 
subpopulation and the overall population.
8.7.
Safety Analysis
All safety data collected on or after the date that study drug was first dispensed up to the date of 
last dose will be summarized by treatment group (according to the drug received). Data for the 
pretreatment and treatment-free follow-up periods will be included in data listings. 
8.7.1.
Key Secondary Safety Analyses
The percent change from baseline in hip and spine BMD at Week 48 will be analyzed using an 
ANOVA model. The model will include treatment group as a fixed effect. The details are
provided in the Statistical Analysis Plan (SAP).
The change from baseline in serum creatinine at Week 48 will be analyzed using an ANCOVA 
model with baseline serum creatinine as a covariate, and treatment group as a fixed effect. The 
details are provided in the SAP.
8.7.2.
Extent of Exposure
A subject’s extent of exposure to study drug data will be generated from the drug administration 
data. Exposure data will be summarized by treatment group. 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 110
25 September 2019
8.7.3.
Adverse Events
Clinical and laboratory adverse events will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term 
(HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment-emergent 
adverse event will be defined as any adverse event that begins on or after the date of first dose of 
treatment up to the date of last dose of treatment. Continuing adverse events diagnosed prior to 
the start of treatment and worsening in severity grade, or non-serious adverse events at baseline 
which become serious, or adverse events resulting in treatment discontinuation after the start of 
treatment will also be considered treatment-emergent.
Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC
and PT) will be provided by treatment group:

Treatment-emergent adverse events

Treatment-emergent study drug-related adverse events

Grade 3 or 4 treatment-emergent adverse event

Grade 3 or 4 treatment-emergent study drug-related adverse event

Grade 2, 3, or 4 treatment-emergent adverse event

Grade 2, 3, or 4 treatment-emergent study drug-related adverse event

AE that caused permanent discontinuation from study drug

AE that caused change in dose or temporary interruption of study drug

Treatment-emergent serious adverse event

Treatment-emergent study drug-related serious adverse event
8.7.4.
Laboratory Evaluations
Selected laboratory data (using conventional units) will be summarized using only observed data. 
Data and change from baseline at all scheduled time points will be summarized.
Graded laboratory abnormalities will be defined using the grading scheme in Appendix 5.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 111
25 September 2019
Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 
one toxicity grade from baseline at any time post baseline up to and including the date of last 
dose of treatment, will be summarized by treatment group. If baseline data are missing, then any 
graded abnormality (i.e., at least a Grade 1) will be considered treatment emergent. 
Laboratory abnormalities that occur before the first dose of treatment or after the subject has 
been discontinued from treatment will be included in a data listing.
8.8.
Pharmacokinetic Analysis
Pharmacokinetic parameters will be listed and summarized for TAF and TFV using descriptive 
statistics (e.g., sample size, arithmetic mean, geometric mean, % coefficient of variation, 
standard deviation, median, minimum, and maximum). Plasma concentrations of TAF and TFV 
over time will be plotted in semilogarithmic and linear formats as mean ± standard deviation.
 
8.9.
Biomarker Analysis
Selected bone biomarkers, including C-type collagen sequence (CTX) and procollagen type 1 
N-terminal propeptide (P1NP), and selected renal biomarkers, including urine retinol binding 
protein, and urine beta-2-microglobulin, will be summarized by treatment group and visit using 
descriptive statistics. The difference in change from baseline in these biomarkers between two 
treatment arms will be tested using Wilcoxon rank sum test.
8.10.
Sample Size
With respect to the primary efficacy endpoint, a sample size of 288 for the TDF 300 mg group 
and 576 for the TAF 25 mg group will have 84% power to rule out the non-inferiority margin of 
10% at a one-sided significance level of 0.025. This assumes a rate of 69% in the TDF group and 
69% in the TAF group in the proportion of subjects with HBV DNA < 29 IU/mL. A similar 
response rate in the TDF group was observed in GS-US-174-0103 {Dӧhner 2000}. 
This sample size (n=576 for the TAF 25 mg arm, n=288 for the TDF 300 mg arm) also provides 
at least 90% power to detect a 1% difference in the percent change from baseline in hip BMD at 
Week 48 (assuming a 1.17% change from baseline in the TDF 300 mg arm and 0.17% change 
from baseline in the TAF 25 mg arm with a common standard deviation of 2.20% and a 
two-sided α = 0.025); at least 90% power to detect a 1% difference in the percentage change 
from baseline in spine BMD at Week 48 (assuming a 1.69% change from baseline in the TDF 
300 mg arm and 0.69% change in the TAF 25 mg arm, with a common standard deviation of 
3.08% and a two-sided α = 0.025); at least 85% power to detect a 0.03 mg/dL difference in the 
change from baseline in serum creatinine at Week 48 (assuming a 0.04 mg/dL change from 
baseline in the TDF 300 mg arm and 0.01 mg/dL change from baseline in the TAF 25 mg arm, 
with a common standard deviation of 0.12); and 16% power to detect a 4% difference in HBeAg 
seroconversion rate (assuming a 19% HBeAg seroconversion rate in the TDF arm and 
23% HBeAg seroconversion rate in the TAF arm). These assumptions were derived from studies 
GS-98-437, GS-98-438, GS-US-174-0102, GS-US-174-0103, and GS-US-174-0121.
CCI


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 112
25 September 2019
For China, approximately 150 additional subjects (100 subjects TAF 25 mg QD and matched 
placebo of TDF 300 mg QD, and 50 subjects TDF 300 mg QD and matched placebo of TAF 
25 mg QD) will be enrolled.
8.11.
Data Monitoring Committee
An external multidisciplinary data monitoring committee (DMC) will review the progress of the 
study and perform interim reviews of safety data and provide recommendation to Gilead whether 
the nature, frequency, and severity of adverse effects associated with study treatment warrant the 
early termination of the study in the best interests of the participants, whether the study should 
continue as planned, or the study should continue with modifications. The DMC may also 
provide recommendations as needed regarding study design, 
The DMC will convene approximately every 24 weeks following the time of randomization of 
the first subject during the blinded portion of the protocol and approximately every 48 weeks 
during the open label period.
The DMC’s specific activities will be defined by a mutually agreed upon charter, which will 
define the DMC’s membership, conduct and meeting schedule.
While the DMC will be asked to advise Gilead regarding future conduct of the study, including 
possible early study termination, Gilead retains final decision-making authority on all aspects of 
the study.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 113
25 September 2019
9.
RESPONSIBILITIES
9.1.
Investigator Responsibilities
9.1.1.
Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 
21 CFR, part 50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable sub-investigators will comply with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary 
interests in the investigational drug under study. This documentation must be provided prior to 
the investigator’s (and any sub-investigator’s) participation in the study. The investigator and 
sub-investigator agree to notify Gilead of any change in reportable interests during the study and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol-defined activities.
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and any accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin any study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC any modifications made to the protocol or any accompanying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary to 
reduce immediate risk to study subjects.
9.1.3.
Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study and before undertaking any study-related procedures. The 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 114
25 September 2019
investigator must use the most current IRB- or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriately 
signed and dated by the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by an impartial witness if required by IRB or IEC or 
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic analysis results.
9.1.4.
Confidentiality
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed by local law) and an identification code will be recorded on any 
form or biological sample submitted to the Sponsor, IRB or IEC, or laboratory. Laboratory 
specimens must be labeled in such as way as to protect subject identity while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory instructions. NOTE: The 
investigator must keep a screening log showing codes, names, and addresses for all subjects 
screened and for all subjects enrolled in the trial. Subject data will be processed in accordance 
with all applicable regulations. 
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, CRF/eCRF, the IMP, and any other study information, 
remain the sole and exclusive property of Gilead during the conduct of the study and thereafter. 
This information is not to be disclosed to any third party (except employees or agents directly 
involved in the conduct of the study or as required by law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure by any employee or agent of the study site to any third party or otherwise into the 
public domain.
9.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study file, and 
(2) subject clinical source documents.
The investigator’s study file will contain the protocol/amendments, CRF and query forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:

Subject identification (name, date of birth, gender);

Documentation that subject meets eligibility criteria, ie, history, physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 115
25 September 2019

Documentation of the reason(s) a consented subject is not enrolled

Participation in study (including study number);

Study discussed and date of informed consent;

Dates of all visits;

Documentation that protocol specific procedures were performed;

Results of efficacy parameters, as required by the protocol;

Start and end date (including dose regimen) of IMP, including dates of dispensing and return;

Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity);

Concomitant medication (including start and end date, dose if relevant; dose changes);

Date of study completion and reason for early discontinuation, if it occurs.
All clinical study documents must be retained by the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an ICH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may be required to retain documents longer if 
specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The 
investigator must notify Gilead before destroying any clinical study records.
Should the investigator wish to assign the study records to another party or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securely away from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away from the site.
9.1.6.
Case Report Forms
For each subject consented, an eCRF will be completed by an authorized study staff member 
whose training for this function is documented according to study procedures. eCRF should be 
completed on the day of the subject visit to enable the sponsor to perform central monitoring of 
safety data. Subsequent to data entry, a study monitor will perform source data verification 
within the EDC system. Original entries as well as any changes to data fields will be stored in the 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 116
25 September 2019
audit trail of the system. Prior to database lock (or any interim time points as described in the 
clinical data management plan), the investigator will use his/her log in credentials to confirm that 
the forms have been reviewed, and that the entries accurately reflect the information in the 
source documents. The eCRF capture the data required per the protocol schedule of events and 
procedures. System-generated or manual queries will be issued to the investigative site staff as 
data discrepancies are identified by the monitor or internal Gilead staff, who routinely review the 
data for completeness, correctness, and consistency. The site coordinator is responsible for 
responding to the queries in a timely manner, within the system, either by confirming the data as 
correct or updating the original entry, and providing the reason for the update (e.g. data entry 
error). At the conclusion of the trial, Gilead will provide the site with a read-only archive copy of
the data entered by that site. This archive must be stored in accordance with the records retention 
requirements outlined in Section 9.1.5.
9.1.7.
Investigational Medicinal Product Accountability and Return
If the site has an appropriate Standard Operating Procedure (SOP) for drug destruction, the site 
may destroy used (empty kits and/or bottles) and unused study drug supplies performed in 
accordance with the site’s (hospital/pharmacy) SOP. If the site does not have acceptable 
procedures in place for drug destruction, arrangements will be made between the site and 
Gilead Sciences (or Gilead Sciences’ representative) for return of unused study drug supplies. 
Gilead recommends that used and unused IMP supplies be returned to the shipping facility from 
which it came for eventual destruction. The study monitor will provide instructions for return. If 
return is not possible, the study monitor will evaluate each study center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. If the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined by 
Gilead QA, the site may destroy used (empty or partially empty) and unused IMP supplies in 
accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained 
for central files. 
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP 
destroyed. Records must show the identification and quantity of each unit destroyed, the method 
of destruction, and the person who disposed of the IMP. Upon study completion, copies of the 
IMP accountability records must be filed at the site. Another copy will be returned to Gilead.
The study monitor will review IMP supplies and associated records at periodic intervals.
9.1.8.
Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed study monitors, to IRBs or IECs, or to regulatory authority or health authority 
inspectors.
9.1.9.
Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 117
25 September 2019
9.2.
Sponsor Responsibilities
9.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Gilead. The investigator must submit all protocol modifications to the IRB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifications can be implemented.
9.2.2.
Study Report and Publications
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in 
certain cases.
Investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after the following conditions have been met:

the results of the study in their entirety have been publicly disclosed by or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the study has been completed at all 
study sites for at least 2 years

The investigator will submit to Gilead any proposed publication or presentation along with 
the respective scientific journal or presentation forum at least 30 days before submission of 
the publication or presentation. 

No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).

The investigator will comply with Gilead’s request to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary.
9.3.
Joint Investigator/Sponsor Responsibilities
9.3.1.
Access to Information for Monitoring
In accordance with regulations and guidelines, the study monitor must have direct access to the 
investigator’s source documentation in order to verify the accuracy of the data recorded in the 
CRF/eCRF.
The monitor is responsible for routine review of the CRF/eCRF at regular intervals throughout 
the study to verify adherence to the protocol and the completeness, consistency, and accuracy of 
the data being entered on them. The monitor should have access to any subject records needed to 
verify the entries on the CRF/eCRF. The investigator agrees to cooperate with the monitor to 
ensure that any problems detected through any type of monitoring (central, on site) are resolved.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 118
25 September 2019
9.3.2.
Access to Information for Auditing or Inspections
Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the 
clinical study. If the investigator is notified of an inspection by a regulatory authority the 
investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to 
provide to representatives of a regulatory agency or Gilead access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
9.3.3.
Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority (ies), IRBs, and IECs. In terminating the study, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 119
25 September 2019
10.
REFERENCES
Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. Mechanism for Effective Lymphoid Cell 
and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-
7340. Mol Pharm 2013;10 (2):459-66.
Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, et al. Hepatitis B virus 
quasispecies susceptibility to entecavir confirms the relationship between 
genotypic resistance and patient virologic response. J Hepatol 2008;48 (6):895-
902.
Bam RA, Birkus G, Babusis D, Yant SR, Cihlar T. Minimal Donor Variation in Cathepsin A 
Expression and Antiviral Activity of GS-7340 in Primary Human CD4+ T Cells 
and Macrophages [Poster Number TUPE016]. XIX International AIDS 
Conference; 2012 July 22-27; Washington, D.C. . 
Birkus G, Bam R, Frey C, Tsai L, Stray K, Yant S, et al. Intracellular activation pathways for 
GS-7340 and the effect of antiviral protease inhibitors  [Poster #577]. Presented 
at: 19th Conference on Retroviruses and Opportunistic Infections (CROI); 2012 
March 5-8; Seattle, WA. 
Centers for Disease Control and Prevention (CDC). Hepatitis B Fact Sheet.  Available at:  
http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm. Accessed August 6, 
2003, 
Dӧhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic 
aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 
2000;343 (26):1910-6.
Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A Randomized, Double-
Blind Comparison of Tenofovir DF (TDF) Versus Adefovir Dipivoxil (ADV) for 
the Treatment of HBEAG-Positive Chronic Hepatitis B (CHB): Study GS-US-
174-0103 [AASLD Abstracts]. Hepatology 2007;46 (4 Supp1):861A.
Marcellin P, Buti M, Kraslev Z, Germanidis G, Kaita K, Kotzev I, et al. A Randomized, Double-
Blind Comparison of Tenofovir DF (TDF) Versus Adefovir Dipivoxil (ADV) for 
the Treatment of HBEAG-Negative Chronic Hepatitis B (CHB): Study GS-US-
174-0102 [AASLD Abstracts]. Hepatology 2007;46 (4 Suppl 1):290A-1A.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis 
during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-
year open-label follow-up study. Lancet 2013;381 (9865):468-75.
Marcellin P, Heathcote E, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil 
for chronic hepatitis B. N Engl J Med 2008;359 (23):2442-55.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Final
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 120
25 September 2019
Marcellin PE, Heathcote EJ, Corsa A, et al. No detectable resistance to tenofovir disoproxil 
fumarate (TDF) following up to 240 weeks of treatment in patients with 
HBEAG+ and HBEAG- chronic hepatitis B virus infection [Abstract 238]. 
Hepatology 2011;54 (4 Suppl.):480A.
Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective 
analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic 
hepatitis C. Clin Chem 2006;52 (10):1887-96.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
antiretroviral agents in HIV-1-infected adults and adolescents. Department of 
Health and Human Services. 1–239. Available at  
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 
August 22.  2012.
Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of 
FibroTest diagnostic value in chronic liver disease. BMC gastroenterology 
2007;7:40.
Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, et al. Longitudinal 
assessment of histology surrogate markers (FibroTest-ActiTest) during 
lamivudine therapy in patients with chronic hepatitis B infection. Am J 
Gastroenterol 2005;100 (9):1970-80.
Robbins BL, Greenhaw JJ, Connelly MC, Fridland A. Metabolic pathways for activation of the 
antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. 
Antimicrob Agents Chemother 1995;39 (10):2304-8.
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term 
monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive 
patients is rare through 5 years of therapy. Hepatology 2009;49 (5):1503-14.
World Health Organization (WHO). Fact Sheet WHO/204.  October, 2000.
Zuckerman AJ. Progress towards the comprehensive control of hepatitis B. Gut 1996;38 (2):S1.


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
11. 
Appendix I. 
Appendix 2. 
Appendix 3. 
APPENDICES 
Investigator Signature Page 
Stud Procedures Table 
Management o 
mica an La oratoty Adverse Events 
Final 
Amendment 3 .4 
Appendix 4. 
Appendix 5. 
Appendix 6. 
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnotmalities 
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Recommendations 
CONFIDENTIAL 
Page 121 
25 September 2019 


Tenofovir Alafenamide (TAF) 
Protocol GS-US-320-0 I I 0 
Gilead Sciences, Inc. 
Appendix 1. 
Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
Final 
Amendment 3.4 
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 
Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg 
QD for the Treatment ofHBeAg-Positive Chronic Hepatitis B 
GS-US-320-0110, Amendment 3.4, 25 September 2019 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
PPD 
~~------PPD---
Stuuy Director 
PPD 
PPD 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) 
Signature 
Date 
Site Number 
CONFIDENTIAL 
Page 122 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 123
25 September 2019
Appendix 2.
Study Procedures Table
Screening 
(45 days)
BL
Week
4
8
12
16
20
24
28
32
36
40
44
48a
56
64
72
80
88
96a,e
108
132e
120e
144e
Visit 
Windows
± 3 days
-14
days
± 3 days
± 14 days
Informed Consent 
X
Review of Inclusion/ 
Exclusion Criteria 
X
X
Medical History, including 
HBV history
X
Review Concomitant 
Medications
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Complete Physical 
Examination including vital 
signs, and weight 
X
X
X
X
X
X
X
X
Height
X
Symptom-directed Physical 
Exam
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
ECGb
X
X
X
X
Vital Signsc
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Randomization 
X
DXAd (spine & hip) 
X
X
X
X
X
X
X
Fracture Risk Assessmentq
X
Study Drug Accountability
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Study Drug 
Dispensed/Retrievede
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 124
25 September 2019
Screening 
(45 days)
BL
Week
4
8
12
16
20
24
28
32
36
40
44
48a
56
64
72
80
88
96a,e
108
132e
120e
144e
Visit 
Windows
± 3 days
-14
days
± 3 days
± 14 days
Dosing in-clinicf
X
X
Serum Chemistry and Liver 
Function Testsg
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Estimated Creatinine 
Clearance 
(by Cockcroft-Gault Method)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Hematology 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Cystatin C 
(for estimated eGFR)
X
Plasma HBV DNA Levels 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum HBsAg (quantitative)
X
X
X
X
X
X
X
X
X
X
X
X
HBV Serologyh
X
X
X
X
X
X
X
X
X
X
X
X
HBV Genotyping (A-H) 
X
Virology 
(resistance surveillance)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
HIV-1, HDV, HCV
X
α-fetoprotein
X
Fibrotest®
X
X
X
X
IL28B Genotype
X
Vitamin D
X
Plasma PK 
X
X
X
X
X
X
X
X
X
X
X
X
Fasting Blood for Bone 
Biomarkersi
X
X
X
X
X
X
X
X
X


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Draft 
Gilead Sciences, lnc. 
Amendment 3 .4 
Week 
Screening 
108 
(45 days) 
BL 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48· 
56 
64 
72 
80 
88 
96 ... 
132' 
120• 
144' 
Visit 
-14 
Windows 
± 3 days 
days 
± 3 days 
± 14 days 
Fasting Urine for Renal 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Biomarkersi 
Fasting Metabolic Panet-i 
X 
X 
X 
X 
X 
X 
X 
Semm Pregnancy Testk 
X 
Urine Pregnancy Testk 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
CONFIDENTIAL 
Page 125 
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 126
25 September 2019
Visit windows
Week
168
192
216
240
264
288
312
336
360
384/EDo
FUp
±28 days
±7 days
Review Concomitant Medications
X
X
X
X
X
X
X
X
X
X
X
Adverse Events 
X
X
X
X
X
X
X
X
X
X
X
Complete Physical Examination including vital signs, and weight 
X
X
Symptom-directed Physical Exam
X
X
X
X
X
X
X
X
X
Body weight
X
X
X
X
X
X
X
X
X
ECGb
X
X
X
X
X
Vital Signsc
X
X
X
X
X
X
X
X
X
DXA (spine & hip)d
X
X
X
X
X
Study Drug Accountability  
X
X
X
X
X
X
X
X
X
X
Study Drug Dispensed/Retrievede
X
X
X
X
X
X
X
X
X
Xe
Serum Chemistry and Liver Function Testsg
X
X
X
X
X
X
X
X
X
X
X
Est Creatinine Clearance (Cockcroft-Gault) 
X
X
X
X
X
X
X
X
X
X
X
Hematology 
X
X
X
X
X
X
X
X
X
X
X
Plasma HBV DNA Levels 
X
X
X
X
X
X
X
X
X
X
X
Serum HBsAg (quantitative)  
X
X
X
X
X
X
X
X
X
X
X
HBV Serologyh
X
X
X
X
X
X
X
X
X
X
X
Virology (resistance surveillance)
X
X
X
X
X
X
X
X
X
X
Fibrotest®
X
X
X
X
X
Fasting Blood for Bone Biomarkersi
X
X
X
X
X
Fasting Urine for Renal Biomarkersi
X
X
X
X
X
Fasting Metabolic Panelj
X
X
X
X
X
Urine Pregnancy Testk
X
X
X
X
X
X
X
X
X
X


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Draft 
Gilead Sciences, lnc. 
Amendment 3 .4 
Week 
168 
192 
216 
240 
264 
288 
312 
336 
360 
384/ED0 
FUP 
Visit windows 
±28 days 
±7 days 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Semm and plasma for storage' 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X (semm only) 
Urine for Storage' 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
a 
The visit window for Week 48 visit is 14 days. The visit window for Week 96 visit is ± 14 days 
b 
Subjects must rest quietly in the supine position for a minimum of 5 minutes prior to the recording 
c 
Vital signs include blood pressure, pulse, respiration rate, and temperature 
d 
DXA scans will be perfomied only at sites in China with capability. The initial (baseline) DXA will be perfomied during Screening and should be completed at least 14 days 
prior to the first dose of study dmg. The Week 48 DXA window is 14 days only. DXA re.quired for Early Discontinuation (ED) visit if not done within the last 24 weeks. 
e 
Subjects already assigned to open-label T AF 25 QD per Amend 2. 1 continue on T AF. Otherwise, blinded study dmg will be dispensed until Week 144 visit. Open-label T AF 
25 mg QD will be dispensed from Week 144 through Week 360. At Week 384/ED visit, study dmg will not be dispensed 
f 
It is preferred that subjects take their study dmg according to a morning dosing schedule; subjects who elect to dose in the evening the previous day are not re.quired to have 
in-clinic dosing and provide the single PK sample being collected at Week 4 and 12 visits. 
g 
Semm chemistry and Liver Function Tests: alkaline phosphatase, AST, ALT, GGT, total bilimbin, direct and indirect bilimbin, total protein, albumin, LOH, CPK, 
bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphoms, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is perfomied in subjects 
with total amylase > 1.5 >< ULN), and PTJ-1. PTH analyzed at all visits except for Screening through Week 96, and then at Weeks 120, 144, and then every 48 weeks through 
Week 384/ED. At Baseline, Weeks 24, 48, 72, 96, 120, 144, 192, 240, 288, 336, and 384/ED, subject will be fasting for semm glucose and metabolic panel. Coagulation 
Panel will be done at Screening and then as a reflex only test for ALT flares. 
h 
1-IBeAg, reflex 1-IBeAb, 1-IBsAg and reflex 1-IBsAb will be done at Screening, Baseline, and every 12 to 24 weeks until week 384/ED and at Follow Up visits 
Weeks 12 and 24. 
Blood for selected bone biomarkers and urine for selected renal biomarkers will be collected in a fasted state. Required for ED visit if the last sample was collected >24 weeks 
prior 
j 
Fasting glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). 
k 
For female subjects of childbearing otential. In the event of a ositive urine test, a semm 
I 
Ill 
CONFIDENTIAL 
Page 127 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
n 
o 
The Early D1scontmuatton (ED) v1s1t should be perfom1ed within 72 hours of the last study dmg dose (within 3 days) 
Draft 
Amendment 3 .4 
p 
Subjects who discontinue study dmg for reasons other than 1-lBsAg loss with confim1ed seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks or up to 
initiation of alternative, commercially available HBV therapy, whichever occurs first. Subjects who lose 1-lBsAg with confim1ed seroconversion to anti-1-lBs should 
discontinue study dmg within 3-6 months following confim1ation of 1-lBsAg loss and seroconversion to anti-HBs or after Week 48, if seroconversion occurs prior to this visit. 
These subjects will be followed off treatment every 4 weeks for 12 weeks and then per the study visit schedule through Week 384/ED. 
q 
Complete the Fracture Risk Assessment specific eCRF at sites in China with DXA capability only. 
r 
Hepatic ultrasound for I-ICC surveillance 
s 
For China only, semm, plasma and urine samples for storage are not being collected for visits Weeks 168 - Week 384/ED and Follow-up visits. 
CONFIDENTIAL 
Page 128 
25 September 2019 


Tenofovir Alafenamide (T AF) 
Protocol GS-US-320-0 I 10 
Gilead Sciences, lnc. 
Appendix 3. 
* 
CONFIDENTIAL 
Page 129 
Draft 
Amendment 3 .4 
Schedule-
25 September 2019 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 130
25 September 2019
Appendix 4.
Management of Clinical and Laboratory Adverse Events
Grade 1
Grade 4
Grade 3
Grade 2
May continue 
dosing at the 
discretion of the 
investigator
Repeat lab to 
confirm toxicity 
grade
Repeat lab to 
confirm toxicity 
grade
If confirmed and possibly and/or probably related to 
investigational medicinal products:
1.
Withhold investigational medicinal products until Grade 2
2.
Restart all investigational medicinal products at full dose
If confirmed and unrelated to 
investigational medicinal products, 
dosing may continue at the 
discretion of the investigator
If confirmed and 
possibly or probably 
related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products
dosing permanently 
and follow at periodic 
intervals at least 
weekly until a return 
to baseline or is 
otherwise explained
If Grade 3 or 4 recurrence that is confirmed and possibly or 
probably related to investigational medicinal products, 
discontinue all investigational medicinal products dosing 
l
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all 
investigational medicinal products at the same dose at the 
discretion of the investigator
I 
I I 
I 
l 
J l 
·~ 
I 
I 
l 
~1 
I 
,______ 
t 
t 
t 
t 
I 
II 
11 
I ~I-~I 


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 131
25 September 2019
Appendix 5.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Version: 18 June 2012
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days
8.5 to 10.0 g/dL 
85 to 100 g/L
7.5 to 8.5 g/dL 
75 to 85 g/L
6.5 to 7.5 g/dL 
65 to 75 g/L
6.5 g/dL
65 g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 
10.0 to 10.9 g/dL
100 to 109 g/L
OR
Any decrease from Baseline
2.5 to 3.5 g/dL
25 to 35 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
OR
Any decrease from Baseline
3.5 to 4.5 g/dL
35 to 45 g/L
7.0 to 9.0 g/dL
70 to 90 g/L
OR
Any decrease from Baseline
4.5 g/dL
45 g/L
7.0 g/dL
70 g/L
Infant, 36–56 Days
(HIV POSITIVE OR
NEGATIVE)
8.5 to 9.4 g/dL
85 to 94 g/L
7.0 to 8.5 g/dL
70 to 85 g/L
6.0 to 7.0 g/dL
60 to < 70 g/L
6.0 g/dL
< 60 g/L
Infant, 22–35 Days
(HIV POSITIVE OR
NEGATIVE)
9.5 to 10.5 g/dL
95 to 105 g/L
8.0 to 9.5 g/dL
80 to 95 g/L
7.0 to 8.0 g/dL
70 to 80 g/L
7.0 g/dL
70 g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE)
12.0 to 13.0 g/dL
120 to 130 g/L
10.0 to 12.0 g/dL
100 to 120 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
9.0 g/dL
90 g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 7 Days
1000 to 1300/mm3
750 to 1000/mm3
500 to 750/mm3
500/mm3
1.00 to 1.30 GI/L
0.75 to 1.00 GI/L
0.50 to 0.75 GI/L
0.50 GI/L
Infant, 2 – 7 Days
1250 to 1500/mm3
1.25 to 1.50 GI/L
1000 to 1250/mm3
1.00 to < 1.25 GI/L
750 to 1000/mm3
0.75 to < 1.00 GI/L
750/mm3
< 0.75 GI/L
Infant, 1 Day
4000 to 5000/mm3
4.00 to 5.00 GI/L
3000 to 4000/mm3
3.00 to < 4.00 GI/L
1500 to 3000/mm3
1.50 to < 3.00 GI/L
1500/mm3
< 1.50 GI/L


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 132
25 September 2019
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
> 13 Years
300 to 400/mm3
300 to 400/ μL
200 to 300/mm3
200 to 300/ μL
100 to 200/mm3
100 to 200/ μL
100/mm3
100/ μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13 Years
600 to 650/mm3
0.60 to 0.65 GI/L
500 to 600/mm3
0.50 to 0.60 GI/L
350 to 500/mm3
0.35 to 0.50 GI/L
350/mm3
0.35 GI/L
Platelets 
100,000 to < 125,000/mm3
100.0 to 125.0 GI/L
50,000 to 100,000/mm3
50.0 to 100.0 GI/L
25,000 to 50,000/mm3
25.0 to 50.0 GI/L
25,000/mm3
25.0 GI/L
WBCs 
2000/mm3 to 2500/mm3
1,500 to 2,000/mm3
1000 to 1,500/mm3
1000/mm3
2.0 GI/L to 2.5 GI/L
1.5 to 2.0 GI/L
1.0 to 1.5 GI/L
1.0 GI/L
Hypofibrinogenemia
100 to 200 mg/dL
75 to 100 mg/dL
50 to 75 mg/dL
50 mg/dL
1.00 to 2.00 g/L
0.75 to 1.00 g/L
0.50 to 0.75 g/L
0.50 g/L
Hyperfibrinogenemia
ULN to 600 mg/dL
600 mg/dL
—
—
ULN to 6.0 g/L
6.0 g/L
—
—
Fibrin Split Product 
20 to 40 μg /mL
40 to 50 μg /mL
50 to 60 μg /mL
60 μg /mL
20 to 40 mg/L
40 to 50 mg/L
50 to 60 mg/L
60 mg/L
Prothrombin Time (PT)
1.00 to 1.25 ULN
1.25 to 1.50 ULN
1.50 to 3.00 ULN
3.00 ULN
International Normalized Ratio 
of prothrombin time (INR)
1.1 to 1.5 x ULN
>1.5 to 2.0 x ULN
>2.0 to 3.0 x ULN
>3.0 x ULN
Activated Partial
Thromboplastin Time (APTT)
1.00 to 1.66 ULN
1.66 to 2.33 ULN
2.33 to 3.00 ULN
3.00 ULN
Methemoglobin 
5.0 to 10.0%
10.0 to 15.0%
15.0 to 20.0%
20.0%


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 133
25 September 2019
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyponatremia 
130 mEq/L to LLN
125 to 130 mEq/L
121 to 125 mEq/L
121 mEq/L
130 mmol/L to LLN
125 to 130 mmol/L
121 to 125 mmol/L
121 mmol/L
Hypernatremia 
146 to 150 mEq/L
150 to 154 mEq/L
154 to 159 mEq/L
159 mEq/L
146 to 150 mmol/L
150 to 154 mmol/L
154 to 159 mmol/L
159 mmol/L
Hypokalemia 
3.0 to 3.4 mEq/L
2.5 to 3.0 mEq/L
2.0 to 2.5 mEq/L
2.0 mEq/
3.0 to 3.4 mmol/L
2.5 to 3.0 mmol/L
2.0 to 2.5 mmol/L
2.0 mmol/L
Hyperkalemia 
5.6 to 6.0 mEq/L
6.0 to 6.5 mEq/L
6.5 to 7.0 mEq/L
7.0 mEq/L
5.6 to 6.0 mmol/L
6.0 to 6.5 mmol/L
6.5 to 7.0 mmol/L
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1 Month
55 to 64 mg/dL
40 to 55 mg/dL
30 to 40 mg/dL
30 mg/dL
3.03 to 3.58 mmol/L
2.20 to 3.03 mmol/L
1.64 to 2.20 mmol/L
1.64 mmol/L
Infant, 1 Month
50 to 54 mg/dL
2.8 to 3.0 mmol/L
40 to 50 mg/dL
2.2 to 2.8 mmol/L
30 to 40 mg/dL
1.7 to 2.2 mmol/L
30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 
116 to 160 mg/dL
160 to 250 mg/dL
250 to 500 mg/dL
500 mg/dL
6.42 to 8.91 mmol/L
8.91 to 13.90 mmol/L
13.90 to 27.79 mmol/L
27.79 mmol/L
Hyperglycemia, Fasting
110 to 125 mg/dL
6.08 to 6.96 mmol/L
>125 to 250 mg/dL
>6.96 to 13.90 mmol/L
>250 to 500 mg/dL
>13.90 to 27.79 mmol/L
>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
7 Days
7.8 to 8.4 mg/dL
7.0 to 7.8 mg/dL
6.1 to 7.0 mg/dL
6.1 mg/dL
1.94 to 2.10 mmol/L
1.74 to 1.94 mmol/L
1.51 to 1.74 mmol/L
1.51 mmol/L
Infant, 7 Days
6.5 to 7.5 mg/dL
1.61 to 1.88 mmol/L
6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L
5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 
5.5 mg/dL
< 1.36 mmol/L


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 134
25 September 2019
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypercalcemia
(corrected for albumin if 
appropriate*)
Adult and Pediatric
7 Days
ULN to 11.5 mg/dL
11.5 to 12.5 mg/dL
12.5 to 13.5 mg/dL
13.5 mg/dL
ULN to 2.88 mmol/L
2.88 to 3.13 mmol/L
3.13 to 3.38 mmol/L
3.38 mmol/L
Infant, 7 Days
11.5 to 12.4 mg/dL
2.86 to 3.10 mmol/L
12.4 to 12.9 mg/dL
> 3.10 to 3.23 mmol/L
12.9 to 13.5 mg/dL
> 3.23 to 3.38 mmol/L
13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized)
3.0 mg/dL to LLN
2.5 to < 3.0 mg/dL
2.0 to 2.5 mg/dL
2.0 mg/dL
0.74 mmol/L to LLN
0.62 to 0.74 mmol/L
0.49 to 0.62 mmol/L
0.49 mmol/L
Hypercalcemia (ionized)
ULN to 6.0 mg/dL
6.0 to 6.5 mg/dL
6.5 to 7.0 mg/dL
7.0 mg/dL
ULN to 1.50 mmol/L
1.50 to 1.63 mmol/L
1.63 to 1.75 mmol/L
1.75 mmol/L
Hypomagnesemia
1.40 to LLN mg/dL
1.2 to <LLN mEq/L
1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L
0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L
0.67 mg/dL
0.6 mEq/L
0.58 mmol/L to LLN
0.43 to 0.58 mmol/L
0.28 to 0.43 mmol/L
0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14 Years
2.0 mg/dL to LLN
1.5 to 2.0 mg/dL
1.0 to 1.5 mg/dL
1.0 mg/dL
0.63 mmol/L to LLN
0.47 to 0.63 mmol/L
0.31 to 0.47 mmol/L
0.31 mmol/L
Pediatric 1 Year–14 Years 
3.0 to 3.5 mg/dL
0.96 to 1.12 mmol/L
2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Pediatric 1 Year
3.5 to 4.5 mg/dL
1.12 to 1.46 mmol/L
2.5 to 3.5 mg/dL
0.80 to < 1.12 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 135
25 September 2019
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyperbilirubinemia 
Adult and Pediatric > 14 Days
1.0 to 1.5 ULN
1.5 to 2.5 ULN
2.5 to 5.0 ULN
5.0 ULN
Infant, 14 Days
(non-hemolytic)
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 to 30.0 mg/dL
> 428 to 513 μmol/L
30.0 mg/dL
> 513 μmol/L
Infant, 14 Days
(hemolytic)
NA
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen
1.25 to 2.50 ULN 
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Hyperuricemia
ULN to 10.0 mg/dL
10.0 to 12.0 mg/dL
12.0 to 15.0 mg/dL
15.0 mg/dL
ULN to 597 μmol/L
597 to 716 μmol/L
716 to 895 μmol/L
895 μmol/L
Hypouricemia
1.5 mg/dL to LLN
1.0 to 1.5 mg/dL
0.5 to 1.0 mg/dL
0.5 mg/dL
87 μmol/L to LLN
57 to 87 μmol/L
27 to 57 μmol/L
27 μmol/L
Creatinine 
1.50 to 2.00 mg/dL
2.00 to 3.00 mg/dL
3.00 to 6.00 mg/dL
6.00 mg/dL
133 to 177 μmol/L
177 to 265 μmol/L
265 to 530 μmol/L
530 μmol/L
Bicarbonate
16.0 mEq/L to LLN 
11.0 to 16.0 mEq/L
8.0 to 11.0 mEq/L
8.0 mEq/L
16.0 mmol/L to LLN
11.0 to 16.0 mmol/L
8.0 to 11.0 mmol/L
8.0 mmol/L
Triglycerides
(Fasting)
NA
500 to 750 mg/dL
750 to 1200 mg/dL
1200 mg/dL
5.64–8.47 mmol/L
8.47–13.55 mmol/L
13.55 mmol/L
LDL
(Fasting)
130 to 160 mg/dL
>160 to 190 mg/dL
> 190 mg/dL
NA
3.35 to 4.15 mmol/L
>4.15 to 4.92 mmol/L
>4.92 mmol/L
Pediatric >2 to <18 years
110 to 130 mg/dL
>130 to 190 mg/dL
> 190 mg/dL
NA
2.84 to 3.37 mmol/L
>3.37 to  4.92 mmol/L
>4.92 mmol/L


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 136
25 September 2019
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypercholesterolemia
(Fasting)
200 to 239 mg/dL
239 to 300 mg/dL
300 mg/dL
NA
5.16 to 6.19 mmol/L
6.19 to 7.77 mmol/L
7.77 mmol/L
Pediatric 18 Years
170 to 199 mg/dL
4.39 to 5.15 mmol/L
199 to 300 mg/dL
5.15 to 7.77 mmol/L
300 mg/dL
7.77 mmol/L
NA
Creatine Kinase
3.0 to 6.0 ULN
6.0 to 10.0 ULN
10.0 to 20.0 ULN
20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
ENZYMES
Grade 1
Grade 2
Grade 3
Grade 4
AST (SGOT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
ALT (SGPT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
GGT
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Alkaline Phosphatase 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Total Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Pancreatic Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Lipase 
1.0 to 1.5 ULN
1.5 to 3.0 ULN
3.0 to 5.0 ULN
5.0 ULN
Albumin
3.0 g/dL to LLN
2.0 to 3.0 g/dL
2.0 g/dL
NA
30 g/L to LLN
20 to 30 g/L
20 g/L


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 137
25 September 2019
URINALYSIS
Grade 1
Grade 2
Grade 3
Grade 4
Hematuria (Dipstick) 
1
2
3-4+
NA
Hematuria (Quantitative) 
See Note below
Females
>ULN –10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
Males
6-10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
Proteinuria (Dipstick)
1
2–3
4
NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years
200 to 999 mg/24 h
999 to 1999 mg/24 h
1999 to 3500 mg/24 h
3500 mg/24 h
Pediatric 3 Mo to 
< 10 Years
201 to 499 mg/m2/24 h
499 to 799 mg/m2/24 h
799 to 1000 mg/m2/24 h
1000 mg/ m2/24 h
Glycosuria (Dipstick)
1
2-3
4
NA
Note: Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 138
25 September 2019
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)
Asymptomatic AND No 
intervention indicated
Asymptomatic AND 
Non-urgent medical 
intervention indicated
Symptomatic, 
non-life-threatening AND 
Non-urgent medical 
intervention indicated 
Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction
NA
NA
Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia 
Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)
NA
Symptomatic AND No 
transfusion indicated
Symptomatic AND 
Transfusion of 2 units 
packed RBCs (for children 
10 cc/kg) indicated
Life-threatening hypotension 
OR Transfusion of 2 units 
packed RBCs indicated
(for children 10 cc/kg) 
indicated
Hypertension (with repeat 
testing at same visit)
140–159 mmHg systolic
OR
90–99 mmHg diastolic
159–179 mmHg systolic
OR
99–109 mmHg diastolic
179 mmHg systolic
OR
109 mmHg diastolic
Life-threatening 
consequences 
(e.g., malignant 
hypertension) OR 
Hospitalization (other than 
ER visit) indicated
Pediatric 17 Years 
(with repeat testing at same 
visit)
NA
91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
≥95th percentile adjusted for 
age, height, and gender 
(systolic and/or diastolic)
Life-threatening 
consequences 
(e.g., malignant 
hypertension) OR 
Hospitalization indicated 
(other than emergency room 
visit)
Hypotension
NA
Symptomatic, corrected with 
oral fluid replacement
Symptomatic, IV fluids 
indicated
Shock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 139
25 September 2019
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Pericardial Effusion
Asymptomatic, small 
effusion requiring no 
intervention
Asymptomatic, moderate or 
larger effusion requiring no 
intervention
Effusion with 
non-life-threatening 
physiologic consequences 
OR Effusion with nonurgent 
intervention indicated
Life-threatening 
consequences 
(e.g., tamponade) OR Urgent 
intervention indicated
Prolonged PR Interval
PR interval 
0.21 to 0.25 sec
PR interval
0.25 sec
Type II 2nd degree AV block 
OR Ventricular pause 
3.0 sec
Complete AV block 
Pediatric 16 Years
1st degree AV block
(PR > normal for age and 
rate)
Type I 2nd degree AV block 
Type II 2nd degree AV block
Complete AV block
Prolonged QTc
Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baseline
Asymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baseline
Asymptomatic, QTc interval 
0.50 sec OR Increase in
interval 0.06 sec above
baseline
Life-threatening 
consequences, e.g., Torsade 
de pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16 Years
Asymptomatic, QTc interval 
0.450 to 0.464 sec 
Asymptomatic, QTc interval 
0.465 to 0.479 sec 
Asymptomatic, QTc interval 
0.480 sec
Life-threatening 
consequences, e.g., Torsade 
de pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism
NA
Deep vein thrombosis AND 
No intervention indicated 
(e.g., anticoagulation, lysis 
filter, invasive procedure) 
Deep vein thrombosis AND 
Intervention indicated 
(e.g., anticoagulation, lysis 
filter, invasive procedure) 
Embolic event 
(e.g., pulmonary embolism, 
life-threatening thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)
Present without loss of 
consciousness 
Present with transient loss of 
consciousness
NA 
NA
Ventricular Dysfunction 
(congestive heart failure, CHF)
NA
Asymptomatic diagnostic 
finding AND intervention 
indicated
New onset with symptoms 
OR Worsening symptomatic 
CHF
Life-threatening CHF


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 140
25 September 2019
RESPIRATORY
Grade 1
Grade 2
Grade 3
Grade 4
Bronchospasm (acute)
FEV1 or peak flow reduced 
to 70% to 80%
FEV1 or peak flow 50% to 
69%
FEV1 or peak flow 25% to 
49% 
Cyanosis OR FEV1 or peak 
flow 25% OR Intubation
Dyspnea or Respiratory Distress
Dyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities 
Dyspnea on exertion causing 
greater than minimal 
interference with usual social 
& functional activities 
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years
Wheezing OR minimal 
increase in respiratory rate 
for age
Nasal flaring OR Intercostal 
retractions OR Pulse 
oximetry 90% to 95%
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%
Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1
Grade 2
Grade 3
Grade 4
Uveitis
Asymptomatic but detectable 
on exam
Symptomatic anterior uveitis 
OR Medical intervention 
indicated
Posterior or pan-uveitis OR 
Operative intervention 
indicated
Disabling visual loss in 
affected eye(s) 
Visual Changes (from baseline)
Visual changes causing no or 
minimal interference with 
usual social & functional 
activities
Visual changes causing 
greater than minimal 
interference with usual social 
& functional activities
Visual changes causing 
inability to perform usual 
social & functional activities
Disabling visual loss in 
affected eye(s)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 141
25 September 2019
SKIN
Grade 1
Grade 2
Grade 3
Grade 4
Alopecia
Thinning detectable by study 
participant or caregiver 
(for disabled adults)
Thinning or patchy hair loss 
detectable by health care 
provider
Complete hair loss
NA
Cutaneous Reaction – Rash
Localized macular rash 
Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions 
Diffuse macular, 
maculopapular, or 
morbilliform rash with 
vesicles or limited number of 
bullae OR Superficial 
ulcerations of mucous 
membrane limited to one site
Extensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two or 
more distinct mucosal sites 
OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation
Slight or localized
Marked or generalized
NA
NA
Hypopigmentation
Slight or localized 
Marked or generalized
NA
NA
Pruritis 
(itching – no skin lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)
Itching causing no or 
minimal interference with 
usual social & functional 
activities
Itching causing greater than 
minimal interference with 
usual social & functional 
activities
Itching causing inability to 
perform usual social & 
functional activities 
NA


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 142
25 September 2019
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Anorexia
Loss of appetite without 
decreased oral intake
Loss of appetite associated 
with decreased oral intake 
without significant weight 
loss 
Loss of appetite associated 
with significant weight loss 
Life-threatening 
consequences OR 
Aggressive intervention 
indicated [e.g., tube feeding 
or total parenteral nutrition]
Ascites
Asymptomatic
Symptomatic AND 
Intervention indicated 
(e.g., diuretics or therapeutic 
paracentesis)
Symptomatic despite 
intervention
Life-threatening 
consequences
Cholecystitis
NA
Symptomatic AND Medical 
intervention indicated
Radiologic, endoscopic, or 
operative intervention 
indicated
Life-threatening 
consequences (e.g., sepsis or 
perforation) 
Constipation 
NA
Persistent constipation 
requiring regular use of 
dietary modifications, 
laxatives, or enemas 
Obstipation with manual 
evacuation indicated
Life-threatening 
consequences 
(e.g., obstruction)
Diarrhea 
Adult and Pediatric 1 Year
Transient or intermittent 
episodes of unformed stools 
OR Increase of 3 stools 
over baseline/24 hr
Persistent episodes of 
unformed to watery stools 
OR Increase of 4–6 stools 
over baseline per 24 hrs. 
Bloody diarrhea OR Increase 
of 7 stools per 24-hour 
period OR IV fluid 
replacement indicated
Life-threatening 
consequences 
(e.g., hypotensive shock)
Pediatric 1 Year
Liquid stools (more 
unformed than usual) but 
usual number of stools
Liquid stools with increased 
number of stools OR Mild 
dehydration
Liquid stools with moderate 
dehydration
Liquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia 
Symptomatic but able to eat 
usual diet
Symptoms causing altered 
dietary intake without 
medical intervention 
indicated
Symptoms causing severely 
altered dietary intake with 
medical intervention 
indicated
Life-threatening reduction in 
oral intake


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 143
25 September 2019
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, Dysphagia-
Odynophagia
Erythema of the mucosa
Patchy pseudomembranes or 
ulcerations 
Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor trauma
Tissue necrosis OR Diffuse 
spontaneous mucosal 
bleeding OR Life-threatening 
consequences 
(e.g., aspiration, choking)
Nausea 
Transient (24 hours) or 
intermittent nausea with no 
or minimal interference with 
oral intake
Persistent nausea resulting in 
decreased oral intake for 
24-48 hours
Persistent nausea resulting in 
minimal oral intake for 
48 hours OR Aggressive
rehydration indicated
(e.g., IV fluids)
Life-threatening 
consequences 
(e.g., hypotensive shock)
Pancreatitis
NA
Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)
Symptomatic AND 
Hospitalization indicated 
(other than ER visit)
Life-threatening 
consequences (e.g., sepsis, 
circulatory failure, 
hemorrhage)
Proctitis 
(functional- symptomatic)
Also see Mucositis/ Stomatitis 
for Clinical Exam
Rectal discomfort AND No 
intervention indicated
Symptoms causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Medical intervention 
indicated 
Symptoms causing inability 
to perform usual social/ 
functional activities OR 
Operative intervention 
indicated 
Life-threatening 
consequences 
(e.g., perforation)
Vomiting
Transient or intermittent 
vomiting with no or minimal 
interference with oral intake
Frequent episodes of 
vomiting with no or mild 
dehydration
Persistent vomiting resulting 
in orthostatic hypotension 
OR Aggressive rehydration 
indicated
Life-threatening 
consequences 
(e.g., hypotensive shock)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 144
25 September 2019
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Alteration in 
Personality-Behavior or in 
Mood (e.g., agitation, anxiety, 
depression, mania, psychosis)
Alteration causing no or 
minimal interference with 
usual social & functional 
activities 
Alteration causing greater 
than minimal interference 
with usual social & 
functional activities 
Alteration causing inability 
to perform usual social & 
functional activities 
Behavior potentially harmful 
to self or others 
(e.g., suicidal/homicidal 
ideation or attempt, acute 
psychosis) OR Causing 
inability to perform basic 
self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)
Changes causing no or 
minimal interference with 
usual social & functional 
activities
Mild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activities
Confusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activities
Delirium OR obtundation, 
OR coma
Ataxia 
Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no or 
minimal interference with 
usual social & functional 
activities
Symptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activities
Symptomatic ataxia causing 
inability to perform usual 
social & functional activities 
Disabling ataxia causing 
inability to perform basic 
self-care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention Deficit 
Disorder) 
Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicated
Disability causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Specialized resources on 
part-time basis indicated
Disability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicated
Disability causing inability to 
perform basic self-care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)
NA
NA
Transient ischemic attack
Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 Years
Mild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting 
Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting 
Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting 
Developmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 145
25 September 2019
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Headache 
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater 
than minimal interference 
with usual social & 
functional activities
Symptoms causing inability 
to perform usual social & 
functional activities
Symptoms causing inability 
to perform basic self-care 
functions OR Hospitalization 
indicated (other than ER 
visit) OR Headache with 
significant impairment of 
alertness or other neurologic 
function 
Insomnia
NA
Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activities
Difficulty sleeping causing 
inability to perform usual 
social & functional activities
Disabling insomnia causing 
inability to perform basic 
self-care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) 
Asymptomatic with 
decreased strength on exam 
OR Minimal muscle 
weak-ness causing no or 
minimal interference with 
usual social & functional 
activities
Muscle weakness causing 
greater than minimal 
interference with usual social 
& functional activities
Muscle weakness causing 
inability to perform usual 
social & functional activities 
Disabling muscle weakness 
causing inability to perform 
basic self-care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)
Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social & 
functional activities 
Sensory alteration or 
paresthesia causing greater 
than minimal interference 
with usual social & 
functional activities 
Sensory alteration or 
paresthesia causing inability 
to perform usual social & 
functional activities
Disabling sensory alteration 
or paresthesia causing
inability to perform basic 
self-care functions
Seizure: (new onset) 
NA
1 seizure 
2–4 seizures 
Seizures of any kind that are 
prolonged, repetitive 
(e.g., status epilepticus), or 
difficult to control 
(e.g., refractory epilepsy)


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 146
25 September 2019
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Seizure: (pre-existing) 
For Worsening of Existing 
Epilepsy the Grades Should Be 
Based on an Increase from 
Previous Level of Control to 
Any of These Levels
NA
Increased frequency of 
pre-existing seizures 
(non-repetitive) without 
change in seizure character 
OR infrequent breakthrough 
seizures while on stable 
meds in a previously 
controlled seizure disorder
Change in seizure character 
from baseline either in 
duration or quality 
(e.g., severity or focality) 
Seizures of any kind that are 
prolonged, repetitive 
(e.g., status epilepticus), or 
difficult to control 
(e.g., refractory epilepsy)
Seizure 
– Pediatric 18 Years
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5 minutes with < 24 hours 
post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
5–20 minutes with 
< 24 hours post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes
Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated with a 
procedure)
NA
Present
NA
NA
Vertigo
Vertigo causing no or 
minimal interference with 
usual social & functional 
activities
Vertigo causing greater than 
minimal interference with 
usual social & functional 
activities 
Vertigo causing inability to 
perform usual social & 
functional activities
Disabling vertigo causing 
inability to perform basic 
self-care functions


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 147
25 September 2019
MUSCULOSKELETAL
Grade 1
Grade 2
Grade 3
Grade 4
Arthralgia
See also Arthritis
Joint pain causing no or 
minimal interference with 
usual social & functional 
activities
Joint pain causing greater 
than minimal interference 
with usual social & 
functional activities
Joint pain causing inability to 
perform usual social & 
functional activities
Disabling joint pain causing 
inability to perform basic 
self-care functions
Arthritis
See also Arthralgia
Stiffness or joint swelling 
causing no or minimal 
interference with usual social 
& functional activities
Stiffness or joint swelling 
causing greater than minimal 
interference with usual social 
& functional activities
Stiffness or joint swelling 
causing inability to perform 
usual social & functional 
activities
Disabling joint stiffness or 
swelling causing inability to 
perform basic self-care 
functions
Bone Mineral Loss
BMD t-score or z-score
–2.5 to –1.0
BMD t-score or z-score
–2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening 
consequences 
Pediatric 21 Years
BMD z-score 
–2.5 to –1.0
BMD z-score < –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening 
consequences 
Myalgia
(non-injection site)
Muscle pain causing no or 
minimal interference with 
usual social & functional 
activities
Muscle pain causing greater 
than minimal interference 
with usual social & 
functional activities
Muscle pain causing inability 
to perform usual social & 
functional activities
Disabling muscle pain 
causing inability to perform 
basic self-care functions
Osteonecrosis
NA
Asymptomatic with 
radiographic findings AND 
No operative intervention 
indicated
Symptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicated
Disabling bone pain with 
radiographic findings 
causing inability to perform 
basic self-care functions


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 148
25 September 2019
SYSTEMIC
Grade 1
Grade 2
Grade 3
Grade 4
Acute Systemic Allergic 
Reaction 
Localized urticaria (wheals) 
with no medical intervention 
indicated
Localized urticaria with 
medical intervention 
indicated OR Mild 
angioedema with no medical 
intervention indicated
Generalized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasm
Acute anaphylaxis OR 
Life-threatening 
bronchospasm OR laryngeal 
edema
Chills
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater 
than minimal interference 
with usual social & 
functional activities 
Symptoms causing inability 
to perform usual social & 
functional activities
NA
Fatigue
Malaise
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater 
than minimal interference 
with usual social & 
functional activities
Symptoms causing inability 
to perform usual social & 
functional activities
Incapacitating 
fatigue/malaise symptoms 
causing inability to perform 
basic self-care functions
Fever (nonaxillary)
37.7C to 38.6C
99.8F to 101.5F
38.7C to 39.3C
101.6F to 102.8F
39.4C to 40.5C
102.9F to 104.9F
40.5C
104.9F
Pain- Indicate Body Site
See also Injection Site Pain, 
Headache, Arthralgia, and 
Myalgia
Pain causing no or minimal 
interference with usual social 
& functional activities
Pain causing greater than 
minimal interference with 
usual social & functional 
activities
Pain causing inability to 
perform usual social & 
functional activities
Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization (other than 
ER visit) indicated
Unintentional Weight Loss
NA
5% to 9% loss in body 
weight from baseline
10% to 19% loss in body 
weight from baseline
20% loss in body weight
from baseline OR Aggressive
intervention indicated
[e.g., tube feeding or total
parenteral nutrition]


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 149
25 September 2019
INJECTION SITE REACTION
Grade 1
Grade 2
Grade 3
Grade 4
Injection Site Pain 
(pain without touching)
Or Tenderness (pain when area 
is touched) 
Pain/tenderness causing no 
or minimal limitation of use 
of limb
Pain/tenderness limiting use
of limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activities
Pain/tenderness causing 
inability to perform usual 
social & functional activities
Pain/tenderness causing 
inability to perform basic 
self-care function OR 
Hospitalization (other than 
ER visit) indicated for 
management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15 Years
Erythema OR Induration
of 5 5 cm to 9 9 cm 
(or 2581 cm2)
Erythema OR Induration OR 
Edema 9 cm any diameter 
(or 81 cm2)
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR Drainage
Necrosis (involving dermis 
and deeper tissue)
Pediatric 15 Years
Erythema OR Induration OR 
Edema present but 2.5 cm 
diameter
Erythema OR Induration OR 
Edema > 2.5 cm diameter but 
< 50% surface area of the 
extremity segment 
(e.g., upper arm/thigh)
Erythema OR Induration OR 
Edema involving 50% 
surface area of the extremity 
segment (e.g., upper 
arm/thigh) OR Ulceration 
OR Secondary infection OR 
Phlebitis OR Sterile abscess 
OR Drainage
Necrosis (involving dermis 
and deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)
Itching localized to injection 
site AND Relieved 
spontaneously or with 48 h 
treatment 
Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48 h 
treatment 
Generalized itching causing 
inability to perform usual 
social & functional activities
NA


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 150
25 September 2019
ENDOCRINE/METABOLIC
Grade 1
Grade 2
Grade 3
Grade 4
Lipodystrophy (e.g., back of 
neck, breasts, abdomen)
Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)
Detectable on physical exam 
by health care provider
Disfiguring OR Obvious 
changes on casual visual 
inspection
NA
Diabetes Mellitus
NA
New onset without need to 
initiate medication OR 
Modification of current meds 
to regain glucose control
New onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite 
treatment modification
Life-threatening 
consequences 
(e.g., ketoacidosis, 
hyperosmolar non-ketotic 
coma) 
Gynecomastia
Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)
Detectable on physical exam 
by health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA
Hyperthyroidism 
Asymptomatic
Symptomatic causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Thyroid suppression therapy 
indicated
Symptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despite 
treatment modification 
Life-threatening 
consequences 
(e.g., thyroid storm)
Hypothyroidism
Asymptomatic
Symptomatic causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Thyroid replacement therapy 
indicated
Symptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despite 
treatment modification 
Life-threatening 
consequences
(e.g., myxedema coma)
Lipoatrophy (e.g., fat loss from 
the face, extremities, buttocks)
Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)
Detectable on physical exam 
by health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 151
25 September 2019
GENITOURINARY
Grade 1
Grade 2
Grade 3
Grade 4
Intermenstrual Bleeding (IMB)
Spotting observed by 
participant OR Minimal 
blood observed during 
clinical or colposcopic exam
Intermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycle
Intermenstrual bleeding 
greater in duration or amount 
than usual menstrual cycle
Hemorrhage with 
life-threatening hypotension 
OR Operative intervention 
indicated
Urinary Tract obstruction 
(e.g., stone)
NA
Signs or symptoms of 
urinary tract obstruction 
without hydronephrosis or 
renal dysfunction
Signs or symptoms of 
urinary tract obstruction with 
hydronephrosis or renal 
dysfunction
Obstruction causing 
life-threatening 
consequences
INFECTION
Grade 1
Grade 2
Grade 3
Grade 4
Infection (any other than HIV 
infection)
Localized, no systemic 
antimicrobial treatment 
indicated AND Symptoms 
causing no or minimal 
interference with usual social 
& functional activities
Systemic antimicrobial 
treatment indicated OR 
Symptoms causing greater 
than minimal interference 
with usual social & 
functional activities
Systemic antimicrobial 
treatment indicated AND 
Symptoms causing inability 
to perform usual social & 
functional activities OR 
Operative intervention (other 
than simple incision and 
drainage) indicated
Life-threatening 
consequences 
(e.g., septic shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 152
25 September 2019
Appendix 6.
Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Recommendations
1. Pregnancy and Contraception Requirements for Males and Females of Childbearing
Potential
The risks of treatment with study drug have not been evaluated. If females are using hormonal 
agents for contraception, the safety and/or efficacy may be affected by possible drug-drug 
interaction. However, it is recommended that the hormonal agent be continued and that a 
non-hormonal method(s) be used concurrently. If females utilize hormonal agents as one of their 
contraceptive methods, it is required that the same hormonal method be used for at least 
3 months before study dosing. Please refer to the latest version of the Investigator’s Brochure for 
GS-7340 for additional information
2. Definition of Female of Childbearing Potential

For the purposes of this study, a female subject of childbearing potential is a nonmenopausal
female who has not had a hysterectomy, bilateral oophorectomy, or medically documented
ovarian failure. This definition includes a pubertal female who has not yet started
menstruating. A woman who has had a tubal sterilization is considered to be of childbearing
potential.

A female subject ≤54 years in age, with the absence of normal menses is considered to be of
childbearing potential. Exceptions must be discussed with the medical monitor.
A female subject may be considered menopausal in either of the following conditions:

Surgical menopause: Appropriate medical documentation of prior complete bilateral
oophorectomy (ie, surgical removal of the ovaries and occurring at the age at which the
procedure was performed)

Age > 54 years, with the cessation (for > 12 months) of previously occurring menses due to
ovarian failure, will not be considered to be childbearing potential.
3. Contraceptive Requirements for Female Subjects
Female subjects of childbearing potential who engage in intercourse must agree to utilize 
protocol specified methods of contraception from the screening visit throughout the study period 
and for 30 days following the last dose of study drug. Female study subjects who are not 
heterosexually active must provide periodic confirmation of continued abstinence from 
heterosexual intercourse and regular pregnancy testing while participating in the study. The 
investigator will counsel subjects on the protocol specified method(s) for avoiding pregnancy in 
case the subject chooses to engage in heterosexual intercourse.
Protocol specified contraceptive methods are as follows: (1) a combination of one hormonal 
method and one barrier method; (2) two barrier methods where one method is the male condom; 
or (3) use of an intrauterine device (IUD) or tubal sterilization; see Appendix Table 1 below; or 
(4) complete abstinence from intercourse. Periodic abstinence from intercourse (e.g. calendar,
ovulation, sumptothermal, post-ovulation methods) is not permitted.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 153
25 September 2019
Acceptable hormonal methods include injectable progesterone, progesterone implants, 
combination oral contraceptives, transdermal contraceptive patch, and vaginal ring. Acceptable 
barrier methods include diaphragm with spermicide, cervical cap with spermicide, and the male 
condom. The use of spermicide is not recommended if the subject or subject’s partner is infected 
with HIV. Female subjects must use either a hormonal method or a barrier method if the partner 
has a vasectomy. If a subject has undergone tubal sterilization or has had a Copper T 380A IUD 
or LNg 20 IUD inserted, no other contraception is needed.  
If tubal sterilization is via the Essure procedure, verification of tubal blockage by 
hysterosalpingogram (HSP) must be performed approximately 3 months after microinsertion. 
Prior to verification, Essure is not considered a reliable form of contraception and the 
contraception methods described below must be used. Female subjects who utilize hormonal 
contraceptives as one of their birth control methods must have used the same method for at least 
3 months before study dosing.
Female subjects of childbearing potential must have a negative serum pregnancy test at screening 
and a negative urine pregnancy test at baseline (Day 1) prior to receiving the first dose of study 
drug. Lactating females must discontinue nursing before IMP administration.
Appendix Table 1.
Protocol Specified Contraceptive Methods
Methods to Use by Themselves
Combination Methods
Hormone Methods
(choose one and use with 
a barrier method)
Barrier Methods
(use both OR choose one and use with 
a hormone method)
Intrauterine Devices (IUDs)

Copper T 380A IUD

LNg 20 IUD
Tubal Sterilization
Estrogen and Progesterone

Oral contraceptives

Transdermal patch

Vaginal ring
Progesterone

Injection

Implant

Diaphragm with spermicide
OR

Cervical cap with spermicide

Male condom
(with or without spermicide)
Partner’s vasectomy must be used with a hormone or barrier method.
The investigator will counsel all subjects on the most effective method(s) for avoiding pregnancy 
during the study.
4. Contraceptive Requirements for Male Subjects
Male subjects must agree to use protocol specified method of contraception during heterosexual 
intercourse and avoid sperm donation from the time of the first dose of study drug and 
throughout the study period, and for at least 30 days after administration of the last dose of study 
medication.


Tenofovir Alafenamide (TAF)
Protocol GS-US-320-0110
Draft
Gilead Sciences, Inc.
Amendment 3.4
CONFIDENTIAL
Page 154
25 September 2019
Use of condoms, with or without spermicide, has been proven to decrease the risk of 
transmission of HIV and other sexually transmitted diseases. The use of spermicide is not 
recommended if the subject or subject’s partner is infected with HIV.
5. Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify the investigator if they become pregnant at any time during 
the study, or if they become pregnant within 30 days of last study drug dose. Subjects who 
become pregnant or who suspect that they are pregnant during the study must report the 
information to the investigator and discontinue study drug immediately. 
Instructions for reporting pregnancy and pregnancy outcome are outlined in Section 7.6.2.1.

SAP_001.pdf: 
 
 
 
 
STATISTICAL ANALYSIS PLAN 
 
 
Study Title: 
A Phase 3, Randomized, Double-Blind Study to Evaluate the 
Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD 
versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the 
Treatment of HBeAg Positive, Chronic Hepatitis B 
 
 
Name of Test Drug: 
Tenofovir Alafenamide (TAF) 
 
 
Study Number: 
GS-US-320-0110 
 
 
Protocol Version: 
Amendment 3.1 
 
 
Protocol Date: 
23 February 2016 
 
 
Analysis Type: 
Final Analysis China 
 
 
Analysis Plan Version: 
Version 1.0 
 
 
Analysis Plan Date: 
25 October 2023 
 
 
Analysis Plan Author: 
 
 
 
CONFIDENTIAL AND PROPRIETARY INFORMATION 
 
PPD
(r) GILEAU 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 2 
 
25 October 2023 
TABLE OF CONTENTS 
TABLE OF CONTENTS .............................................................................................................................................. 2 
LIST OF IN-TEXT TABLES ........................................................................................................................................ 4 
LIST OF ABBREVIATIONS ........................................................................................................................................ 5 
1. 
INTRODUCTION ................................................................................................................................................ 8 
1.1. 
Study Objectives ...................................................................................................................................... 8 
1.2. 
Study Design .......................................................................................................................................... 10 
1.2.1. 
Design Configuration and Participant Population ................................................................ 10 
1.2.2. 
Treatment Groups ................................................................................................................. 10 
1.2.3. 
Key Eligibility Criteria ......................................................................................................... 10 
1.2.4. 
Study Periods/Phases ............................................................................................................ 11 
1.2.5. 
Schedule of Assessments ...................................................................................................... 11 
1.2.6. 
Randomization ..................................................................................................................... 12 
1.2.7. 
Site and/or Stratum Enrollment Limits ................................................................................. 12 
1.2.8. 
Study Duration ..................................................................................................................... 12 
1.3. 
Sample Size and Power .......................................................................................................................... 13 
2. 
TYPE OF PLANNED ANALYSIS .................................................................................................................... 14 
2.1. 
Data Monitoring Committee (DMC) Analysis ....................................................................................... 14 
2.2. 
Week 48 Analysis (Primary Analysis) ................................................................................................... 14 
2.3. 
Final Analysis (Week 384) ..................................................................................................................... 14 
3. 
GENERAL CONSIDERATIONS FOR DATA ANALYSES ............................................................................ 15 
3.1. 
Analysis Sets .......................................................................................................................................... 15 
3.1.1. 
Randomized Analysis Set ..................................................................................................... 15 
3.1.2. 
Safety Analysis Set ............................................................................................................... 15 
3.1.3. 
Open-Label Safety Analysis Set ........................................................................................... 15 
3.1.4. 
Full Analysis Set (FAS) ....................................................................................................... 15 
3.1.5. 
Serologically Evaluable Full Analysis Set ........................................................................... 15 
3.1.6. 
DXA Analysis Set ................................................................................................................ 16 
3.2. 
Participant Grouping .............................................................................................................................. 16 
3.3. 
Strata and Covariates .............................................................................................................................. 16 
3.4. 
Missing Data and Outliers ...................................................................................................................... 16 
3.4.1. 
Missing Data ........................................................................................................................ 16 
3.4.2. 
Outliers ................................................................................................................................. 17 
3.5. 
Data Handling Conventions and Transformations ................................................................................. 17 
3.6. 
Analysis Windows ................................................................................................................................. 18 
3.6.1. 
Definition of Study Day 1 and Other Definitions ................................................................. 18 
3.6.2. 
Analysis Windows ................................................................................................................ 19 
3.6.3. 
Selection of Data in the Event of Multiple Records in a Window........................................ 27 
4. 
PARTICIPANT DISPOSITION ......................................................................................................................... 29 
4.1. 
Participant Enrollment ........................................................................................................................... 29 
4.2. 
Disposition of Participants ..................................................................................................................... 29 
4.3. 
Extent of Exposure ................................................................................................................................. 30 
4.3.1. 
Duration of Exposure to Blinded Study Drug ...................................................................... 30 
4.3.2. 
Adherence with Blinded Study Drug Regimen .................................................................... 30 
4.3.3. 
Duration of Exposure to Open-Label Study Drug ................................................................ 31 
4.3.4. 
Adherence with Open-Label Study Drug Regimen .............................................................. 32 
4.4. 
Protocol Deviations ................................................................................................................................ 33 
4.5. 
Assessment of COVID-19 Impact .......................................................................................................... 33 
4.5.1. 
Study Drug or Study Discontinuation Due to COVID-19 .................................................... 33 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 3 
 
25 October 2023 
4.5.2. 
Protocol Deviations Due to COVID-19 ............................................................................... 33 
4.5.3. 
Missed and Virtual Visits due to COVID-19 ....................................................................... 33 
4.5.4. 
Adverse Events Due to COVID-19 ...................................................................................... 33 
4.5.5. 
Overall Assessment of COVID-19 Pandemic Impact .......................................................... 34 
5. 
BASELINE CHARACTERISTICS .................................................................................................................... 35 
5.1. 
Demographics and Baseline Characteristics .......................................................................................... 35 
5.2. 
Medical History ...................................................................................................................................... 36 
6. 
EFFICACY ANALYSES ................................................................................................................................... 37 
6.1. 
Primary Efficacy Endpoints ................................................................................................................... 37 
6.2. 
Secondary Efficacy Endpoints ............................................................................................................... 37 
6.2.1. 
Definition of Secondary Efficacy Endpoints ........................................................................ 37 
6.2.2. 
Analysis Methods for Secondary Efficacy End points ......................................................... 39 
6.3. 
Changes From Protocol-Specified Efficacy Analyses ............................................................................ 39 
7. 
SAFETY ANALYSES ........................................................................................................................................ 40 
7.1. 
Adverse Events ...................................................................................................................................... 40 
7.1.1. 
Adverse Event Dictionary .................................................................................................... 40 
7.1.2. 
Adverse Event Severity ........................................................................................................ 40 
7.1.3. 
Relationship of AEs to Study Drug ...................................................................................... 40 
7.1.4. 
Relationship of AEs to Study Procedure .............................................................................. 40 
7.1.5. 
Serious AEs .......................................................................................................................... 41 
7.1.6. 
Treatment-Emergent AEs ..................................................................................................... 41 
7.1.7. 
Summaries of AEs and Deaths ............................................................................................. 43 
7.1.8. 
Potential Uveitis Events ....................................................................................................... 44 
7.1.9. 
Potential Cardiovascular Events ........................................................................................... 44 
7.2. 
Laboratory Evaluations .......................................................................................................................... 45 
7.2.1. 
Summaries of Numeric Laboratory Results ......................................................................... 45 
7.2.2. 
Graded Laboratory Values ................................................................................................... 46 
7.2.3. 
ALT Elevation ...................................................................................................................... 48 
7.3. 
Bone Safety Analyses ............................................................................................................................ 48 
7.3.1. 
Bone Mineral Density (BMD) .............................................................................................. 48 
7.3.2. 
Bone Biomarkers .................................................................................................................. 49 
7.3.3. 
Fracture Events ..................................................................................................................... 49 
7.3.4. 
Bone Events ......................................................................................................................... 50 
7.4. 
Renal Safety Analyses ............................................................................................................................ 50 
7.4.1. 
Confirmed Renal Abnormalities........................................................................................... 50 
7.4.2. 
Serum Creatinine .................................................................................................................. 50 
7.4.3. 
Estimated Glomerular Filtration Rate .................................................................................. 51 
7.4.4. 
Treatment-Emergent Proteinuria (Dipstick) ......................................................................... 52 
7.4.5. 
Urine Creatinine, Urine RBP to Creatinine Ratio and 
Beta-2-Microglobulin to Creatinine Ratio............................................................................ 52 
7.4.6. 
Proteinuria by Quantitative Assessment ............................................................................... 53 
7.4.7. 
Other Renal Biomarkers ....................................................................................................... 53 
7.5. 
Ophthalmologic Assessment .................................................................................................................. 54 
7.6. 
Body Weight .......................................................................................................................................... 54 
7.7. 
Prior Hepatitis B Medications ................................................................................................................ 54 
7.8. 
Concomitant Medications ...................................................................................................................... 54 
7.9. 
Electrocardiogram (ECG) Results .......................................................................................................... 55 
7.10. 
Other Safety Measures ........................................................................................................................... 56 
7.11. 
Changes From Protocol-Specified Safety Analyses ............................................................................... 56 
8. 
REFERENCES ................................................................................................................................................... 57 
9. 
SOFTWARE ....................................................................................................................................................... 58 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 4 
 
25 October 2023 
10. SAP REVISION .................................................................................................................................................. 59 
11. APPENDICES .................................................................................................................................................... 60 
 
Appendix 1. 
Adverse Events of COVID-19 ................................................................................................ 61 
Appendix 2. 
Determining Missing and Virtual Visits Due to COVID-19 .................................................. 62 
 
 
LIST OF IN-TEXT TABLES 
 
Table 3-1. 
Analysis Windows for HBV DNA, Hematology, Serum Chemistry and Liver 
Function Tests, Urinalysis, Urine Pregnancy Test, eGFR (by CG and CKD-EPI), 
UACR, UPCR, TmP/GFR, FEPO4, FEUA, Weight, and Vital Sign Assessments ................ 21 
Table 3-2. 
Analysis Windows for Safety ECG and Fibrotest .................................................................. 22 
Table 3-3. 
Analysis Windows for BMD Results from DXA and Fasting Lipid Panel ............................ 22 
Table 3-4. 
Analysis Windows for Serum HBsAg (Quantitative) and HBV Serology ............................. 23 
Table 3-5. 
Analysis Windows for Fasting Glucose, Fasting Total Cholesterol, Fasting 
Triglycerides, Renal, and Bone Biomarkers ........................................................................... 24 
Table 3-6. 
Analysis Windows for PTH .................................................................................................... 25 
Table 3-7. 
Analysis Windows for Hepatic Ultrasound ............................................................................ 26 
Table 3-8. 
Analysis Windows for Post-Treatment Assessments Except HBV Serology ......................... 26 
Table 3-9. 
Analysis Windows for Post-Treatment HBV Serology .......................................................... 26 
Table 7-1. 
Normal, Osteopenia, and Osteoporosis as Defined by T-Score .............................................. 49 
Table 7-2. 
Method of Serum Creatinine Correction ................................................................................ 51 
Table 11-1. 
Example Search Terms for “COVID-19” and “Virtual” Used to Identify 
Missed/Virtual Visits .............................................................................................................. 62 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 5 
 
25 October 2023 
LIST OF ABBREVIATIONS 
 
AASLD 
American Association for the Study of Liver Diseases 
AE 
adverse event 
ALT 
alanine aminotransferase (SGPT) 
ANCOVA 
analysis of covariance 
ANOVA 
analysis of variance 
Anti-HBe 
antibody to HBeAg 
Anti-HBs 
antibody to HBsAg 
AST 
aspartate aminotransferase (SGOT) 
BLQ 
below the limit of quantitation 
BMD 
bone mineral density 
BMI 
body mass index 
bsAP 
bone specific alkaline phosphatase 
CDER 
Center for Drug Evaluation and Research 
CG 
Cockcroft-Gault 
CHB 
chronic hepatitis B 
CI 
confidence interval 
CKD 
chronic kidney disease 
CKD-EPI 
Chronic Kidney Disease Epidemiology Collaboration formula for calculating 
glomerular filtration rate 
CLCr 
creatinine clearance 
CMH 
Cochran-Mantel-Haenszel  
CRF 
case report form 
CTX 
c-type collagen sequence 
CV 
coefficient of variation 
DMC 
data monitoring committee 
DNA 
deoxyribonucleic acid 
DXA 
dual-energy x-ray absorptiometry 
ECG 
electrocardiogram 
eCRF 
electronic case report form 
ED 
early discontinuation 
eGFR 
estimated glomerular filtration rate 
ESDD 
early study drug discontinuation 
FAS 
Full Analysis Set 
FDA 
Food and Drug Administration 
FEPO4 
fractional excretion of filtered phosphate 
FEUA 
fractional excretion of uric acid 
GFR 
glomerular filtration rate 
Gilead 
Gilead Sciences, Inc. 
HBeAb 
hepatitis B e antibody 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 6 
 
25 October 2023 
HBeAg 
hepatitis B e antigen 
HBsAb 
hepatitis B surface antibody 
HBsAg 
hepatitis B surface antigen 
HBV 
hepatitis B virus 
HCC 
hepatocellular carcinoma 
HCV 
hepatitis C virus 
HDL 
high density lipoprotein 
HDV 
hepatitis D virus 
HIV 
human immunodeficiency virus 
HLGT 
high-level group term 
HLT 
high-level term 
IVRS 
interactive voice response system   
IWRS 
interactive web response system 
LDL 
low density lipoprotein 
LLN 
lower limit of the normal range 
LLT 
lower-level term 
LOCF 
last observation carried forward 
M = E  
missing = excluded 
M = F  
missing = failure 
MDRD 
Modification of Diet in Renal Disease 
MedDRA 
Medical Dictionary for Regulatory Activities 
MH 
Mantel-Haenszel  
OC 
osteocalcin 
P1NP 
procollagen type 1 N-terminal propeptide 
PBMC 
peripheral blood mononuclear cell 
PK 
pharmacokinetic 
pol/RT 
polymerase/reverse transcriptase 
PT 
preferred term 
Q 
quartile 
Q1 
first quartile 
Q3 
third quartile 
QD 
QD 
RBP 
retinol binding protein 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SD 
standard deviation 
SOC 
system organ class 
TAF 
tenofovir alafenamide  
TDF 
tenofovir disoproxil fumarate (Viread®) 
TFFU 
Treatment-free Follow-up 
TFLs 
tables, figures, and listings 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 7 
 
25 October 2023 
TFV 
Tenofovir 
TFV-DP 
tenofovir-diphosphate 
TmP 
tubular maximum reabsorption rate of phosphate 
UACR 
urine albumin to creatinine ratio 
ULN 
upper limit of normal 
UPCR 
urine protein to creatinine ratio 
WHO 
World Health Organization 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 8 
 
25 October 2023 
1. 
INTRODUCTION 
GS-US-320-0110 is a Phase 3 randomized, double-blind, noninferiority study to compare the 
antiviral activity of tenofovir alafenamide (TAF) 25 mg QD versus tenofovir disoproxil fumarate 
(TDF) 300 mg QD for the treatment of hepatitis B e antigen (HBeAg)-positive, 
chronic hepatitis B (CHB) in treatment-naive and treatment-experienced participants. For the 
non-China cohort, 875 participants were planned to be randomized in a 2:1 ratio to receive the 
blinded treatment groups for 144 weeks (96 weeks for participants who reached Week 96 prior to 
consenting for Amendment 3), and were stratified by plasma hepatitis B virus (HBV) DNA level 
(≥ 8 log10 IU/mL vs < 8 log10 IU/mL) and oral antiviral treatment status (treatment-naive vs 
treatment-experienced). All participants who completed the double-blind phase were eligible for 
participation in the open-label TAF 25 mg extension period for an additional 240 weeks 
(through Week 384/ED). Participants who already entered the open-label phase at Week 96 per 
Amendment 1 or 2 and consented to Amendment 3 later were to continue open-label TAF 25 mg 
QD through Week 384/ED. 
Treatment-naive participants are defined as participants with < 12 weeks of previous oral 
antiviral treatment with any nucleoside or nucleotide analogue. Treatment-experienced 
participants are defined as participants with ≥ 12 weeks of previous treatment with any 
nucleoside or nucleotide analogue. 
For China, approximately 150 additional participants (100 in TAF group and 50 in TDF group) 
were planned to be enrolled as agreed upon for local registration purposes. All China cohort 
participants were to receive the blinded treatment for 144 weeks based on Amendment 3.1, and 
those who completed the double-blind phase were eligible for participation in the open-label 
TAF 25 mg extension period for an additional 240 weeks (through Week 384/ED). 
This statistical analysis plan (SAP) describes the statistical analysis methods and data 
presentations to be used in tables, figures, and listings (TFLs) in the final clinical study report 
(CSR) for China (participants enrolled China only). This SAP is based on the study protocol 
amendment 3.1 dated 23 February 2016 and the electronic case report form (eCRF). The SAP 
will be finalized before database finalization. Any changes made after the finalization of the SAP 
will be documented in the CSR for China. 
1.1. 
Study Objectives 
The primary and secondary objectives and end points on or before Week 48 were presented in 
the Week 48 CSR for China. This SAP will focus on the efficacy and safety analyses of all 
participants after Week 48. 
The primary objectives of this study are as follows: 
• To compare the efficacy of TAF 25 mg versus TDF 300 mg QD for the treatment of 
HBeAg-positive, CHB at Week 48 in treatment-naive and treatment-experienced 
participants. The primary efficacy parameter is the proportion of participants with plasma 
HBV DNA levels below 29 IU/mL 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 9 
 
25 October 2023 
• To compare the safety and tolerability of TAF 25 mg QD versus TDF 300 mg QD for the 
treatment of HBeAg-positive, CHB at Week 48 in treatment-naive and treatment-experienced 
participants 
The key secondary safety objectives of this study are as follows: 
• To compare the safety of TAF 25 mg QD versus TDF 300 mg QD as determined by the 
percent change from baseline in hip and spine bone mineral density (BMD) at Week 48  
• To compare the safety of TAF 25 mg QD versus TDF 300 mg QD as determined by the 
change from baseline in serum creatinine at Week 48 
• To compare the safety of TAF 25 mg QD versus TDF 300 mg QD as determined by 
treatment-emergent proteinuria through Week 48 
The key secondary efficacy objective of this study is as follows: 
• To compare the serological response (loss of HBeAg with seroconversion to antibody to 
HBeAg [anti-HBe]) of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, CHB at Week 48 
Other secondary objectives of this study are as follows: 
• To compare the efficacy of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, CHB in regard to the proportion of participants with plasma HBV DNA 
levels below 29 IU/mL at Weeks 96 and 144 
• To compare the efficacy of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, CHB in regard to the proportion of participants with plasma HBV DNA 
levels below 29 IU/mL (target not detected) at Weeks 48, 96, and 144 
• To compare the biochemical (alanine aminotransferase [ALT] normalization) response of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, CHB at 
Weeks 48, 96, and 144 
• To compare the serological response (loss of HBeAg with seroconversion to anti-HBe) of 
TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-positive, CHB at 
Weeks 96, and 144 
• To compare the serological response (loss of hepatitis B surface antigen [HBsAg] with 
seroconversion to anti-HBs) of TAF 25 mg QD versus TDF 300 mg QD for the treatment of 
HBeAg-positive, CHB at Weeks 48, 96, and 144 
• To compare the change in fibrosis as assessed by FibroTest® of TAF 25 mg QD versus TDF 
300 mg QD for the treatment of HBeAg-positive, CHB at Weeks 48, 96, and 144 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 10 
 
25 October 2023 
• To compare the incidence of drug resistant mutations of TAF 25 mg QD versus TDF 300 mg 
QD at Weeks 48, 96, and 144 
• To compare the change from baseline in ophthalmologic findings by fundoscopic 
examination of TAF 25 mg QD versus TDF 300 mg QD at Weeks 24, 48, 72, 96, and 144 in 
a subset of participants 
• To characterize the pharmacokinetics of TAF and tenofovir (TFV) and determine 
intracellular concentrations of tenofovir diphosphate (TFV-DP) within peripheral blood 
mononuclear cells (PBMCs) in participants receiving TAF or TDF 
• To evaluate the comparative open-label efficacy, safety and drug resistance mutations of 
TAF 25 mg QD through Week 384 in participants initially randomized to TAF and in 
participants sequentially treated with TDF 300 mg QD for 96 weeks (Amendments 1 and 2.1) 
or for 144 weeks (Amendment 3.1) and then switched to open-label TAF 25 mg QD 
• To compare the safety and tolerability of TAF 25 mg QD versus TDF 300 mg QD for the 
treatment of HBeAg-positive, CHB beyond Week 48 during the double-blind phase in 
treatment-naive and treatment-experienced participants 
1.2. 
Study Design 
1.2.1. 
Design Configuration and Participant Population 
GS-US-320-0110 is a randomized, double-blind, noninferiority study to compare the antiviral 
activity of TAF 25 mg versus TDF 300 mg for the treatment of HBeAg-positive, CHB in 
treatment-naive and treatment-experienced participants. 
1.2.2. 
Treatment Groups 
Participants were randomized in a 2:1 ratio to the following 2 treatment groups: 
• TAF group: TAF 25 mg QD + matched placebo of TDF 300 mg QD 
• TDF group: TDF 300 mg QD + matched placebo of TAF 25 mg QD 
For China, approximately 150 additional participants were planned to be randomized in a 2:1 
ratio (TAF: TDF) to the treatment groups for local registration purpose. 
1.2.3. 
Key Eligibility Criteria 
Participants were to have met the following key eligibility criteria: 
• Documented evidence of chronic HBV infection (eg, HBsAg positive for more than 
6 months) 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 11 
 
25 October 2023 
• HBeAg-positive, CHB with the following: HBeAg-positive at screening; screening 
HBV DNA ≥ 2 × 104 IU/mL; screening serum ALT level > 60 U/L (males) or 
> 38 U/L (females) and ≤ 10 × ULN (by central laboratory range) 
• Estimated creatinine clearance (CLCr) ≥ 50 mL/min (using the Cockcroft-Gault [CG] 
method) based on serum creatinine and actual body weight as measured at screening 
1.2.4. 
Study Periods/Phases 
The duration of randomized, double-blind treatment is 144 weeks (96 weeks under 
Amendments 1 and 2.1). All participants who complete double-blind phase are eligible for 
participation in the open-label TAF 25 mg extension period for an additional 240 weeks (through 
Week 384/ED). Participants who already entered the open-label phase at Week 96 per 
Amendment 2.1 and consented to Amendment 3.1 later will continue on open-label TAF 25 mg 
QD through Week 384/ED. All participants who complete double-blind period of treatment are 
eligible for participation in the open-label TAF 25 mg QD extension period. Participants who 
permanently discontinue study drug (either prematurely [early discontinuation, ED] or at the end 
of open-label phase [Week 384]) for reasons other than HBsAg loss with confirmed 
seroconversion to anti-HBs will be followed every 4 weeks for 24 weeks off treatment or until 
initiation of alternative, commercially available HBV therapy, whichever occurs first. 
Participants with HBsAg loss, with confirmed seroconversion to anti-HBs should discontinue 
study drug within 3-6 months following confirmation of seroconversion to anti-HBs, or after 
Week 48, if seroconversion occurs prior to this visit. Participants with HBsAg loss with 
confirmed seroconversion to anti-HBs prior to Week 48 are not permitted to discontinue study 
drug prior to the Week 48 visit. After Week 48, these participants who discontinue study drug 
will be followed off treatment every 4 weeks for 12 weeks and then per the study visit schedule 
through Week 384/ED. Discontinuation of study drug for participants experiencing HBsAg loss 
with confirmed seroconversion to anti-HBs, who have known bridging fibrosis or cirrhosis, 
should be considered on a case by case basis. 
1.2.5. 
Schedule of Assessments 
Laboratory analyses (serum chemistry, liver tests, hematology, urinalysis, plasma HBV DNA 
levels, pregnancy testing [for females of childbearing potential]), vital signs, adverse events 
(AEs), and concomitant medications will be performed at screening, baseline, and every 4 weeks 
thereafter through Week 48, every 8 weeks through Week 96, every 12 weeks through 
Week 144, and every 24 weeks through Week 384/ED visit.  
HBV serology (HBeAg, reflex hepatitis B e antibody [HBeAb], HBsAg, and reflex hepatitis B 
surface antibody [HbsAb]) will be performed at screening and baseline, and every 
12 to 16 weeks through Week 144, and every 24 weeks through Week 384/ED, and at Follow up 
Weeks 12 and 24. Quantitative serum HBsAg will be assessed at screening, baseline, every 
12-16 weeks until Week 144, every 24 weeks until Week 384/ED, and at all Follow Up visits. 
Bone and renal biomarker testing will be performed at baseline and then at defined intervals 
throughout the study. IL28B polymorphism genotype, HBV genotyping and vitamin D 
assessments will be performed at baseline only. FibroTest® will be performed at baseline, and 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 12 
 
25 October 2023 
every 48 weeks thereafter through Week 384/ED. Fasting metabolic assessments (fasting glucose 
and lipid panel) will be conducted at baseline, every 24 weeks until Week 144, and every 
48 weeks until Week 384/ED visit.  
Complete physical examinations will be performed at screening, baseline, and Weeks 24, 48, 
72, 96, 120, 144, 240, and 384/ED. Symptom directed physical examinations including body 
weight assessment will be conducted at all other visits. Electrocardiogram (ECG) will be 
performed at screening and every 48 weeks thereafter. 
At sites in China with the capability only, DXA scans of the hip and spine will be conducted 
during the screening period, and should be conducted at least 14 days prior to the first dose of 
study drug, and will be subsequently conducted every 24 weeks through Week 144, and every 48 
weeks thereafter until Week 384/ ED visit, if not done within the last 24 weeks of ED visit. 
Fracture risk assessment will be evaluated at Baseline. In China, this fracture risk assessment 
will be evaluated at sites with DXA capability only. 
Hepatic ultrasound for surveillance of hepatocellular carcinoma will be performed starting at 
Week 96 and then every 24 weeks thereafter until Week 384/ED. Plasma, serum, and urine will 
be collected at baseline and at every visit thereafter for storage. 
Treatment-free Follow-up (TFFU) assessments after premature study drug discontinuation will 
occur every 4 weeks for 24 weeks and include the following: vital signs, hematology, serum 
chemistry, liver function tests, and plasma HBV DNA. Plasma, serum and urine will be collected 
for storage. HBeAg, reflex HBeAb, HBsAg and reflex HBsAb will be evaluated at Follow Up 
Weeks 12 and 24. 
1.2.6. 
Randomization 
Participants will be randomized in a 2:1 ratio to the 2 treatment groups (TAF vs TDF, 
respectively). Randomization will be stratified by plasma HBV DNA level (≥ 8 log10 IU/mL vs 
< 8 log10 IU/mL) and oral antiviral treatment status (treatment-naive vs treatment-experienced). 
1.2.7. 
Site and/or Stratum Enrollment Limits 
Twenty-five centers participated in China. There was no enrollment limit for individual sites. 
1.2.8. 
Study Duration 
The duration of the double-blind treatment is 144 weeks (96 weeks under Amendment 1 and 
2.1). After completing the double-blind period of treatment, all participants will be eligible 
to receive open-label TAF 25 mg once daily, for up to an additional 240 weeks (through 
Week 384/ED). Participants who already entered the open-label phase at Week 96 per 
Amendment 1 or 2.1 and consented to Amendment 3.1 later will continue on open-label TAF 
25 mg QD through Week 384/ED. Participants who permanently discontinue study drug (either 
prematurely [ED] or at the end of study [Week 384]) will be followed every 4 weeks for 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 13 
 
25 October 2023 
24 weeks off treatment or until initiation of alternative, commercially available HBV therapy, 
whichever occurs first. 
Participants with HBsAg loss, with confirmed seroconversion to anti-HBs should discontinue 
study drug within 3 to 6 months following confirmation of seroconversion to anti-HBs or after 
Week 48, if seroconversion occurs prior to this visit. These participants will be followed off 
treatment every 4 weeks for 12 weeks and then per the study visit schedule through 
Week 384/ED. 
1.3. 
Sample Size and Power 
For China, approximately 150 additional participants (100 in TAF group and 50 in TDF group) 
were to be enrolled for local registration purposes. 
The sample size and power calculation described below was for non-China participants. With 
respect to the primary efficacy end point of proportion of participants with plasma HBV DNA 
levels below 29 IU/mL at Week 48, a sample size of 288 for the TDF group and 576 for the TAF 
group will have 84% power to rule out the noninferiority margin of 10% at a 1-sided significance 
level of 0.025. This assumes the expected difference (TAF − TDF) in proportion of participants 
with HBV DNA < 29 IU/mL is 0 and the proportion of participants with HBV DNA < 29 IU/mL 
in the TDF group is 69%. A similar response rate in the TDF group was observed in 
Study GS-US-174-0103. 
This sample size (n = 576 for the TAF 25 mg group, n = 288 for the TDF 300 mg group) also 
provides the following:  
• At least 90% power to detect a 1% difference in the percentage change from baseline in 
hip BMD at Week 48 (assuming a –1.17% change from baseline in TDF 300 mg group and 
−0.17% change from baseline in the TAF 25 mg group, with a common standard deviation 
(SD) of 2.20% and a 2-sided α = 0.025) 
• At least 90% power to detect a 1% difference in the percent change from baseline in spine BMD 
at Week 48 (assuming a –1.69% change from baseline in the TDF 300 mg group and −0.69% 
change in the TAF 25 mg group, with a common SD of 3.08% and a 2-sided α = 0.025) 
• At least 85% power to detect a 0.03 mg/dL difference in the change from baseline in serum 
creatinine at Week 48 (assuming a 0.04 mg/dL change from baseline in the TDF 300 mg 
group and 0.01 mg/dL change from baseline in the TAF 25 mg group, with a common 
SD of 0.12) 
• 16% power to detect a 4% difference in HBeAg seroconversion rate (assuming a 
19% HBeAg seroconversion rate in the TDF 300 mg group and 23% HBeAg seroconversion 
rate in the TAF 25 mg group).  
The preceding assumptions were derived from Studies GS-98-437, GS-98-438, 
GS-US-174-0102, GS-US-174-0103, and GS-US-174-0121. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 14 
 
25 October 2023 
2. 
TYPE OF PLANNED ANALYSIS 
The final analysis for Non-China participants has already been conducted which occurred after 
the last participant completed the study or prematurely discontinued study. This statistical 
analysis plan (SAP) describes the analysis plan for the final analysis of participants enrolled in 
China only. 
2.1. 
Data Monitoring Committee (DMC) Analysis 
An external multidisciplinary data monitoring committee (DMC) will review the progress of the 
study and perform interim reviews of safety data and provide recommendation to Gilead whether 
the nature, frequency, and severity of adverse effects associated with study treatment warrant 
early termination of the study in the best interests of the participants and whether the study 
should continue as planned or with modifications. The DMC may also provide recommendations 
as needed regarding study design. 
The DMC was convened approximately every 24 weeks during the blinded portion of the study 
and approximately every 48 weeks during the open-label phase. More details are documented in 
the independent DMC charter. The last DMC meeting was conducted on 24 October 2019 where 
the DMC members concluded that they would transfer the primary responsibilities for 
monitoring study conduct and patient safety to Gilead and stand ready to re-engage should 
concerns arise regarding any aspects of the study. 
2.2. 
Week 48 Analysis (Primary Analysis) 
The Week 48 analysis was conducted after the last participant completed the Week 48 visit or 
prematurely discontinued study drug in China. 
2.3. 
Final Analysis (Week 384) 
The final analysis will be conducted after the last participant completes the Week 384 visit or 
prematurely discontinues study drug in China. 
Since no participants entered the TFFU phase after completing the Week 384 visit, this statistical 
analysis plan (SAP) describes the analysis plan for the Week 384 analysis only and is considered 
as Final analysis.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 15 
 
25 October 2023 
3. 
GENERAL CONSIDERATIONS FOR DATA ANALYSES 
3.1. 
Analysis Sets 
Analysis sets define which participants are included in an analysis. The assignment of 
participants to analysis sets was done before the study blind was broken for analysis. A summary 
of the number and percentage of participants in each analysis set will be provided by treatment 
group and in total. 
3.1.1. 
Randomized Analysis Set 
The Randomized Analysis Set includes all participants who were randomized into the study. This 
is the primary analysis set for by-participant listings. 
3.1.2. 
Safety Analysis Set 
The Safety Analysis Set includes all randomized participants who have received at least 1 dose 
of study drug. Participants will be analyzed according to the treatment they actually received. 
The actual treatment received will differ from the randomized treatment only when their actual 
treatment differs from randomized treatment for the entire double-blinded treatment duration.  
3.1.3. 
Open-Label Safety Analysis Set 
The Open-Label Safety Analysis Set includes all randomized participants who have received at 
least 1 dose of open-label study drug. Participants will be analyzed according to the treatment 
they actually received during the double-blind phase.  
3.1.4. 
Full Analysis Set (FAS) 
The FAS includes all randomized participants who have received at least 1 dose of study drug. 
Participants will be analyzed according to the treatment to which they were randomized.  
3.1.5. 
Serologically Evaluable Full Analysis Set 
3.1.5.1. 
Serologically Evaluable Full Analysis Set for HBeAg Loss/Seroconversion 
The Serologically Evaluable Full Analysis Set for HBeAg loss/seroconversion includes all 
participants who were randomized and had received at least 1 dose of study drug, and with 
HBeAg positive and HBeAb negative or missing at baseline. Participants will be analyzed 
according to the treatment they were randomized to. 
3.1.5.2. 
Serologically Evaluable Full Analysis Set for HBsAg Loss/Seroconversion 
The Serologically Evaluable Full Analysis Set for HBsAg loss/seroconversion includes all 
participants who were randomized and had received at least 1 dose of study drug, and with 
HBsAg positive and HBsAb negative or missing at baseline. Participants will be analyzed 
according to the treatment they were randomized to. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 16 
 
25 October 2023 
3.1.6. 
DXA Analysis Set 
DXA scans will be performed only at sites in China with capability. 
3.1.6.1. 
Hip DXA Analysis Set 
The Hip DXA Analysis Set includes all participants who were randomized and had received at 
least 1 dose of study drug, and had nonmissing baseline hip BMD values. Participants will be 
analyzed according to the treatment they actually received. 
3.1.6.2. 
Spine DXA Analysis Set 
The Spine DXA Analysis Set includes all participants who were randomized and had received at 
least 1 dose of study drug, and had nonmissing baseline spine BMD values. Participants will be 
analyzed according to the treatment they actually received. 
3.2. 
Participant Grouping 
Participants will be grouped into the following treatment groups: 
Entire study treatment period and double-blind phase summaries: 
• Double-blind TAF 25 mg 
• Double-blind TDF 300 mg 
Open-label phase summaries: 
• Double-blind TAF 25 mg participants who switched to open-label TAF 25 mg (TAF-TAF) 
• Double-blind TDF 300 mg participants who switched to open-label TAF 25 mg (TDF-TAF) 
3.3. 
Strata and Covariates 
Randomization was stratified by plasma HBV DNA level (≥ 8 log10 IU/mL vs < 8 log10 IU/mL) 
and oral antiviral treatment status (treatment-naive vs treatment-experienced) at screening. HBV 
DNA strata will be reclassified using baseline HBV DNA level for stratified statistical analysis. 
3.4. 
Missing Data and Outliers 
3.4.1. 
Missing Data 
A missing datum for a given study analysis window may be due to any of the following reasons: 
• A visit occurring in the window but data were not collected or were unusable  
• A visit not occurring in the window 
• A participant permanently discontinuing from the study before reaching the window 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 17 
 
25 October 2023 
For the primary endpoint and the secondary efficacy endpoints involving proportions, missing 
data will be handled using M = F approach. Sensitivity analyses will also be performed including 
M = E approach. 
For the remaining endpoints, values for missing data will not be imputed, unless specified 
otherwise.  
3.4.2. 
Outliers 
Outliers will be identified during data management and data analysis process, but no sensitivity 
analyses will be done to evaluate the impact of outliers on efficacy or safety outcomes, unless 
specified otherwise. All data will be included in the analysis.  
3.5. 
Data Handling Conventions and Transformations 
The following conventions will be used for the imputation of date of birth when it is partially 
missing or not collected: 
• If only month and year of birth is collected, then “15” will be imputed as the day of birth 
• If only year of birth is collected, then “01 July” will be imputed as the day and month of birth 
• If year of birth is missing, then date of birth will not be imputed. 
Laboratory Data that are continuous in nature but are below the lower limit of quantitation 
(LOQ) or above the upper LOQ will be imputed as follows except for the scenarios described 
below for direct bilirubin, urine creatinine, and serum cystatin C:  
• A value that is 1 unit less than the LOQ will be used for calculation of descriptive statistics if 
the datum is reported in the form of “< x” (x is considered as the LOQ). For example, if the 
values are reported as < 50 and < 5.0, then values of 49 and 4.9 will be used for calculation 
of summary statistics, respectively.  
• A value that is 1 unit above the LOQ will be used for calculation of descriptive statistics if 
the datum is reported in the form of “> x” (x is considered as the LOQ). Values with decimal 
points will follow the same logic as stated above.  
• The limit of quantitation will be used for calculation of descriptive statistics if the data is 
reported in the form of “≤ x” or “≥ x” (x is considered as the LOQ). 
For direct bilirubin, a value of “< 0.1” is imputed as 0.09. For urine creatinine, a value of “< 1” is 
handled as a missing value in its summary and the calculation of related ratios. For serum 
cystatin C, a value of “< 0.10” is handled as a missing value in the calculation of estimated 
glomerular filtration rate (eGFR). 
Logarithm (base 10) will be used to transform HBV DNA and quantitative HBsAg data.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 18 
 
25 October 2023 
For HBV DNA, if the value in IU/mL (TaqMan) is above the upper limit of quantification, the 
corresponding diluted value (TaqDil), if available, will be used. 
3.6. 
Analysis Windows 
3.6.1. 
Definition of Study Day 1 and Other Definitions 
Study Day 1 is defined as the day when the first dose of blinded study drug was taken, as 
recorded on the Study Drug Administration eCRF form. 
Open-Label Study Day 1 is defined as the day when the first dose of the open-label study drug 
was taken, as recorded on the Study Drug Administration eCRF form. 
Study days are calculated relative to Study Day 1. For events that occurred on or after 
Study Day 1 date, study days are calculated as (visit date − Study Day 1 + 1). For events that 
occurred prior to Study Day 1, study days are calculated as (visit date − Study Day 1). 
Open-Label study days are calculated relative to Open-Label Study Day 1. For events that 
occurred on or after Open-Label Study Day 1 date, study days are calculated as 
(visit date − Open-Label Study Day 1 + 1).  
Follow-up days are for visits that occur during the 24-week TFFU period and calculated as (visit 
date – last dose date). 
Last Dose Date of Blinded Study Drug is the latest non-missing end date of blinded study drug, 
recorded on the Study Drug Administration eCRF form with “Study Drug Permanently 
Discontinued” box checked for participants who prematurely discontinued blinded study drug or 
who completed blinded study drug according to Blinded Study Drug Completion eCRF. If the 
last dose date of blinded study drug is missing (eg, due to lost to follow up) for participants who 
prematurely discontinued blinded study drug, or for participants who are still on blinded study 
drug, the latest of nonmissing blinded study drug start dates and end dates, the clinical visit dates 
and the laboratory visit dates excluding the dates of open-label and 24-week TFFU visits will be 
used to impute the last dose date of blinded study drug.  
For participants who prematurely discontinued blinded study drug or who completed blinded 
study drug but did not enter open-label phase, the Last Dose Date is the same as Last Dose Date 
of Blinded Study Drug.  
For participants who completed blinded study drug and entered open-label phase, the 
Last Dose Date is the latest non-missing end date of open-label study drug, recorded on the 
Study Drug Administration eCRF form with “Study Drug Permanently Discontinued” box 
checked for participants who prematurely discontinued open-label study drug or who completed 
open-label study drug according to the Open-Label Study Drug Completion eCRF. If the last 
dose date is missing (eg, due to lost to follow up) for participants who prematurely discontinued 
open-label study drug, or for participants who are still on open-label study drug, the latest of 
nonmissing open-label study drug start dates and end dates, the clinical visit dates and the 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 19 
 
25 October 2023 
laboratory visit dates excluding the dates of 24-week TFFU visits will be used to impute the last 
dose date. 
Last Study Date is the latest of nonmissing study drug (blinded or open-label) start dates and 
end dates, the clinic visit and the laboratory visit dates including the 24-week TFFU visit date for 
participants who prematurely discontinued the study or who completed the study according to 
Study Completion eCRF. 
Baseline value for the double-blind phase (except DXA BMD) is defined as the last 
nonmissing value obtained on or prior to Study Day 1. For DXA BMD, the baseline value is 
defined as the last nonmissing value on or prior to Study Day 14. Baseline value for the 
open-label phase (except DXA BMD) is defined as the last nonmissing value obtained on or 
prior to Open-label Study Day 1. For DXA BMD, it is defined as the last nonmissing value on or 
prior to Open-Label Study Day 14 and the last dose date of open-label study drug. 
3.6.2. 
Analysis Windows 
Participant visits might not occur on protocol specified days. Therefore, for the purpose of 
analysis, observations will be assigned to analysis windows.  
The following windows (shown on Table 3-1 to Table 3-7) apply to baseline and on-treatment 
assessments only.  
For participants who prematurely discontinued the blinded study drug (except participants who 
discontinue study drug after Week 48 due to HBsAg loss with confirmed seroconversion to 
anti-HBs during the double-blind phase), laboratory and DXA assessments up to and including 
the last dose date of the blinded study drug, will be considered as on-treatment during the 
double-blind phase. For participants who completed the double-blind phase, laboratory 
assessments up to and including the last dose date of the double-blind study drug + 1 day, and 
DXA assessments on or prior to the last dose date of the double-blind study drug + 14 days, will 
be considered as on-treatment during the double-blind phase. 
For participants who prematurely discontinued the open-label study drug (except participants 
who discontinue study drug after Week 48 due to HBsAg loss with confirmed seroconversion to 
anti-HBs during the open-label phase), laboratory and DXA assessments up to and including the 
last dose date of the open-label study drug + 3 days, will be considered as on-treatment during 
the open-label phase. For participants completed the open-label phase, laboratory assessments up 
to and including the last dose date of the open-label study drug + 3 days, and DXA assessments 
up to and including the last dose date of the open-label study drug + 14 days, will be considered 
as on-treatment during the open-label phase. For participants who have not discontinued the 
open-label study drug permanently, data collected up to database finalization date will be 
considered as on-treatment of the open-label phase. 
For participants who discontinue study drug early due to HBsAg loss with confirmed 
seroconversion, all efficacy data including data collected after the last dose date of the study drug 
will be reassigned analysis visits using the on-treatment assessment windows 
(Table 3-1, Table 3-2, and Table 3-4).  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 20 
 
25 October 2023 
The analysis windows for HBV DNA, hematology, serum chemistry and liver function tests, 
urinalysis, urine pregnancy test, eGFR (by CG and Chronic Kidney Disease Epidemiology 
Collaboration [CKD-EPI]), renal biomarkers urine albumin to creatinine ratio (UACR), urine 
protein to creatinine ratio (UPCR), renal tubular maximum reabsorption rate of phosphate to the 
glomerular filtration rate (TmP/GFR), urine fractional excretion of filtered phosphate (FEPO4), 
fractional excretion of uric acid (FEUA), weight, and vital sign assessments are presented in 
Table 3-1.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 21 
 
25 October 2023 
Table 3-1. 
Analysis Windows for HBV DNA, Hematology, Serum Chemistry and 
Liver Function Tests, Urinalysis, Urine Pregnancy Test, eGFR 
(by CG and CKD-EPI), UACR, UPCR, TmP/GFR, FEPO4, FEUA, 
Weight, and Vital Sign Assessments 
Visit ID 
Nominal Day 
Lower Limit 
Upper Limit 
Baseline 
 
 
1 
Week 4 
28 
2 
41 
Week 8 
56 
42 
69 
Week 12 
84 
70 
97 
Week 16 
112 
98 
125 
Week 20 
140 
126 
153 
Week 24 
168 
154 
181 
Week 28 
196 
182 
209 
Week 32 
224 
210 
237 
Week 36 
252 
238 
265 
Week 40 
280 
266 
293 
Week 44 
308 
294 
321 
Week 48 
336 
322 
363 
Week 56 
392 
364 
419 
Week 64 
448 
420 
475 
Week 72 
504 
476 
531 
Week 80 
560 
532 
587 
Week 88 
616 
588 
643 
Week 96 
672 
644 
713 
Week 108 
756 
714 
797 
Week 120 
840 
798 
881 
Week 132 
924 
882 
965 
Week 144 
1008 
966 
1091 
Week 168 
1176 
1092 
1259 
Week 192 
1344 
1260 
1427 
Week 216 
1512 
1428 
1595 
Week 240 
1680 
1596 
1763 
Week 264 
1848 
1764 
1931 
Week 288 
2016 
1932 
2099 
Week 312 
2184 
2100 
2267 
Week 336 
2352 
2268 
2435 
Week 360 
2520 
2436 
2603 
Week 384 
2688 
2604 
2771 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 22 
 
25 October 2023 
The analysis windows for safety ECG and fibrotest are presented in Table 3-2. 
Table 3-2. 
Analysis Windows for Safety ECG and Fibrotest 
Visit ID 
Nominal Day 
Lower Limit 
Upper Limit 
Baseline 
 
 
1 
Week 48 
336 
2 
503 
Week 96 
672 
504 
839 
Week 144 
1008 
840 
1175 
Week 192 
1344 
1176 
1511 
Week 240 
1680 
1512 
1847 
Week 288 
2016 
1848 
2183 
Week 336 
2352 
2184 
2519 
Week 384 
2688 
2520 
2855 
 
The analysis windows for BMD results from DXA and fasting lipid panel including direct low 
density lipoprotein (LDL), high density lipoprotein (HDL) and total cholesterol to HDL ratio, are 
presented in Table 3-3. 
Table 3-3. 
Analysis Windows for BMD Results from DXA and Fasting Lipid 
Panel 
Visit ID 
Nominal Day 
Lower Limit 
Upper Limit 
Baseline 
 
 
1(14a) 
Week 24 
168 
2(15a) 
251 
Week 48 
336 
252 
419 
Week 72 
504 
420 
587 
Week 96 
672 
588 
839 (755b) 
Week 120b 
840 
756b 
923b 
Week 144 
1008 
840 (924b) 
1175 
Week 192 
1344 
1176 
1511 
Week 240 
1680 
1512 
1847 
Week 288 
2016 
1848 
2183 
Week 336 
2352 
2184 
2519 
Week 384 
2688 
2520 
2855 
a 
This applies to DXA only. Upper limit for baseline DXA BMD is Day 14 and lower limit for Week 24 DXA BMD is 
Day 15. 
b 
This applies to the participants who consented to Amendment 3.1. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 23 
 
25 October 2023 
The analysis windows for serum HBsAg (quantitative) and HBV serology are presented in 
Table 3-4. 
Table 3-4. 
Analysis Windows for Serum HBsAg (Quantitative) and 
HBV Serology 
Visit ID 
Nominal Day 
Lower Limit 
Upper Limit 
Baseline 
 
 
1 
Week 12 
84 
2 
125 
Week 24 
168 
126 
209 
Week 36 
252 
210 
293 
Week 48 
336 
294 
391 
Week 64 
448 
392 
503 
Week 80 
560 
504 
615 
Week 96 
672 
616 
713 
Week 108 
756 
714 
797 
Week 120 
840 
798 
881 
Week 132 
924 
882 
965 
Week 144 
1008 
966 
1091 
Week 168 
1176 
1092 
1259 
Week 192 
1344 
1260 
1427 
Week 216 
1512 
1428 
1595 
Week 240 
1680 
1596 
1763 
Week 264 
1848 
1764 
1931 
Week 288 
2016 
1932 
2099 
Week 312 
2184 
2100 
2267 
Week 336 
2352 
2268 
2435 
Week 360 
2520 
2436 
2603 
Week 384 
2688 
2604 
2771 
 
The analysis windows for fasting glucose, fasting total cholesterol, fasting triglycerides, renal 
biomarkers including urine retinol binding protein (RBP) to creatinine ratio, urine 
beta-2-microglobulin to creatinine ratio, and bone biomarkers including C-type collagen 
sequence (CTX), procollagen type 1 N-terminal propeptide (P1NP), osteocalcin (OC), and bone 
specific alkaline phosphatase (bsAP) are presented in Table 3-5. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 24 
 
25 October 2023 
Table 3-5. 
Analysis Windows for Fasting Glucose, Fasting Total Cholesterol, 
Fasting Triglycerides, Renal, and Bone Biomarkers 
Visit ID 
Nominal Day 
Lower Limit 
Upper Limit 
Baseline 
 
 
1 
Week 4 
28 
2 
55 
Week 12 
84 
56 
125 
Week 24 
168 
126 
251 
Week 48 
336 
252 
419 
Week 72 
504 
420 
587 
Week 96 
672 
588 
839 (755a) 
Week 120a 
840 
756a 
923a 
Week 144 
1008 
840 (924a) 
1175 
Week 192 
1344 
1176 
1511 
Week 240 
1680 
1512 
1847 
Week 288 
2016 
1848 
2183 
Week 336 
2352 
2184 
2519 
Week 384 
2688 
2520 
2855 
a 
This applies to the participants who consented to Amendment 3.1. 
The analysis window for serum parathyroid hormone (PTH) is presented in Table 3-6. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 25 
 
25 October 2023 
Table 3-6. 
Analysis Windows for PTH 
Visit ID 
Nominal Day 
Lower Limit 
Upper Limit 
Baseline 
 
 
1 
Week 4 
28 
2 
41 
Week 8 
56 
42 
69 
Week 12 
84 
70 
97 
Week 16 
112 
98 
125 
Week 20 
140 
126 
153 
Week 24 
168 
154 
181 
Week 28 
196 
182 
209 
Week 32 
224 
210 
237 
Week 36 
252 
238 
265 
Week 40 
280 
266 
293 
Week 44 
308 
294 
321 
Week 48 
336 
322 
363 
Week 56 
392 
364 
419 
Week 64 
448 
420 
475 
Week 72 
504 
476 
531 
Week 80 
560 
532 
587 
Week 88 
616 
588 
643 
Week 96 
672 
644 
713 
Week 108 
756 
714 
797 
Week 120 
840 
798 
881 
Week 132 
924 
882 
965 
Week 144 
1008 
966 
1175 
Week 192 
1344 
1176 
1511 
Week 240 
1680 
1512 
1847 
Week 288 
2016 
1848 
2183 
Week 336 
2352 
2184 
2519 
Week 384 
2688 
2520 
2855 
 
The analysis window for hepatic ultrasound for hepatocellular carcinoma (HCC) surveillance is 
presented in Table 3-7. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 26 
 
25 October 2023 
Table 3-7. 
Analysis Windows for Hepatic Ultrasound 
Visit ID 
Nominal Day 
Lower Limit 
Upper Limit 
Baseline 
 
 
1 
Week 96 
672 
588 
755 
Week 120 
840 
756 
923 
Week 144 
1008 
924 
1091 
Week 168 
1176 
1092 
1259 
Week 192 
1344 
1260 
1427 
Week 216 
1512 
1428 
1595 
Week 240 
1680 
1596 
1763 
Week 264 
1848 
1764 
1931 
Week 288 
2016 
1932 
2099 
Week 312 
2184 
2100 
2267 
Week 336 
2352 
2268 
2435 
Week 360 
2520 
2436 
2603 
Week 384 
2688 
2604 
2855 
Hepatic ultrasound data was collected for the participants who consented to Amendment 3.1. 
Data collected after the last dose date will be considered as post-treatment visits. Although 
there’s no participant entering TFFU phase after completing Week 384 visit, participants who 
prematurely discontinued study drug could enter TFFU phase. The analysis windows for 
post-treatment assessments are presented in Table 3-8 and Table 3-9. 
Table 3-8. 
Analysis Windows for Post-Treatment Assessments Except 
HBV Serology 
Visit ID 
Nominal Follow-Up Day 
Lower Limit 
Upper Limit 
Follow-Up Baseline 
 
 
3 
Follow-Up Week 4 
28 
4 
41 
Follow-Up Week 8 
56 
42 
69 
Follow-Up Week 12 
84 
70 
97 
Follow-Up Week 16 
112 
98 
125 
Follow-Up Week 20 
140 
126 
153 
Follow-Up Week 24 
168 
154 
181 
 
Table 3-9. 
Analysis Windows for Post-Treatment HBV Serology 
Visit ID 
Nominal Follow-Up Day 
Lower Limit 
Upper Limit 
Follow-Up Baseline 
 
 
3 
Follow-Up Week 12 
84 
4 
125 
Follow-Up Week 24 
168 
126 
209 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 27 
 
25 October 2023 
3.6.3. 
Selection of Data in the Event of Multiple Records in a Window 
Depending on the statistical analysis method, single values are required for each analysis 
window. For example, change from baseline by visit usually requires a single value, whereas a 
time-to-event analysis would not require 1 value per analysis window. When a single value is 
needed, the following rule(s) will be used.  
For baseline of the double-blind and open-label phases, the last available record on or prior to the 
first dose of blinded and open-label study drug will be selected, respectively. For DXA BMD 
baseline, the last value on or prior to Study Day 14, and on or prior to Open-Label Study Day 14 
and the last dose date of open-label study drug will be selected for the double-blind and the 
open-label phases, respectively. If there are multiple records with the same time or no time 
recorded on the same day for numeric observations, an average will be computed for that day, 
with the exception for HBV DNA and Quantitative HBsAg for which geometric mean will be 
taken. If there are multiple records with the same time or no time recorded on the same day for 
categorical observations, the most conservative value will be taken, eg, negative will be selected 
over positive for HBeAg and HBsAg, and positive will be selected over negative for HBeAb and 
HBsAb. 
The following specified rules will be used for postbaseline visits: 
• ALT: The largest value will be included in the analysis when 2 or more ALT values occur 
within the same visit window. 
• BMD: The latest record in the window will be selected. 
• HBV DNA and Quantitative HBsAg: The record closest to the nominal day for that visit 
will be selected. If there are 2 records equidistant from the nominal day, the latest will be 
selected. If there is more than 1 record on the selected day, the geometric mean will be taken. 
• Serology: For HBeAg, HBeAb, HBsAg, and HBsAb, the record closest to the nominal day 
for that visit will be selected. If there are 2 records equidistant from the nominal day, the 
latest will be selected. If there is more than 1 record on the selected day, the most 
conservative value will be taken, ie, positive will be selected over negative for HBeAg and 
HBsAg, and negative will be selected over positive for HBeAb and HBsAb. 
For all other laboratory parameters:  
• If multiple valid nonmissing numeric observations exist in a window, then records will be 
chosen as follows: 
 The record closest to the nominal day for that visit will be selected. If there are 2 records 
equidistant from the nominal day, the latest will be selected. If there is more than 1 record 
on the selected day, the average will be taken. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 28 
 
25 October 2023 
• If multiple valid nonmissing categorical observations (eg, safety ECG results) exist in a 
window, then records will be chosen as follows: 
 The most conservative value (eg, abnormal will be selected over normal for safety ECG) 
within the window will be selected. In the event that 2 values within a window are of 
equal abnormality, the value collected nearest to the nominal date will be used. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 29 
 
25 October 2023 
4. 
PARTICIPANT DISPOSITION 
4.1. 
Participant Enrollment 
All necessary summaries on participant enrollment and the randomization schedule have been 
performed as part of Week 48 CSR and will not be repeated for the final CSR.  
Key study dates (first participant screened, first participant randomized, last participant 
randomized, and last participant last visit for the clinical study report) will be provided. 
4.2. 
Disposition of Participants 
The summary of participant disposition will be provided by treatment group and overall. This 
summary will include the number of participants in the Randomized Analysis Set, participants 
randomized but not treated, participants in the Safety Analysis Set, participants in the 
Open-Label Safety Analysis Set. 
In addition, the number and percentage of the participants in the following categories will be 
summarized using the Safety Analysis Set: 
Double-Blind Phase 
• Prematurely discontinued double-blind study treatment (with summary of reasons for 
discontinuing treatment) 
• Completed double-blind study treatment 
Open-Label Phase 
• Willing to enter open-label phase  
• Entered open-label phase  
• Prematurely discontinued open-label study treatment (with summary of reasons for 
discontinuing treatment) 
• Completed open-label study treatment 
TFFU Phase 
• Entered TFFU period 
• Completed TFFU 
• Discontinued TFFU 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 30 
 
25 October 2023 
Study Completion 
• Remaining on study 
• Prematurely discontinued study (with summary of reasons for discontinuing study) 
• Started another HBV therapy 
• Completed protocol-planned duration of the study 
No inferential statistics will be generated. A data listing of reasons for premature study 
drug/study discontinuation will be provided. 
4.3. 
Extent of Exposure 
Exposure data described below will be summarized for the double-blind phase and open-label 
phase separately. 
4.3.1. 
Duration of Exposure to Blinded Study Drug 
Duration of exposure to blinded study drug will be defined as (last dose date of blinded study 
drug – first dose date of blinded study drug + 1), regardless of temporary interruptions in study 
drug administration, and will be expressed in weeks (recorded to 1 decimal place, eg, 4.5 weeks). 
If subjects are still on blinded study drug, the latest of blinded study drug start and end dates, 
and the clinic and laboratory visit dates (excluding the open-label and 24-week treatment-free 
follow-up visit dates) will be used to impute the last dose date of blinded study drug for 
calculating the duration of blinded study drug exposure. 
Duration of exposure to blinded study drug will be summarized using descriptive statistics 
(sample size, mean, standard deviation [SD], median, Q1, Q3, minimum, and maximum) and as 
the number and percentage of subjects exposed for specified periods, eg, ≥ 4 weeks (28 days), 
≥ 8 weeks (56 days), etc. 
Summaries will be provided by treatment group for subjects in the Safety Analysis Set. No 
inferential statistics will be provided. 
4.3.2. 
Adherence with Blinded Study Drug Regimen 
Study drug regimen adherence will be computed based on tablet counts for the active drug only 
(eg, adherence in TAF group only includes TAF and not placebo for TDF). The numbers of 
tablets of study drug dispensed and returned are captured on study drug accountability forms. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 31 
 
25 October 2023 
Adherence (%) of study drug regimen will be calculated as follows:  
prescribed
 
 tablets
of
Number 
 taken
 tablets
of
Number 
100
 
 
(%)
 
Adherence
×
=
 
 =  100 ×
∑No. of tablets taken at each dispensing period   [1]
(∑No. of tablets prescribed at each dispensing period [2]) + 1 
 
[1] Number of tablets taken at a distinct dispensing period for a study drug is calculated as the minimum of (a) the daily number    
     of tablets prescribed for the study drug multiplied by (the duration of treatment +1 day) at the dispensing period of the same 
     dispensing date, and (b) the number of tablets taken for the study drug (number of tablets dispensed minus the number of  
     tablets returned). Total number of tablets taken is determined by summing the number of tablets taken from all evaluable  
     dispensing periods. 
[2] Number of tablets prescribed at a distinct dispensing period for a study drug is calculated as the daily number of tablets  
      prescribed for the study drug multiplied by the duration of treatment at the dispensing period of the same dispensing date.  
      Total number of tablets prescribed is determined by summing the number of tablets prescribed from all evaluable dispensing  
      periods. 
The duration of treatment at a dispensing period for a study drug is calculated as the minimum 
of (a) the last returned date of the same dispensing period for the study drug, (b) date of 
premature discontinuation of the study drug, and (c) next dispensing date of the study drug, 
minus dispensing date of the study drug. 
The next dispensing date is the following dispensing date of the study drug regardless of the 
bottle return date. 
For a record where the number of tablets returned was missing (with “Yes” answered for “Was 
bottle returned?” question), it is assumed the number of tablets returned was 0. If the number of 
tablets dispensed was missing or any study drug bottle was not returned or the bottle return status 
was unknown for the same dispensing date, then all records for the same dispensing date for that 
study drug will be excluded from both denominator and numerator calculation. 
Adherence up to the Week 144 Visit will be calculated for subjects in the Safety Analysis Set. 
The number and percentage of subjects who return at least 1 bottle and have calculable 
adherence during the study, descriptive statistics for adherence up to Week 144 visit for a study 
drug regimen (sample size, mean, SD, median, Q1, Q3, minimum, and maximum) along with the 
number and percentage of subjects belonging to adherence categories (eg, < 80%, ≥ 80% to 
< 90%, ≥ 90% to < 95%, ≥ 95%) will be provided by treatment group for the Safety Analysis 
Set. No inferential statistics will be provided. 
4.3.3. 
Duration of Exposure to Open-Label Study Drug 
Duration of exposure to open-label study drug will be summarized for participants in the 
Open-Label Safety Set. It is defined as (Last Dose Date of Open-Label Study Drug – First Dose 
Date of Open-Label Study Drug + 1) / 7 in weeks, regardless of temporary interruptions in study 
drug administration, and will be summarized using descriptive statistics (ie, sample size, mean, 
standard deviation [SD], median, first quartile [Q1], third quartile [Q3], minimum and 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 32 
 
25 October 2023 
maximum) by treatment group. The number and percentage of participants exposed will be 
summarized by prespecified period, eg, ≥ 12 weeks (84 days), ≥ 24 weeks (168 days), etc. 
If participants are still on open-label study drug at the time of the data-cut, the latest date of the 
open-label study drug start and end dates, the clinic visit dates, and laboratory visit dates 
(excluding the 24-week TFFU visit dates) will be used to impute the last dose date of the 
open-label study drug for calculating the duration of the open-label study drug exposure. 
4.3.4. 
Adherence with Open-Label Study Drug Regimen 
Study drug regimen adherence will be computed based on tablet counts for open-label study drug 
for participants in the Open-Label Safety Set. The numbers of tablets of open-label study drug 
dispensed and returned are captured on study drug accountability forms. The same formula used 
for the adherence of double-blind study drug regimen will be used for the calculation of 
adherence to the open-label study drug regimen. 
The duration of treatment at a dispensing period for the open-label study drug is calculated as 
the minimum of (a) the last returned date of the same dispensing period for the open-label study 
drug, (b) date of premature discontinuation of open-label study drug, and (c) next dispensing 
date of open-label study drug, minus the dispensing date of the open-label study drug. 
The next dispensing date is the following dispensing date of open-label study drug regardless of 
the bottle return date.  
For a record where the number of tablets returned was missing (with “Yes” answered for 
“Was bottle returned?” question), it is assumed the number of tablets returned was 0. If the 
number of tablets dispensed was missing or any open-label study drug bottle was not returned or 
the bottle return status was unknown for the same dispensing date, then all records for the same 
dispensing date for the open-label study drug will be excluded from both denominator and 
numerator calculation. 
Adherence for open-label study drug will be calculated using all data from the entire open-label 
dosing period up to the date of permanent discontinuation of the open-label study drug for 
participants who prematurely discontinued open-label study drug, or completed open-label study 
drug. 
The number and percentage of participants who return at least 1 bottle and have calculable 
adherence during the open-label phase, descriptive statistics for adherence up to the visits 
mentioned above for the open-label study drug (sample size, mean, SD, median, Q1, Q3, 
minimum, and maximum) along with the number and percentage of participants belonging to 
adherence categories (eg, < 80%, ≥ 80% to < 90%, ≥ 90% to < 95%, ≥ 95%) will be provided by 
treatment group for the Open-Label Safety Analysis Set. No inferential statistics will be 
provided. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 33 
 
25 October 2023 
4.4. 
Protocol Deviations 
Protocol deviations occurring after participants entered the study are documented during routine 
monitoring. The number and percentage of participants with important protocol deviations (e.g., 
at least 1, with 1, 2, 3 or more important protocol deviations), and the total number of important 
protocol deviations by deviation category (e.g., eligibility criteria, informed consent) will be 
summarized by treatment group for the Full Analysis Set. A by participant listing will be 
provided for those participants with important protocol deviations. A listing of participants who 
received the wrong study treatment will also be provided. 
4.5. 
Assessment of COVID-19 Impact 
This study was ongoing during the novel coronavirus (COVID-19) pandemic which had an 
impact on the study conduct. Some participants were unable to attend onsite visits due to shelter 
in place guidelines, site closures, or other reasons. This section describes how special situations 
due to COVID-19 will be handled in the analysis. 
4.5.1. 
Study Drug or Study Discontinuation Due to COVID-19 
A by-participant listing of reasons for premature study drug or study discontinuation due to 
COVID-19 will be provided if applicable. 
4.5.2. 
Protocol Deviations Due to COVID-19 
A by-participant listing will be provided for participants with important protocol deviations 
related to COVID-19 if applicable. A separate listing will be provided for participants with 
non-important protocol deviations related to COVID-19 if applicable. 
4.5.3. 
Missed and Virtual Visits due to COVID-19 
A by-participant listing of participants with missed or virtual visits due to COVID-19 will be 
provided by participant ID number in ascending order. 
Information regarding missed or virtual visits due to COVID-19 will be collected as free text in 
the CRF comment fields. The determination of missed or virtual visits due to COVID-19 will be 
done using Natural Language Processing (NLP) to search the CRF comment fields. A detailed 
explanation of the algorithm is given in Appendix 2. 
4.5.4. 
Adverse Events Due to COVID-19 
AEs of COVID-19 will be included in analyses of AEs if applicable, which will be determined 
through COVID-19 SMQ narrow search. A by-participant listing of AEs of COVID-19 will be 
provided if applicable. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 34 
 
25 October 2023 
4.5.5. 
Overall Assessment of COVID-19 Pandemic Impact 
For participants affected by COVID-19 infection and/or pandemic while participating in the 
study, a listing of the following individual COVID-19 related outcome categories will be 
provided: 
• Death due to COVID-19 
• Adverse event of COVID-19, as determined by COVID-19 SMQ narrow search  
• Specific adverse event directly associated with the pathogen causing COVID-19, as 
determined by Medical Search Term (MST)  
• Hospitalization (using data from AE eCRF) due to adverse event of COVID-19 as defined 
above 
• Study drug discontinuation due to COVID-19 
• Study discontinuation due to COVID-19 
• Missed visits due to COVID-19   
• Missed key assessments due to COVID-19 (Key assessments are the assessments 
contributing to primary and key secondary end points which happened before COVID-19 
pandemic) 
In addition, composite broad COVID-19 impact indicator will be derived based on the following 
individual categories defined above: death, adverse event, hospitalization, study drug 
discontinuation, study discontinuation, missed visits, and missed key assessments. Composite 
specific COVID-19 impact indicator will be derived based on death and specific adverse event. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 35 
 
25 October 2023 
5. 
BASELINE CHARACTERISTICS 
5.1. 
Demographics and Baseline Characteristics 
Participant demographic data (eg, age, sex, race, and ethnicity) and baseline characteristics 
(eg, body weight, height, body mass index [BMI], and Vitamin D) will be summarized by 
treatment group and overall, using descriptive statistics (sample size, mean, SD, median, Q1, Q3, 
minimum, and maximum) for continuous data and by the number and percentage of participants 
for categorical data. Age is calculated as age in years at the first dose of study drug.  
In addition, the following baseline characteristics and medical history will be summarized: 
• BMI categories (< 18.5 kg/m2 [underweight], ≥ 18.5 - 25.0 kg/m2 [normal], 
≥ 25.0 - 30.0 kg/m2 [overweight], and ≥ 30.0 kg/m2 [obese]) 
• HBV DNA (log10 IU/mL) 
• HBV DNA categories (≥ 8 log10 IU/mL, < 8 log10 IU/mL) 
• ALT (U/L) 
• ALT level based on central laboratory normal range (≤ ULN, > ULN - 5 × ULN, 
> 5 × ULN - 10 × ULN, > 10 ULN) 
• ALT level based on American Association for the Study of Liver Diseases (AASLD) normal 
range with the ULN as 25 U/L for female and 35 U/L for male (≤ ULN, > ULN - 5 × ULN, 
> 5 × ULN - 10 × ULN, > 10 ULN)  
• Estimated GFR by CG, CKD-EPI creatinine, and CKD-EPI Cystatin C methods 
• HBeAg status (positive, negative) 
• Previous oral nucleoside/nucleotide treatment experience (yes, no) 
• Previous interferon experience (yes, no) 
• Years positive for HBV  
• HBV Genotype (A, B, C, D, E, F, etc) 
• FibroTest score 
• Fibrosis stage by fibrotest score (0 - 0.48, 0.49 - 0.74, 0.75 - 1) 
• Cirrhosis history (yes, no, indeterminate/unknown) 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 36 
 
25 October 2023 
• Proteinuria by urinalysis (dipstick) (Grade 0, Grade 1, Grade 2, Grade 3) 
• Medical history: diabetes mellitus (yes, no), hypertension (yes, no), cardiovascular disease 
(yes, no), and hyperlipidemia (yes, no)  
• Clinical BMD status (normal, osteopenia, osteoporosis) 
• IL28B Genotype  
Diabetes mellitus, hypertension, cardiovascular disease, and hyperlipidemia above are 
determined by medical history and/or concomitant medication data, which will be reviewed by 
the Gilead medical monitor before unblinding. 
5.2. 
Medical History 
A listing of medical history data will be provided for the Randomized Analysis Set. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 37 
 
25 October 2023 
6. 
EFFICACY ANALYSES 
For the final analyses, efficacy data will be summarized for the double-blind and open-label 
phase up to Week 384 using Missing = Failure (M = F) based on participants in the FAS and 
Missing = Excluded (M = E) approach based on participants in the FAS if applicable. 
No statistical comparisons will be performed for the efficacy analyses. All efficacy data up to the 
week 384 (i.e., final) data finalization including data collected during 24-week TFFU period for 
participants who prematurely discontinued study drug will be listed. 
HBV DNA lab values based on the Roche COBAS® Taqman® assay (with LLOQ of 29 IU/mL, 
on or before Week 64 visit), Roche AmpliPrep/COBAS® TaqMan® 2.0 assay (with LLOQ of 
20 IU/mL, after Week 64 visit) and Roche COBAS 6800 assay (with LLOQ of 10 IU/mL, at 
Week 360 and 384 visits) will be used for HBV DNA analysis. If the value in IU/mL (TaqMan) 
is above the upper limit of quantification, the corresponding diluted value (TaqDil), if available, 
will be used. 
6.1. 
Primary Efficacy Endpoints 
The primary efficacy end point is the proportion of participants with HBV DNA < 29 IU/mL at 
Week 48, which has been analyzed in the previous Week 48 interim analysis, and will not be 
repeated for this final analysis (refer to Week 48 SAP for the statistical analysis method for the 
primary efficacy end point). 
6.2. 
Secondary Efficacy Endpoints 
6.2.1. 
Definition of Secondary Efficacy Endpoints 
For the definitions below, double-blind baseline will be used. 
The key secondary efficacy end point is as follows: 
• The proportion of participants with HBeAg loss and seroconversion to anti-HBe at Week 48 
Other secondary efficacy end points are as follows: 
• The proportion of participants with plasma HBV DNA < 29 IU/mL at Weeks 96, 144, 240, 
and 384 
• The proportion of participants with plasma HBV DNA < 29 IU/mL (target not detected) at 
Weeks 48, 96, 144, 240, and 384 
• The proportion of participants with ALT normalization (by central laboratory and AASLD 
criteria) at Weeks 48, 96, 144, 240, and 384 
• The proportion of participants with HBeAg loss at Weeks 48, 96, 144, 240, and 384 
• The proportion of participants with HBsAg loss at Weeks 48, 96, 144, 240, and 384 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 38 
 
25 October 2023 
• The proportion of participants with HBeAg seroconversion to anti-HBe at Weeks 48, 96, 
144, 240, and 384 
• The proportion of participants with HBsAg seroconversion to anti- HBs at Weeks 96, 144, 
240, and 384 
• The change from baseline in fibrosis as assessed by FibroTest® at Weeks 48, 96, 144, 240, 
and 384 
• The incidence of drug resistant mutations at Weeks 48, 96, 144, 240, and 384 
• The change from baseline in log10 (HBV DNA) (IU/mL) at Weeks 48, 96, 144, 240, and 384 
• The change from baseline in log10 (HBsAg) (IU/mL) at Weeks 48, 96, 144, 240, and 384 
• The change from baseline in ALT at Weeks 48, 96, 144, 240, and 384 
Incidence of drug resistant mutations will be reported in a separate virology report. 
For the final analysis, the following definitions will be used: 
• HBeAg loss is defined as HBeAg test result changes from HBeAg positive at baseline to 
HBeAg negative at a postbaseline visit with baseline HBeAb negative or missing 
• HBsAg loss is defined as HBsAg test result changes from HBsAg positive at baseline to 
HBsAg negative at a postbaseline visit with baseline HBsAb negative or missing 
• HBeAg seroconversion is defined as HBeAg loss and HBeAb test result changes from 
HBeAb negative or missing at baseline to HBeAb positive at a postbaseline visit  
• HBsAg seroconversion is defined as HBsAg loss and HBsAb test result changes from 
HBsAb negative or missing at baseline to HBsAb positive at a postbaseline visit  
• ALT normalization is defined as ALT > ULN (by central laboratory normal range or AASLD 
normal range) at baseline but within normal range at a postbaseline visit 
Both baseline and postbaseline borderline serology results will be imputed using the following 
rules: 
• HBsAg and HBeAg borderline/equivocal will be considered as HBsAg positive and HBeAg 
positive 
• HBsAb and HBeAb borderline/equivocal will be considered as HBsAb negative and HBeAb 
negative 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 39 
 
25 October 2023 
6.2.2. 
Analysis Methods for Secondary Efficacy End points 
The analyses for the secondary efficacy endpoints will be conducted using the FAS. All the 
secondary efficacy endpoints involving proportions will be analyzed using the same statistical 
method (M = F) applied to the analysis of the primary efficacy endpoint. Sensitivity analyses will 
be performed using the M = E approach as well. No statistical comparisons will be performed. 
The change from baseline in log10 (HBV DNA) (IU/mL), log10 (HBsAg) (IU/mL), and ALT 
will be summarized by visit using observed data (ie, missing will be excluded). In addition, the 
proportion of participants with HBV DNA < 29 IU/mL (M = F and M = E), ALT normalization 
(M = F and M = E), mean change from double-blind baseline in log10 (HBV DNA) (IU/mL), 
log10 (HBsAg) (IU/mL), and ALT (U/L) will be plotted over time for participants in the FAS.  
Fibrosis assessed by FibroTest® at each visit and the change from baseline in FibroTest score 
will be summarized using descriptive statistics (sample size, mean, SD, median, Q1, Q3, 
minimum, and maximum) by treatment group. A shift table of fibrosis stage based on FibroTest 
score by visit will also be provided. Mean change from double-blind baseline in FibroTest score 
will be plotted with 95% CI over time using observed data for participants in the FAS. No 
statistical comparisons will be performed. A listing of fibrosis assessment by FibroTest® will 
also be provided. 
6.3. 
Changes From Protocol-Specified Efficacy Analyses 
Change from baseline in log10 (HBV DNA) (IU/mL), log10 (HBsAg) (IU/mL), and ALT were 
added in the SAP as secondary efficacy end points to fully explore the treatment effect of TAF 
versus TDF. The Randomized Analysis Set was not defined in the protocol but is added in the 
SAP. All these changes which were previously documented in the Week 48 China Analysis SAP 
have been carried over to this SAP. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 40 
 
25 October 2023 
7. 
SAFETY ANALYSES 
For the Final analysis, cumulative safety data (AEs, laboratory abnormalities, etc.) and exposure 
data will be summarized for (1) participants in the Safety Analysis Set during the double-blind 
phase, (2) participants in the Open-Label Safety Analysis Set during the open-label phase. 
By-visit summary tables will be presented for the entire study treatment period (double-blind and 
open-label phase combined), based on participants in the Safety Analysis Set, starting from the 
double-blind phase baseline. No by-visit summaries for safety measurements will be generated 
for the TFFU phase. 
For the analyses of events occurring during open-label phase, baseline will be reset as the last 
nonmissing value obtained on or prior to Open-Label Study Day 1 except for DXA BMD, which 
is defined as the last nonmissing value obtained on or prior to Open-Label Study Day 14. 
All safety data, including data collected during the TFFU period for participants prematurely 
discontinued study drug, will be included in data listings. 
7.1. 
Adverse Events 
7.1.1. 
Adverse Event Dictionary 
Adverse Events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). System Organ Class (SOC), high-level group term (HLGT), high-level term (HLT), 
preferred term (PT), and lower-level term (LLT) will be attached to the clinical database. 
7.1.2. 
Adverse Event Severity 
Adverse events are graded by the investigator as Grade 1 (mild), Grade 2 (moderate), Grade 3 
(severe) or Grade 4 (life threatening) according to toxicity criteria specified in Appendix 5 of the 
clinical study protocol. The severity grade of events for which the investigator did not record 
severity will be categorized as “missing” for tabular summaries and data listings, and will be 
considered the least severe for the purposes of sorting for data presentation. 
7.1.3. 
Relationship of AEs to Study Drug 
Related AEs are those for which the investigator answers “Yes” to the question “Related to 
Study Treatment?” in the eCRF. Events for which the investigator did not record relationship to 
study drug will be considered related to study drug for summary purposes. Data listings will 
show relationship as missing. 
7.1.4. 
Relationship of AEs to Study Procedure 
AEs for which ‘Yes’ is marked for question ‘Related to Study Procedures?’ in the eCRF will be 
identified and included in AE listing. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 41 
 
25 October 2023 
7.1.5. 
Serious AEs 
Serious AEs are those identified as serious in the eCRF, where ‘Yes’ was marked for ‘AE 
serious’. The clinical database will be reconciled with the serious AE database (from the 
Drug Safety and Public Health Department) before database finalization. 
7.1.6. 
Treatment-Emergent AEs 
7.1.6.1. 
Definition of Treatment-Emergent 
Summaries of treatment-emergent AEs are defined for the double-blind and the open-label 
phases separately. 
Treatment-emergent AEs occurring during the double-blind phase are defined as: 
• Any AE with an onset date on or after the blinded study drug start date and no later than the 
blinded study drug stop date for those who discontinued blinded study drug, or  
• Any AE leading to blinded study drug discontinuation. 
Treatment-emergent AEs occurring during the open-label phase are defined as: 
• Any AE with an onset date on or after the open-label study drug start date and no later than 
the open-label study drug stop date + 3 days for those who discontinued open-label study 
drug, or 
• Any AE leading to open-label study drug discontinuation.  
7.1.6.2. 
Incomplete Dates 
If an AE onset date is incomplete or completely missing, the following rules will be used to 
define treatment-emergent AE during the double-blind and open-label phases:  
Events with Missing Onset Day and/or Month 
The event is treatment-emergent during the double-blind phase if the following criteria are met: 
• The month and year (or year) of onset date is the same as or after the month and year (or 
year) of the first dose of the blinded study drug, and 
• For those who discontinued the blinded study drug permanently only: the month and year (or 
year) of onset date is the same as or before the month and year (or year) of the date of the last 
dose of the blinded study drug, and  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 42 
 
25 October 2023 
• End date is as follows: 
 The (complete) end date is on or after the first dose date of the blinded study drug, or 
 The month and year (or year) of end date is the same or after the month and year (or year) 
of the first dose of the blinded study drug, or 
 End date is completely missing 
The event is treatment-emergent during the open-label phase if the following criteria are met: 
• The month and year (or year) of onset date is the same as or after the month and year (or 
year) of the first dose of the open-label study drug, and 
• For those who discontinued the open-label study drug permanently only: the month and year 
(or year) of onset date is the same as or before the month and year (or year) of the date of the 
last dose of the open-label study drug + 3 days, and  
• End date is as follows: 
 The (complete) end date is on or after the first dose date of the open-label study drug, or 
 The month and year (or year) of end date is the same or after the month and year (or year) 
of the first dose of the open-label study drug, or 
 End date is completely missing 
Events with Completely Missing Onset Date 
An AE with a completely missing onset date is defined as treatment-emergent AE during the 
double-blind phase if end date is as follows: 
• The (complete) end date is on or after the first dose date of the blinded study drug, or 
• The month and year (or year) of end date is the same or after the month and year (or year) of 
the first dose of the blinded study drug, or 
• End date is completely missing 
An AE with a completely missing onset date is defined as treatment-emergent AE during the 
open-label phase if end date is as follows: 
• The (complete) end date is on or after the first dose date of the open-label study drug, or 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 43 
 
25 October 2023 
• The month and year (or year) of end date is the same or after the month and year (or year) of 
the first dose of the open-label study drug, or 
• End date is completely missing 
7.1.7. 
Summaries of AEs and Deaths 
Adverse events will be summarized for (1) participants in the Safety Analysis Set during the 
Double-Blind phase, and (2) participants in the Open-Label Safety Analysis Set during the 
open-label phase. The full set of AE summaries as described below will be generated for both 
(1) and (2). 
A brief summary of AEs (ie, the number and percentage of participants) will be presented by 
treatment group for the double-blind and open-label phases separately for the following: (1) any 
treatment-emergent AE, (2) any Grade 3 or 4 treatment emergent AE, (3) any Grade 2, 3 or 
4 treatment-emergent AE, (4) any treatment emergent study drug-related AE, (5) any Grade 3 
or 4 treatment-emergent study drug-related AE, (6) any Grade 2, 3 or 4 treatment-emergent 
study drug-related AE, (7) any treatment-emergent serious adverse event (SAE), (8) any 
treatment-emergent study drug-related SAE, (9) any treatment-emergent AE leading to 
premature study drug discontinuation, (10) any treatment emergent AE leading to dose 
modification or study drug interruption, and (11) any treatment-emergent death. 
Treatment-emergent death refers to death that occurs between the first dose date and the last dose 
date + 3 days (inclusive). 
Summaries (number and percentage of participants) of AEs (by SOC, HLT [if specified below], 
and PT) will be provided by treatment group and overall for the double-blind phase on Safety 
Analysis Set and the open-label phase based on the Open-Label Safety Analysis Set as follows: 
• All treatment-emergent AEs summarized by SOC, HLT, and PT 
• Any Grade 3 or 4 treatment-emergent AEs 
• Any Grade 2, 3, or 4 treatment-emergent AEs 
• All treatment-emergent study drug-related AE summarized by SOC, HLT, and PT 
• Any Grade 3 or 4 treatment-emergent study drug-related AEs 
• Any Grade 2, 3, or 4 treatment-emergent study drug-related AEs 
• All treatment-emergent SAEs 
• All treatment-emergent study drug-related SAEs 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 44 
 
25 October 2023 
• All treatment-emergent AEs leading to premature discontinuation from study drug 
• All treatment-emergent AEs leading to dose modification or study drug interruption 
Multiple events will be counted once only per participant in each summary. For data 
presentation, SOC (and HLT) will be ordered alphabetically, with PT sorted by decreasing total 
frequency. For summaries by severity grade, the most severe event will be selected.  
In addition to the by-treatment summaries, data listings will be provided for the following: 
• All AEs (including AEs in the TFFU phase) 
• Grade 3 and 4 AEs 
• SAEs 
• Study drug-related SAEs 
• Deaths 
• AEs leading to premature discontinuation of study drug 
• AEs leading to dose modification or study drug interruption 
7.1.8. 
Potential Uveitis Events 
Analysis will be performed to detect AEs where the symptoms reported may potentially 
represent uveitis. The list of PTs for potential uveitis events were defined as events from the 
predefined MST list consisting of ocular PTs, initially reviewed by an external ophthalmologist, 
and maintained by Patient Safety (PS) through MedDRA upversioning for safety monitoring of 
posterior uveitis. 
A summary (number and percentage of participants) of treatment-emergent potential uveitis 
events by PT will be provided by treatment group for the double-blind phase on Safety Analysis 
Set and the open-label phase based on the Open-Label Safety Analysis Set. A data listing of 
potential uveitis events will be provided. 
7.1.9. 
Potential Cardiovascular Events 
Potential cardiovascular events are defined as events with predefined list of MedDRA PTs based 
on 3 MedDRA SMQs based on the latest MedDRA version: Ischemic central nervous system 
vascular conditions, Other ischemic heart disease, and Myocardial infarction.  
A summary (number and percentage of participants) of potential treatment-emergent 
cardiovascular events and serious cardiovascular events by PT will be provided by treatment 
group for the double-blind phase on Safety Analysis Set and the open-label phase based on the 
Open-Label Safety Analysis Set. data listing of potential cardiovascular events will be provided. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 45 
 
25 October 2023 
7.2. 
Laboratory Evaluations 
Laboratory data collected during the study will be analyzed and summarized using both 
quantitative and qualitative methods. Summaries of graded laboratory data will be provided for 
double-blind phase on Safety Analysis Set and the open-label phase based on the Open-Label 
Safety Analysis Set. Summaries of numerical laboratory data by visit will be provided for the 
entire study period for participants in the Safety Analysis Set from baseline to Week 384. 
The analyses will be based on values reported in conventional units. When values are below the 
LOQ, they will be listed as such, and the closest imputed value will be used for the purpose of 
calculating summary statistics as specified in Section 3.4. 
A by-participant listing for laboratory test results will be provided by participant ID number and 
visit in chronological order for hematology, serum chemistry, urine chemistry, and urinalysis 
separately. Values falling outside of the relevant reference range and/or having a severity grade 
of 1 or higher on the Gilead Grading Scale for Severity of Adverse Events and Laboratory 
Abnormalities will be flagged in the data listings, as appropriate. 
7.2.1. 
Summaries of Numeric Laboratory Results 
Descriptive statistics (sample size, mean, SD, median, Q1, Q3, minimum, and maximum) will be 
provided by treatment group for each laboratory test during the entire study period specified in 
the study protocol as follows: 
• Baseline values 
• Values at each postbaseline analysis window 
• Change from baseline to each postbaseline analysis window 
• Percentage change from baseline to each postbaseline analysis window (if specified)  
In the case of multiple values in an analysis window, data will be selected for analysis as 
described in Section 3.6.3. 
Median (Q1, Q3) change from the double-blind baseline in selected safety end points including 
the fasting lipid panel parameters, and fasting glucose over time will be plotted by treatment 
group for the entire study treatment period (double-blind and open-label phases combined), for 
participants in the Safety Analysis Set. 
7.2.1.1. 
Metabolic Assessments 
For the lipid panel and glucose measurements, only those under fasting status will be 
summarized.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 46 
 
25 October 2023 
Fasting lipid data (including total cholesterol, LDL, HDL and triglycerides) will also be analyzed 
using the following National Cholesterol Education Program (NCEP) Adult Treatment Panel 
(ATP) III categories {National Cholesterol Education Program (NCEP) 2001}: 
• For total cholesterol (mg/dL): < 200 (desirable), 200-239 (borderline high), and 
≥ 240 (high) 
• For LDL (mg/dL): < 100 (optimal), 100-129 (near optimal/above optimal), 
130-159 (borderline high), 160-189 (high), and ≥ 190 (very high) 
• For HDL (mg/dL): < 40 (low), 40-59 (normal), and ≥ 60 (high) 
• For triglycerides (mg/dL): < 150 (normal), 150-199 (borderline high), 200-499 (high), and 
≥ 500 (very high) 
The number and proportion of participants for the above categories of each lipid parameter will 
be summarized by its baseline category for each treatment group at each visit for the entire study 
treatment period. 
7.2.1.2. 
Calcium Corrected for Albumin 
Calcium corrected for albumin will be calculated and summarized. The following formula will 
be used when both serum calcium and albumin results for a given blood draw are available and 
serum albumin value is < 4.0 g/dL.  
Calcium corrected for albumin (mg/dL) = serum calcium (mg/dL) + 0.8 × (4.0 – albumin (g/dL)) 
When albumin value is ≥ 4.0 g/dL, the actual calcium results will be used. Toxicity grading for 
calcium will be applied based on the corrected values. 
7.2.2. 
Graded Laboratory Values 
The criteria specified in the protocol will be used to grade laboratory results as Grade 0, 
Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) or Grade 4 (life-threatening). Grade 0 
includes all values that do not meet criteria for an abnormality of at least Grade 1. Some 
laboratory tests have criteria for both increased and decreased levels; analysis for each direction 
(ie, increased, decreased) will be presented separately.  
For triglycerides, LDL, and total cholesterol, the protocol-specified toxicity grade scale is for 
fasting test values; non-fasting lipid results (or lipid results without known fasting status) will not 
be graded or summarized by toxicity grades.  
If any laboratory toxicity grading scale overlaps with normal reference ranges (eg, Grade 1 scale 
overlaps with normal reference ranges), laboratory values within normal range will not be graded 
except for lipid tests.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 47 
 
25 October 2023 
7.2.2.1. 
Treatment-Emergent Laboratory Abnormalities 
Treatment-emergent laboratory abnormalities occurring in the double-blind phase are defined as 
values that increase by at least 1 toxicity grade from baseline at any postbaseline visit up to and 
including the last does date of the blinded study drug (or ‘last dose date of the blinded study drug 
+ 1’ for those who enter the open-label phase) for those who discontinued blinded study drug 
permanently, or values that increase by at least 1 toxicity grade from baseline at any postbaseline 
visit for those who are still on the blinded study drug. If the relevant baseline laboratory data are 
missing, any laboratory abnormality of at least Grade 1 will be considered treatment-emergent. 
Treatment-emergent laboratory abnormalities occurring in the open-label phase are defined as 
values that increase by at least 1 toxicity grade from the open-label baseline at any open-label 
postbaseline visit up to and including the last dose date of open-label study drug + 3 days for 
those who discontinued open-label study drug prematurely (or ‘last dose date of the open-label 
study drug + 3 days’ for those who completed the open-label phase), or values that increase by at 
least 1 toxicity grade from the open-label baseline at any open-label postbaseline visit for those 
who are still on the open-label study drug. For the analyses of abnormalities occurring during 
open-label treatment, baseline will be the last available record on or prior to Open-Label Study 
Day 1.  
Fasting glucose and nonfasting glucose are graded based on different grading scales. 
Treatment-emergent laboratory abnormalities will be summarized for fasting glucose. Since 
nonfasting glucose was not assessed at baseline, the maximum postbaseline grade will be 
summarized. 
7.2.2.2. 
Treatment-Emergent Marked Laboratory Abnormalities 
Treatment-emergent marked laboratory abnormalities occurring in the double-blind phase are 
defined as values that worsen by at least 3 grades from baseline at any postbaseline visit up to and 
including the last dose date of the blinded study drug for those who discontinued blinded study drug 
prematurely (or ‘last dose date of the blinded study drug + 1 day’ for those who completed 
double -blind phase), or values that worsen by at least 3 grades from baseline at any postbaseline 
visit for those who are still on blinded study drug. If relevant baseline laboratory data are missing, 
any laboratory abnormalities of at least Grade 3 or 4 will be considered as treatment-emergent 
marked laboratory abnormalities. 
Treatment-emergent marked laboratory abnormalities occurring in the open-label phase are defined 
as values that worsen by at least 3 grades from the open-label baseline at any open-label 
postbaseline visit up to and including the last dose date of open-label study drug + 3 days for those 
who discontinued open-label study drug prematurely (or ‘last dose date of the open-label study drug 
+ 3 days’ for those who completed the open-label phase), or values that worsen by at least 3 grades 
from the open-label baseline at any open-label postbaseline visit for those who are still on 
open-label study drug. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 48 
 
25 October 2023 
7.2.2.3. 
Summaries of Laboratory Abnormalities 
The following summaries (number and percentage of participants) of laboratory abnormalities 
will be provided by treatment group (participants categorized according to most severe 
abnormality grade) for the double-blind and open-label phase: 
• Treatment-emergent laboratory abnormalities 
• Treatment-emergent Grade 3 and 4 laboratory abnormalities 
• Treatment-emergent marked laboratory abnormalities 
For all summaries of laboratory abnormalities, the denominator is the number of participants 
with any nonmissing postbaseline (or open-label postbaseline) value in the given study period. A 
listing of treatment-emergent Grade 3 or 4 laboratory abnormalities will be provided. 
7.2.3. 
ALT Elevation 
An ALT elevation is defined as serum ALT > 2 × baseline value and > 10 × ULN, with or 
without associated symptoms. Confirmed ALT elevation (ALT flare) is defined as ALT 
elevations at 2 consecutive postbaseline visits. All treatment-emergent ALT elevations including 
confirmed ALT elevations will be summarized for the double blind and the open-label phases 
separately. For analyses of ALT elevation during open-label treatment, baseline will be the last 
available record on or prior to Open-Label Study Day 1. All treatment emergent and 
nontreatment-emergent ALT elevations will be included in a listing. 
7.3. 
Bone Safety Analyses 
The BMD-related analyses for the entire study treatment period will be based on participants in 
the Hip or Spine DXA Analysis Set. The analyses of fracture events and bone events during 
double-blind phase will be based on the Safety Analysis Set, and the summaries for the open-
label phase will be based on Open-Label Safety Analysis Set. 
7.3.1. 
Bone Mineral Density (BMD) 
Observed BMD values will be used for all the analyses described below: Percentage change from 
baseline in hip BMD and spine BMD during the entire study treatment period will be 
summarized by treatment group and visit using descriptive statistics for participants in the Hip 
and Spine DXA Analysis Sets.  
For each participant and each visit, the clinical BMD status will be defined for hip and spine 
BMD based on the corrected t-score in Table 7-1. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 49 
 
25 October 2023 
Table 7-1. 
Normal, Osteopenia, and Osteoporosis as Defined by T-Score 
Clinical Status 
BMD T-Score 
Normal 
t-score ≥ -1.0 
Osteopenia 
-2.5 ≤ t-score < -1.0 
Osteoporosis 
t-score < -2.5 
 
The number and percentage of participants in each clinical BMD status (normal, osteopenia, and 
osteoporosis) will be summarized by visit and by baseline clinical status for both hip and spine.  
The number and percentage of participants in each category based on percentage change from 
baseline in hip BMD and spine BMD (> 7% decrease, > 5% to ≤ 7% decrease, > 3% to ≤ 5% 
decrease, > 1% to ≤ 3% decrease, > 0 to ≤ 1% decrease, 0 to ≤ 1% increase, > 1% to ≤ 3% 
increase, > 3% to ≤ 5% increase, > 5% to ≤ 7% increase, > 7% increase) will be summarized by 
treatment group and visit.  
The number and percentage of participants in each category based on percentage change from 
baseline in femoral neck (≥ 7% decrease, ≥ 5% to < 7% decrease, ≥ 3% to < 5% decrease, 
≥ 1% to < 3% decrease, ≥ 0 to < 1% decrease, ≥ 0 to < 1% increase, ≥ 1% to < 3% increase, 
≥ 3% to < 5% increase, ≥ 5% to < 7% increase, ≥ 7% increase) will be summarized by treatment 
group and visit.  
Median (Q1, Q3) and mean (95% CIs) of percentage change from the double-blind baseline in 
observed hip BMD and spine BMD over time will be plotted by treatment group for the entire 
study treatment period for participants in the DXA Analysis Set. 
7.3.2. 
Bone Biomarkers 
Bone biomarkers include serum CTX, P1NP, PTH, OC, and bsAP. 
Baseline, postbaseline, change from baseline, and percentage change from baseline in bone 
biomarkers will be summarized by treatment group and visit using descriptive statistics.  
Median (Q1, Q3) percentage change from the double-blind baseline in each bone biomarker over 
time will be plotted by treatment group for the entire study treatment period for participants in 
the Safety Analysis Set. 
7.3.3. 
Fracture Events 
The PTs for fracture events were defined based on HLGT of Fractures from latest version of 
MedDRA. The number and percentage of subjects who experienced fracture events will be 
summarized by treatment group for the double-blind and the open-label phase separately. A data 
listing of fracture events will be provided. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 50 
 
25 October 2023 
7.3.4. 
Bone Events 
The PTs for bone events were defined based on the broad search for bone mineral density and 
bone-disorder-related PTs, including fractures, using the latest version of MedDRA. The number 
and percentage of participants who experienced treatment-emergent bone events will be 
summarized by treatment group for the double-blind and the open-label phase separately. A data 
listing of bone events will be provided. 
7.4. 
Renal Safety Analyses 
7.4.1. 
Confirmed Renal Abnormalities 
Confirmed renal abnormalities are defined as follows: 
• Confirmed increase from baseline in creatinine of at least 0.5 mg/dL or 
• Confirmed CLCr by CG below 50 mL/min or 
• Confirmed phosphorus < 2 mg/dL 
Treatment-emergent confirmed renal abnormalities will be summarized for the double-blind and 
the open-label phase separately. For analyses of confirmed renal abnormalities during the open 
label treatment, baseline will be the last available record on or prior to Open-Label Study Day 1.  
All confirmed renal abnormalities including those that occur during the TFFU period will be 
listed.  
7.4.2. 
Serum Creatinine 
The baseline and change from baseline in serum creatinine will be summarized using descriptive 
statistics.  
Median (Q1, Q3) and mean (95% CIs) of change from the double-blind baseline in observed 
serum creatinine over time will be plotted by treatment group for the entire study treatment 
period for participants in the Safety Analysis Set. 
A positive shift in serum creatinine values was observed due to a lot calibration change on 
01 July, 2018, occurring across Covance laboratory sites worldwide. A correction was therefore 
applied to records on or after 01 July, 2018 to serum creatinine, following the regression 
equation specified in Table 7-2. The corrected serum creatinine values will be used for the 
analyses of serum creatinine, serum creatinine toxicity, eGFR estimated by the Cockcroft Gault 
formula, eGFR by the CKD-EPI method and other relevant parameters.  
The corrected values must be in the same unit as the original values after going through the 
regression formula in Table 7-2. 
• If the unit of serum creatinine is “μmol/L”, then use the formula directly.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 51 
 
25 October 2023 
• If the unit of serum creatinine is “mg/dL”, the values should be converted to “μmol/L” before 
using the formula.  
After the correction, unit of serum creatinine should be converted back to “mg/dL” for summary 
and comparison purpose.  
Table 7-2. 
Method of Serum Creatinine Correction 
Regional Lab Center 
Accession Numbera 
Regular Regression for Serum 
Creatinine (μmol/L)b, c 
Indianapolis  
starts with 65 
Y=1.002×X+1.77 
Geneva  
starts with 62 or 63 
Y=1.025×X+2.62 
Shanghai  
starts with 67 
Y=0.971×X+5.42 
Singapore  
starts with 64 or 66 
Y=1.009×X−1.42 
Japan  
start with 68 
Y=1.033×X+7.25 
a 
Accession numbers specified which regional lab center tested the sample. For example, samples with accession number 
starting with 65 were tested in Indianapolis Auto Chemistry Center. 
b 
X and Y are the serum creatinine values from previous lot before 01 July, 2018 and serum creatinine values from new lot on 
or after 01 July, 2018, respectively.  
c 
The serum creatinine correction is based on the unit of umol/L. The unit should be converted to mg/dL for summary 
purposes.  
7.4.3. 
Estimated Glomerular Filtration Rate 
The following formulae will be used to calculate eGFR:  
• CG: 
eGFRCG (mL/min) = [(140 – age (yrs)) × weight (kg) × (0.85 if female)] / (SCr (mg/dL) × 72), 
where weight is actual total body mass in kilograms, and SCr is serum creatinine. 
• CKD-EPI Creatinine Based: 
eGFRCKD-EPI, creatinine (mL/min/1.73 m2) = 141 × min(SCr/κ,1)α × max(SCr/κ,1)-1.209 × 0.993Age × 
1.018 (if female) × 1.159 (if black), 
where κ is 0.7 for females and 0.9 for males, α is –0.329 for females and –0.411 for males, 
min indicates the minimum of SCr/κ or 1, and max indicates the maximum of SCr/κ or 1 
{Levey 2009}. 
• CKD-EPI Cystatin C based: 
eGFRCKD-EPI, cysC (mL/min/1.73 m2) = 133 × min(SCys/0.8, 1)-0.499 × max(SCys/0.8, 1)-1.328 × 
0.996age [× 0.932 if female], 
where SCys is serum cystatin C. 
Change from baseline in eGFRCG and eGFRCKD-EPI, creatinine at each postbaseline visit during the 
entire study treatment period will also be provided.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 52 
 
25 October 2023 
The number and proportion of participants with decrease from baseline of ≥ 25% and ≥ 50% in 
eGFRCG and eGFRCKD-EPI, creatinine will be summarized by treatment groups for the double-blind 
phase and the open-label phase. Baseline for the open-label phase will be the last available 
record on or prior to the first dose date of open-label study drug. 
The number and proportion of participants in each stage of chronic kidney disease (CKD) will be 
summarized by double-blind baseline stages of CKD at the entire study period based on 
participants in the Safety Analysis Set.  
The stages of CKD are defined as follows: 
• Stage 1: eGFRCG ≥ 90 mL/min 
• Stage 2: eGFRCG ≥ 60 and < 90 mL/min 
• Stage 3: eGFRCG ≥ 30 and < 60 mL/min 
• Stage 4: eGFRCG ≥ 15 and < 30 mL/min 
• Stage 5: eGFRCG < 15 mL/min 
Cystatin C will be collected for each participant at baseline visit (Amendment 2 and after) and 
whenever their postbaseline eGFR by CG < 50 mL/min. Therefore, eGFRCKD-EPI, cysC will be 
summarized as the baseline disease characteristics only. All postbaseline eGFRCKD-EPI, cysC with 
percentage change from baseline will be listed. 
Median (Q1, Q3) change from the double-blind baseline in eGFR by CG and CKD-EPI 
creatinine methods over time will be plotted by treatment group for the entire study treatment 
period (double-blind and open-label phases combined) for participants in the Safety Analysis 
Set. 
7.4.4. 
Treatment-Emergent Proteinuria (Dipstick) 
Treatment-emergent proteinuria by urinalysis (dipstick) will be summarized by treatment group 
for the double-blind and the open-label phase separately. A listing of participants with 
treatment-emergent proteinuria will be provided. 
7.4.5. 
Urine Creatinine, Urine RBP to Creatinine Ratio and Beta-2-Microglobulin 
to Creatinine Ratio 
Baseline, postbaseline, change from baseline and percentage change from baseline in urine 
creatinine, urine RBP to creatinine ratio and beta-2-microglobulin to creatinine ratio will be 
summarized by treatment group and visit using descriptive statistics, during the entire study 
treatment period.  


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 53 
 
25 October 2023 
Median (Q1, Q3) percentage change from the double-blind baseline in the 2 ratios over time will 
be plotted by treatment group for the entire study treatment period, for participants in the Safety 
Analysis Set. 
7.4.6. 
Proteinuria by Quantitative Assessment 
Baseline, postbaseline, changes from baseline, and percentage change from baseline in UPCR 
and UACR will be summarized by treatment group and visit using descriptive statistics, for the 
entire study treatment period. 
The number and proportion of participants with UPCR ≤ 200 mg/g versus > 200 mg/g will be 
summarized by baseline category for each postbaseline visit during the entire study treatment 
period {KDIGO Guideline Development Staff 2013}. 
The number and proportion of participants with UACR < 30 mg/g versus ≥ 30 mg/g will be 
summarized by baseline category for each postbaseline visit during the entire study treatment 
period {KDIGO Guideline Development Staff 2013}. 
Median (Q1, Q3) percentage change from the double-blind baseline in the 2 ratios over time will 
be plotted by treatment group for the entire study treatment period for participants in the Safety 
Analysis Set. 
7.4.7. 
Other Renal Biomarkers 
Other renal biomarkers include TmP/GFR, FEPO4, and FEUA. 
TmP/GFR based on serum creatinine {Barth 2000} will be calculated as follows: 
[
]
86
.0
)
8.0
(
1
/
3.0
/
86
.0
/
4
4
>
×
×
−
×
=
≤
×
=
TRP
if
SPO
TRP
TRP
GFR
TmP
TRP
if
SPO
TRP
GFR
TmP
 
where TRP (tubular reabsorption of phosphate) is calculated by: 
UCr
SCr
SPO
UPO
TRP
×
−
=
4
4
1
 
where SCr is serum creatinine concentration (mg/dL), UPO4 is urine phosphate concentration 
(mg/dL), SPO4 is serum phosphate concentration, and UCr is urine creatinine concentration 
(mg/dL). 
Urine FEPO4 will be calculated as follows: 
FEPO4 (%) = (SCr × UPO4) / (SPO4 × UCr) × 100 (%) 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 54 
 
25 October 2023 
Urine FEUA will be calculated as follows: 
FEUA (%) = (SCr × UUa) / (SUa × UCr) × 100 (%) 
Where UUa and SUa are urine and serum uric acid (mg/dL), respectively.  
The baseline, postbaseline, and change from baseline in TmP/GFR, FEPO4, and FEUA will be 
summarized by treatment group and visit using descriptive statistics, during the entire study 
treatment period.  
Median (Q1, Q3) change from the double-blind baseline in TmP/GFR, FEPO4, and FEUA over 
time will be plotted by treatment group for the entire study treatment period, for participants in 
the Safety Analysis Set. 
7.5. 
Ophthalmologic Assessment 
As no Ophthalmologic assessment was performed in China, no analysis will be conducted. 
7.6. 
Body Weight 
Body weight at each visit and change from baseline in body weight will be summarized using 
descriptive statistics (sample size, mean, SD, median, Q1, Q3, minimum, and maximum) by 
treatment group for each postbaseline analysis window, during the entire study treatment period. 
In the case of multiple values in an analysis window, data will be selected for analysis as 
described in Section 3.6.3. 
7.7. 
Prior Hepatitis B Medications 
Prior HBV medications will be summarized by treatment group. No inferential statistics will be 
computed. A listing of prior HBV medications will also be provided. 
7.8. 
Concomitant Medications 
Concomitant medications (ie, medications other than study drug that are taken while receiving 
study drug) will be coded using the WHO Drug Dictionary. The WHO preferred name and drug 
code will be attached to the clinical database. Use of concomitant medications for the 
double-blind, the open-label phases, and will be summarized (number and percentage of 
participants) separately by treatment group and WHO drug class and preferred name. Multiple 
drug use (by preferred name) will be counted only once per participant. The summary will be 
sorted alphabetically by drug class and then by decreasing total frequency within a class.  
If the start or stop date of concomitant medications is incomplete, the month and year 
(or year alone if month is not recorded) of start or stop date will be used to determine if the 
medications are concomitant as follows. The medication is concomitant for the double-blind 
phase if the month and year of start or stop (or year of the start or stop) of the medication do not 
meet any of following criteria: 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 55 
 
25 October 2023 
• The month and year of start of the medication is after the date of the last dose of blinded 
study drug 
• The month and year of stop of the medication is before the date of the first dose of blinded 
study drug 
The medication is concomitant for the open-label phase if the month and year of start or stop 
(or year of the start or stop) of the medication do not meet any of following criteria: 
• The month and year of start of the medication is after the date of the last dose of open-label 
study drug 
• The month and year of stop of the medication is before the date of the first dose of open-label 
study drug 
If both the start and stop date of the medication are missing, the medication will be considered as 
concomitant during both double-blind and open-label phases. 
If the start and stop date of the medications are not missing, and the start date is not after the last 
dose date of the blinded study drug and the stop date is not before the first dose date of the 
blinded study drug, or the medications are marked as ongoing and start date is on or before the 
last dose date of the blinded study drug, the medications are considered concomitant during the 
double-blind phase. 
Similarly, if the start and stop date of the medications are not missing, and the start date is not 
after the last dose date of the open-label study drug and the stop date is not before the first dose 
date of the open-label study drug, or the medications are marked as ongoing and start date is on 
or before the last dose date of the open-label study drug, the medications are considered 
concomitant during the open-label phase. 
Summaries of concomitant medications will be provided for the double-blind phase using the 
Safety Analysis Set and the open-label phase using the Open-Label Safety Analysis Set. 
No inferential statistics will be provided. Participants with any concomitant medication use will 
also be listed. 
7.9. 
Electrocardiogram (ECG) Results 
The number and percentage of participants in the Safety Analysis Set with an investigator’s ECG 
assessment of normal, abnormal but not clinically significant, or abnormal and clinically 
significant will be summarized by treatment group and by baseline result for each visit, during 
the entire study period. No inferential statistics will be provided.  
A by-participant listing of safety ECG results will be provided including treatment, assessment 
date and time, and ECG results. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 56 
 
25 October 2023 
7.10. 
Other Safety Measures 
A data listing will be provided for participants experiencing pregnancy during the study.  
Listings of cirrhosis and hepatocellular carcinoma assessment results will be provided. 
Alcohol use at baseline will also be listed. 
7.11. 
Changes From Protocol-Specified Safety Analyses 
Treatment-emergent proteinuria was not included as a key secondary safety end point in Protocol 
Amendment 3.1 and is added in the SAP.  
As no Ophthalmologic assessment was performed in China, no analysis will be conducted. 
Comparison of the safety and tolerability of TAF versus TDF for the treatment of HBeAg 
positive, CHB beyond Week 48 during the double-blind phase in treatment-naive and 
treatment-experienced participants was not included as a secondary objective of this study 
and was documented in the Week 48 China Analysis SAP and is carried over to this SAP. 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 57 
 
25 October 2023 
8. 
REFERENCES 
Barth JH, Jones RG, Payne RB. Calculation of renal tubular reabsorption of phosphate: the 
algorithm performs better than the nomogram. Ann Clin Biochem 2000;37 ( Pt 
1):79-81. 
KDIGO Guideline Development Staff. KDIGO 2012 Clinical Practice Guideline for the 
Evaluation and Management of Chronic Kidney Disease. Kidney international. 
Supplement 2013;3 (1):v-150. 
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new 
equation to estimate glomerular filtration rate. Ann Intern Med 2009;150 (9):604-
12. 
National Cholesterol Education Program (NCEP). Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. 
National Institute of Health  May, 2001. 
 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 58 
 
25 October 2023 
9. 
SOFTWARE 
nQuery Advisor® (Statistical Solutions Ltd., Version 6.0, Cork, Ireland) was used for the sample 
size and power calculation. 
SAS® (SAS Institute Inc., Version 9.4, Cary, NC) is to be used for all programming of tables, 
listings, and figures. 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 59 
 
25 October 2023 
10. 
SAP REVISION 
Revision Date 
(dd month yyyy) 
Section 
Summary of Revision 
Reason for Revision 
 
 
 
 
 
 
 
 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 60 
 
25 October 2023 
11. 
APPENDICES 
Appendix 1. 
Adverse Events of COVID-19 
Appendix 2. 
Determining Missing and Virtual Visits Due to COVID-19 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 61 
 
25 October 2023 
Appendix 1. 
Adverse Events of COVID-19 
An adverse event record will be flagged as adverse events for COVID-19 if its Medical 
Dictionary for Regulatory Activities (MedDRA) preferred term (PT) is included in the 
pre-specified PT list, which includes all PTs from the narrow search of the following COVID-19 
SMQs under based the latest MedDRA version provided by Gilead GLPS (search name: 
COVID-19 (SMQ) – Narrow) and reviewed by Gilead medical monitors. 
SMQ Source 
AEs for COVID-19  
COVID-19 (SMQ) (Narrow Scope) 
 


TAF, GS-US-320-0110 Final China 
 
Statistical Analysis Plan 
Version .1.0 
CONFIDENTIAL 
Page 62 
 
25 October 2023 
Appendix 2. 
Determining Missing and Virtual Visits Due to COVID-19 
This appendix describes the clinical trial site collection of COVID-19 data pertaining to 
missed/virtual visits and the data processing algorithm that will be used to determine which visits 
are missing and which visits are virtual. 
Data Collection 
A COVID-19 supplement to the eCRF Completion Guidelines (CCG) was provided by Clinical 
Data Management to instruct clinical trial sites with data entry expectations pertaining to 
scenarios related to the COVID-19 pandemic. If a visit was missed, sites were instructed to enter 
“Visit missed due to COVID-19” and if an in-person visit was conducted virtually, sites were 
instructed to enter “Virtual visit due to COVID-19”. 
Determination of Missed and Virtual Visits 
Natural Language Processing (NLP) will be used to search the CRF comment fields to identify 
instances of “COVID-19”, “Virtual”, or synonyms (see Table 11-1). The search terms will be 
maintained in a global lookup table and can be modified to tune the NLP model. Any comments 
with COVID-19 search terms, “Missed visit” or “Virtual visit” will be assigned as follows: 
i. If COVID-19 terms are identified through NLP and the visit date is missing, then result is 
“Missed Visit” 
ii. If COVID-19 and Virtual terms are identified through NLP for a visit, then result is “Virtual 
Visit”. When there are multiple records for the same participant and the same visit, if one 
record could be categorized as “Virtual Visit”, all records associated with this participant and 
this visit will be categorized as “Virtual Visit” 
iii. Otherwise result is missing 
Table 11-1. 
Example Search Terms for “COVID-19” and “Virtual” Used to 
Identify Missed/Virtual Visits 
Search Terms for “COVID-19” 
Search Terms for “Virtual” 
COVID19 
CORONA 
CORONAVIRUS 
PANDEMIC 
OUTBREAK 
CRISIS 
LOCKDOWN 
QUARANTINE 
SHELTER 
 
VIRTUAL 
TELEMED 
TELEHEALTH 
TELEPHONE 
REMOTE 
TELEMEDICINE 
TELECONSULTATION 
TELEPHONICALLY 
PHONE 
HOME VISIT 
ZOOM 
SKYPE